Pharmaceutical uses and synthesis of benzobicyclooctanes

ABSTRACT

Benzobicyclooctane compounds, their use in inhibiting cellular events involving TNF-α and IL-8, and in the treatment of inflammation events in general; a combinatorial library of diverse bicyclooctanes and process for their synthesis as a library and as individual compounds.

[0001] This application claims the benefit of U.S. Provisional Patent Application No. 60/257,532, filed Dec. 22, 2000, where this provisional application is incorporated herein by reference in its entirety.

TECHNICAL FIELD

[0002] The present invention is generally directed to benzobicyclooctanes, their use in inhibiting cellular events involving TNF-α or IL-8, and in the treatment of inflammation events in general; the application also provides a combinatorial library of diverse bicyclooctanes and methods for their synthesis in a library format as well as individual

compounds. BACKGROUND OF THE INVENTION

[0003] One process for discovering new therapeutically active compounds for a given indication involves the screening of all compounds from available compound collections. From the compounds tested, one or more structures is selected as a promising lead. A large number of related analogues are then synthesized in order to develop a structure-activity relationship (SAR). The SARs direct the development and then selection of one or more optimal compounds following traditional one-at-a-time synthesis and biological testing. This optimization process is long and labor intensive.

[0004] Adding significant numbers of new structures to the compound collections used in this initial screening step of the discovery and optimization process cannot be accomplished with traditional one-at-a-time synthesis methods, except over a time frame of months or even years. Faster methods are needed that allow for the preparation of libraries of related compounds in a matter of days or a few weeks. This need is particularly apparent when it comes to synthesizing more complex compounds.

[0005] Combinatorial approaches have recently been extended to “organic” or non-peptide, libraries. The organic libraries at present, however, are limited in diversity and generally relate to peptidomimetic compounds; in other words, organic molecules that repeat a peptide chain pharmacophore. There is a need in the art for additional approaches to the preparation of new organic libraries.

[0006] Cytokines are pleiotropic extracellular proteins that are released and recognized by a wide variety of cell types. Via a series of complex interactions they are responsible for regulating many of the events involved in growth and differentiation of an organism. Among the cytokines, tumor necrosis factor-α (TNF-α) has been shown to play an important role in the genesis of certain chronic inflammatory and autoimmune diseases. TNF-α is secreted mainly by macrophages and monocytes in response to a variety of inflammatory agents. Other cell types such as NK cells, T cells, B cells, Kupfer cells, and glial cells also produce TNF-α.

[0007] TNF-α is synthesized as an inactive 26 kDa pro-protein which is cleaved by the metalloprotease TNF-α Converting Enzyme (TACE) to afford the active 17 kDa cytokine protein. The cytokine exerts its biological effects by interacting with two high affinity receptors of molecular weights 55 kDa (TNFR1 or p55) and 75 kDa (TNFR2 or p75) found on the surface of most cell types. As a result of TNF-α binding to its receptors, a cascade of signaling events occurs within the cell. The exact nature and sequence of events is dependent upon cell type and receptor. Two of the most important physiological effects of TNF-α binding to its receptors are the upregulation of new genes by activation of the transcription factor NFκB, and induction of programmed cell death or apoptosis.

[0008] Apoptosis is a normal physiological process whereby incompetent cells become targeted for disposal by the immune system. The process involves a series of morphological changes to the apoptotic cell, including a change of surface chemistry. This change in surface chemistry is recognized by macrophages that rapidly phagocytose the cell. A number of stimuli can induce apoptosis, including DNA damage, UV radiation, growth factor deprivation, bacterial and viral infection, and ligation of cell surface receptors. TNF-α has been shown to induce apoptosis by binding to TNFR1. Under normal biochemical circumstances the process of apoptosis is integral in regulating the homeostatic balance between cell death and cell proliferation. However in many autoimmune diseases this balance is shifted; not only do unwanted cells undergo apoptosis but healthy cells as well. These diseases are often associated with increased levels of TNF-α. There is a need in the art for compounds that can modulate binding of TNF-α to cell receptors, and/or modulate the consequential intracellular events.

[0009] Transcription factors are a family of proteins that bind to DNA and serve to upregulate gene expression. Often they remain in an inactive form until acted upon by a biochemical signal. One such transcription factor is nuclear factor kappa B (NFκB), which can be activated by the binding of TNF-α to TNFR1 and/or TNFR2. NFκB regulates many of the cytokines and other proinflammatory molecules associated with inflammatory and autoimmune diseases. Classes of proteins subject to regulation by NFκB and which have been demonstrated to be involved with disease states are cytokines and growth factors, adhesion molecules, chemokines, and immunoreceptors.

[0010] The inhibition of TNF-α induced apoptosis and of NFκB activation is one means of preventing and/or treating autoimmune and inflammatory diseases including, but not limited to, rheumatoid arthritis, inflammatory bowel disease, psoriasis, atherosclerosis, asthma, reperfusion injury, ischemia, sepsis, graft vs. host disease, adult respiratory distress syndrome, multiple sclerosis, and a host of severe invasive infections such as fulminant hepatitis, AIDS and bacterial meningitis, and allergic inflammation of the lungs and airways.

[0011] Interleukin-8 (IL-8) is a chemokine (chemotactic cytokine) which plays an important role in the recruitment of neutrophils to sites of inflammation. It is a member of the CXC subfamily of chemokines, members of which contain a single amino acid residue between the first two cysteines. In addition to inducing the chemotaxis of neutrophils, IL-8 exerts other immunomodulatory effects such as release of superoxide, mobilization of intracellular Ca++, upregulation of cell surface integrins, and activation of phospholipase D. All of these cellular events are the result of IL-8 binding to one of its two high affinity receptors. The two receptors, known as IL8RA or CXCR1 and IL8RB or CXCR2, bind the ligand with a K_(d) of ca. 2 nM.

[0012] Numerous reports in the literature have associated increased levels of IL-8 with the development of inflammatory and autoimmune diseases such as Inflammatory Bowel Disease (IBD), psoriasis, rheumatoid arthritis, Acute Respiratory Distress Syndrome (ARDS), cancer, atherosclerosis, reperfusion injury, and graft vs. host disease. The inhibition of IL-8 or other CXC chemokines from binding to CXCR1 and/or CXCR2 receptors is one means of preventing and/or treating these diseases.

[0013] Although treatment regimens are available for the symptomatic amelioration of some or all of these diseases, there still exists the need for compositions and methods for preventing and/or treating the inflammation which is often associated with the disease.

[0014] The present invention satisfies these needs and provides related advantages as well, as described more fully herein.

SUMMARY OF THE INVENTION

[0015] The present invention overcomes the known limitations to classical organic synthesis of bicyclooctanes, and the shortcomings in applying combinatorial chemistry to bicyclooctanes, as well as providing compounds which are useful in inhibiting TNF-α, IL-8, apoptotic-mediated processes, and inflammatory conditions. Moreover, the present invention provides a library of diverse bicyclooctanes useful in elucidating the structure-function relationship in biological processes, such as inflammation.

[0016] In one embodiment, the present invention provides a compound of formula

[0017] and optical isomers, diastereomers, enantiomers and pharmaceutically acceptable salts thereof in isolation or mixture, where, independently at each location:

[0018] R¹ is selected from the following six formulae:

[0019] R² is —OR⁹ or —NR⁹R⁹;

[0020] R³ is selected from hydrogen, halogen, hydroxyl or protected hydroxyl, amino or protected amino, and C₁-C₈alkyl or C₁-C₈haloalkyl;

[0021] R⁴ and R⁵ are independently selected from R⁹, —OR⁹, —NR⁹R⁹ and —N═N—R⁹, or R⁴ and R⁵ may together form a group selected from ═O, ═CR⁸R⁸ and ═NR¹⁰, or R⁴ and R⁵ may together with the carbon to which they are both attached form a spiro carbocyclic or heterocyclic ring;

[0022] R⁶ is selected from hydrogen, inorganic groups having 1-8 atoms exclusively selected from boron, sulfur, phosphorous, silicon and hydrogen, and organic groups having 1-20 carbons and optionally containing 1-4 heteroatoms selected from nitrogen, oxygen and silicon;

[0023] R⁷ is selected from halogen, hydroxyl or protected hydroxyl, amino or protected amino, and C₁-C₈alkyl or C₁-C₈haloalkyl;

[0024] R⁸ is selected from hydrogen, alkyl, aryl and heteroalkyl;

[0025] R⁹ is selected from hydrogen and organic groups having 1-30 carbons and optionally containing 1-4 heteroatoms selected from nitrogen, oxygen and silicon, with the provision that two R⁹ groups both joined to a common atom may be joined together so as to form a ring with the common atom;

[0026] R¹⁰ is selected from —R⁹, —OR⁹, —NR⁹R⁹, —NH—C(O)R⁹; —NH—C(O)OR⁹ and —NH—C(S)NHR⁹; and

[0027] n is 0, 1, 2 or 3;

[0028] with the proviso that when R⁶ is hydrogen and R⁴ and R⁵ together form ═O and R¹ is CO₂R⁹, then R² is not OCH₃.

[0029] In one embodiment R¹ is

[0030] In one embodiment R¹ is

[0031] In one embodiment R¹ is

[0032] In any of the above embodiments, R⁸ is, in one embodiment, selected from hydrogen and C₁-C₈ alkyl. In a further embodiment, R⁸ is hydrogen.

[0033] In one embodiment R¹ is

[0034] In one embodiment R¹ is

[0035] In one embodiment R¹ is

[0036] In one embodiment, R¹ is selected from the following five formulae:

[0037] In one embodiment R¹ is selected from the following four formulae:

[0038] In any of the above embodiments, in a further embodiment, R⁹ is independently selected at each occurrence from hydrogen, R¹¹, R¹², R¹³, R¹⁴ and R¹⁵ where R¹¹ is selected from alkyl, heteroalkyl, aryl and heteroaryl; R¹² is selected from (R¹¹)_(p)-alkylene, (R¹¹)_(p)-heteroalkylene, (R¹¹)_(p)-arylene and (R¹¹)_(p)-heteroarylene; R¹³ is selected from (R¹²)_(p)-alkylene, (R¹²)_(p)-heteroalkylene, (R¹²)_(p)-arylene, and (R¹²)_(p)-heteroarylene; R ¹⁴ is selected from (R¹³)_(p)-alkylene, (R¹³)_(p)-heteroalkylene, (R¹³)_(p)-arylene, and (R¹³)_(p)-heteroarylene, R¹⁵ is selected from (R¹⁴)_(p)-alkylene, (R¹⁴)_(p)-heteroalkylene, (R¹⁴)_(p)-arylene, and (R¹⁴)_(p)-heteroarylene, and p is selected from 0, 1, 2, 3, 4 and 5, with the provision that two R⁹ groups both joined to a common atom may be joined together so as to form a ring with the common atom.

[0039] In any of the above embodiments, in a further embodiment, R⁹ is independently selected at each occurrence from R¹¹, R¹², R¹³, R¹⁴ and R¹⁵ where R¹¹ is selected from alkyl, heteroalkyl, aryl and heteroaryl; R¹² is selected from (R¹¹)_(p)-alkylene, (R¹¹)_(p)-heteroalkylene, (R¹¹)_(p)-arylene and (R¹¹)_(p)-heteroarylene; R¹³ is selected from (R¹²)_(p)-alkylene, (R¹²)_(p)-heteroalkylene, (R¹²)_(p)-arylene, and (R¹²)_(p)-heteroarylene; R¹⁴ is selected from (R¹³)_(p)-alkylene, (R¹³)_(p)-heteroalkylene, (R¹³)_(p)-arylene, and (R¹³)_(p)-heteroarylene, R¹⁵ is selected from (R¹⁴)_(p)-alkylene, (R¹⁴)_(p)-heteroalkylene, (R¹⁴)_(p)-arylene, and (R¹⁴)_(p)-heteroarylene, and p is selected from 0, 1, 2, 3, 4 and 5.

[0040] In any of the above embodiments, in a further embodiment, R⁹ is selected from hydrogen, heteroalkyl, C₁-C₁₅alkyl, (heteroaryl)C₁-C₁₅alkylene, (C₆-C₁₀aryl)C₁-C₁₅alkylene, C₆-C₁₀aryl fused to C₁-C₁₅alkylene, (alkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene, (C₆-C₁₀aryl)(C₆-C₁₀arylene)C₁-C₁₅alkylene, (C₁-C₁₅alkyl)_(p)(heteroarylene)C₁-C₁₅alkylene, and (heteroalkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene, or two R⁹ groups bonded to a common nitrogen of R¹ may be joined together to form a 5-8 membered heterocycle including the common nitrogen, where this 5-8 membered heterocycle may be substituted with 0-5 groups selected from alkyl and heteralkyl, where p is selected from 1, 2, 3, 4 and 5.

[0041] In any of the above embodiments, in a further embodiment, R⁹ is selected from hydrogen, heteroalkyl, C₁-C₁₅alkyl, (C₆-C₁₀aryl)C₁-C₁₅alkylene, (heteroaryl)C₁-C₁₅alkylene, and (heteroalkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene, or the two R⁹ groups joined to a common nitrogen of R¹ may be joined together to form a 5-8 membered heterocycle including the common nitrogen.

[0042] In any of the above embodiments, in a further embodiment, R⁹ is selected from heteroalkyl, C₁-C₁₅alkyl, (C₆-C₁₀aryl)C₁-C₁₅alkylene, (C₆-C₁₀aryl)(C₆-C₁₀arylene)C₁-C₁₅alkylene, (C₁-C₁₅alkyl)_(p)(heteroarylene)C₁-C₁₅alkylene, and C₆-C₁₀aryl fused to C₁-C₁₅alkylene.

[0043] In any of the above embodiments, in a further embodiment, R⁹ is selected from hydrogen, heteroalkyl, C₁-C₁₅alkyl, (C₆-C₁₀aryl)C₁-C₁₅alkylene, (C₆-C₁₀aryl)(C₆-C₁₀arylene)C₁-C₁₅alkylene, (C₁-C₁₅alkyl)_(p)(heteroarylene)C₁-C₁₅alkylene, and C₆-C₁₀aryl fused to C₁-C₁₅alkylene.

[0044] In any of the above embodiments, in a further embodiment, R⁹ is selected from hydrogen, heteroalkyl, C₁-C₁₅alkyl, (heteroaryl)C₁-C₁₅alkylene, and (heteroalkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene.

[0045] In any of the above embodiments, in a further embodiment, R⁹ is selected from hydrogen, heteroalkyl, C₁-C₁₅alkyl, (heteroaryl)C₁-C₁₅alkylene, (C₆-C₁₀aryl)C₁-C₁₅alkylene, (alkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene, or the two R⁹ groups of R¹ may be joined together to form a 5-8 membered heterocycle including the common nitrogen, where this 5-8 membered heterocycle may be substituted with 0-5 groups selected from alkyl and beteralkyl.

[0046] In any of the above embodiments, in a further embodiment, R² is —OR⁹.

[0047] In any of the above embodiments, in a further embodiment, R² is —NR⁹R⁹.

[0048] In any of the above embodiments, in a further embodiment, R⁹ of R² is selected from hydrogen, R¹¹, R¹², R¹³, R¹⁴ and R¹⁵ where R¹¹ is selected from alkyl, heteroalkyl, aryl and heteroaryl; R¹² is selected from (R¹¹)_(p)-alkylene, (R¹¹)_(p)-heteroalkylene, (R¹¹)_(p)-arylene and (R¹¹)_(p)-heteroarylene; R¹³ is selected from (RK²)_(p)-alkylene, (R¹²)_(p)-heteroalkylene, (R¹²)_(p)-arylene, and (R¹²)_(p)-heteroarylene; R¹⁴ is selected from (R¹³)_(p)-alkylene, (R¹³)_(p)-heteroalkylene, (R¹³)_(p)-arylene, and (R¹³)_(p)-heteroarylene, R¹⁵ is selected from (R¹⁴)_(p)-alkylene, (R¹⁴)_(p)-heteroalkylene, (R¹⁴)_(p)-arylene, and (R¹⁴)_(p)-heteroarylene, and p is selected from 0, 1, 2, 3, 4 and 5.

[0049] In any of the above embodiments, in a further embodiment, R⁹ of R² is selected from hydrogen, heteroalkyl, C₁-C₁₅alkyl, (C₆-C₁₀aryl)(C₆-C₁₀arylene)C₁-C₁₅alkylene, (C₁-C₁₅alkyl)_(p)(heteroarylene)C₁-C₁₅alkylene, (C₁-C₁₅alkyl)_(p)(heteroarylene)-heteroalkylene, (heteroalkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene, and (C₁-C₁₅alkyl)_(p)(C₆-C₁₀arylene)heteroalkylene.

[0050] In any of the above embodiments unless otherwise inconsistent with a previous definition, in a further embodiment R² is —OR⁹ where R⁹ is selected from a heteroalkyl group having preferably 1-10 carbons and 1-4 heteroatoms selected from nitrogen, oxygen, silicon and sulfur.

[0051] In any of the above embodiments unless otherwise inconsistent with a previous definition, in a further embodiment R² is —NR⁹R⁹ and R⁹ is selected from hydrogen, heteroalkyl, C₁-C₁₅alkyl, (heteroaryl)C₁-C₁₅alkylene, (heteroalkyl)_(p)(aryl)-heteroalkylene, (heteroalkyl)_(p)(aryl)C₁-C₁₅alkylene, and (C₁-C₁₅alkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene.

[0052] In any of the above embodiments, in a further embodiment, R³ is selected from hydrogen and alkyl.

[0053] In any of the above embodiments, in a further embodiment, R³ is hydrogen.

[0054] In any of the above embodiments, in a further embodiment, R⁴ and R⁵ are independently selected from R⁹, —OR⁹, —NR⁹R⁹ and —N═N—R⁹.

[0055] In any of the above embodiments, in a further embodiment, R⁹ of R⁴ and R⁵ is selected from hydrogen, R¹¹, R¹², R¹³, R¹⁴ and R¹⁵ where R¹¹ is selected from alkyl, heteroalkyl, aryl and heteroaryl; R¹² is selected from (R¹¹)_(p)-alkylene, (R¹¹)_(p)-heteroalkylene, (R¹¹)_(p)-arylene and (R¹¹)_(p)-heteroarylene; R¹³ is selected from (R¹² _(p)-alkylene, (R¹²)_(p)-heteroalkylene, (R¹²)_(p)-arylene, and (R¹²)_(p)-heteroarylene; R¹⁴ is selected from (R¹³)_(p)-alkylene, (R¹³)_(p)-heteroalkylene, (R¹³)_(p)-arylene, and (R¹³)_(p)-heteroarylene, R¹⁵ is selected from (R¹⁴)_(p)-alkylene, (R¹⁴)_(p)-heteroalkylene, (R¹⁴)_(p)-arylene, and (R¹⁴)_(p)-heteroarylene, and p is selected from 0, 1, 2, 3, 4 and 5.

[0056] In any of the above embodiments, in a further embodiment, each of R⁴ and R⁵ is hydrogen.

[0057] In any of the above embodiments unless otherwise inconsistent with a previous definition, in a further embodiment, at least one of R⁴ and R⁵ is selected from C₁-C₁₅alkyl, heteroalkyl, and C₆-C₁₀aryl.

[0058] In any of the above embodiments unless otherwise inconsistent with a previous definition, in a further embodiment, one of R⁴ and R⁵ is hydrogen and the other of R⁴ and R⁵ is selected from hydrogen, —OR⁹, —NR⁹R⁹ and —N═N—R⁹ where the R⁹ is selected from hydrogen, R¹¹, R¹², R¹³, R¹⁴ and R¹⁵ where R¹¹ is selected from alkyl, heteroalkyl, aryl and heteroaryl; R¹² is selected from (R¹¹)_(p)-alkylene, (R¹¹)_(p)-heteroalkylene, (R¹¹)_(p)-arylene and (R¹¹)_(p)-heteroarylene; R¹³ is selected from (R¹²)_(p)-alkylene, (R¹²)_(p)-heteroalkylene, (R¹²)_(p)-arylene, and (R¹²)_(p)-heteroarylene; R¹⁴ is selected from (R¹³)_(p)-alkylene, (R¹³)_(p)-heteroalkylene, (R¹³)_(p)-arylene, and (R¹³)_(p)-heteroarylene, R¹⁵ is selected from (R¹⁴)_(p)-alkylene, (R¹⁴)_(p)-heteroalkylene, (R¹⁴)_(p)-arylene, and (R¹⁴)_(p)-heteroarylene, and p is selected from 0, 1, 2, 3, 4 and 5.

[0059] In any of the above embodiments unless otherwise inconsistent with a previous definition. in a further embodiment, R⁴ and R⁵ together form a group selected from ═O, ═CR⁸R⁸ and ═NR¹⁰.

[0060] In any of the above embodiments unless otherwise inconsistent with a previous definition, in a further embodiment R⁴ and R⁵ together form ═O.

[0061] In any of the above embodiments unless otherwise inconsistent with a previous definition, in a further embodiment R⁴ and R⁵ together form ═NR¹⁰ and R¹⁰ is —OR⁹ where R⁹ is selected from hydrogen, C₆-C₁₀aryl, C₁-C₈alkyl, heteroalkyl, (C₆-C₁₀aryl)heteroalkyl, (C₆-C₁₀aryl)C₁-C₁₅alkylene, (heteroalkyl)_(p)(heteroarylene)C₁-C₁₅alkylene, (heteroalkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene, and (C₁-C₁₅alkyl)_(p)(C₆-C₁₀arylene)heteroalkylene.

[0062] In any of the above embodiments unless otherwise inconsistent with a previous definition, in a further embodiment R⁴ and R⁵ together form ═NR¹⁰ and R¹⁰ is —N(R⁹)(R⁹) where R⁹ is selected from hydrogen, C₁-C₈alkyl, heteroalkyl, C₆-C₁₀aryl, (C₆-C₁₀aryl)heteroalkylene, (heteroalkyl)_(p)C₆-C₁₀arylene, (C₁-C₁₅alkyl)_(p)C₆-C₁₀arylene, (heteroalkyl)_(p)(C₆-C₁₀arylene)heteroalkylene, (C₁-C₁₅alkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene, and (C₁-C₁₅alkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅heteroalkylene.

[0063] In any of the above embodiments unless otherwise inconsistent with a previous definition, in a further embodiment R⁴ and R⁵ together form ═CR⁸R⁸, and one of R⁸ is hydrogen while the other R⁸ is selected from hydrogen, C₁-C₈alkyl and heteroalkyl.

[0064] In any of the above embodiments unless otherwise inconsistent with a previous definition, in a further embodiment R⁸ is selected from hydrogen and C₁-C₈alkyl, and R¹⁰ is selected from hydrogen, R¹¹, R¹², R¹³, R¹⁴ and R¹⁵ where R¹¹ is selected from alkyl, heteroalkyl, aryl and heteroaryl; R¹² is selected from (R¹¹)_(p)-alkylene, (R¹¹)_(p)-heteroalkylene, (R¹¹)_(p)-arylene and (R¹¹)_(p)-heteroarylene; R¹³ is selected from (R¹²)_(p)-alkylene, (R¹²)_(p)-heteroalkylene, (R¹²)_(p)-arylene, and (R¹²)_(p)-heteroarylene; R¹⁴ is selected from (R¹³)_(p)-alkylene, (R¹³)_(p)-heteroalkylene, (R¹³)_(p)-arylene, and (R¹³)_(p)-heteroarylene, R¹⁵ is selected from (R¹⁴)_(p)-alkylene, (R¹⁴)_(p)-heteroalkylene, (R 4)_(p)-arylene, and (R¹⁴)_(p)-heteroarylene, and p is selected from 0, 1, 2, 3, 4 and 5.

[0065] In any of the above embodiments unless otherwise inconsistent with a previous definition, in a further embodiment R⁸ is hydrogen.

[0066] In any of the above embodiments unless otherwise inconsistent with a previous definition, in a further embodiment R¹⁰ is R¹¹.

[0067] In any of the above embodiments unless otherwise inconsistent with a previous definition, in a further embodiment R⁴ and R⁵ together with the carbon to which they are both attached form a spiro carbocyclic or heterocyclic ring.

[0068] In any of the above embodiments unless otherwise inconsistent with a previous definition, in a further embodiment R⁶ is selected from hydrogen, R¹¹, R¹², R¹³, R¹⁴ and R¹⁵ where R¹¹ is selected from alkyl, heteroalkyl, aryl and heteroaryl; R¹² is selected from (R¹¹)_(p)-alkylene, (R¹¹)_(p)-heteroalkylene, (R¹¹)_(p)-arylene and (R¹¹)_(p)-heteroarylene; R¹³ is selected from (R¹²)_(p)-alkylene, (R¹²)_(p)-heteroalkylene, (R¹²)_(p)-arylene, and (R¹²)_(p)-heteroarylene; R¹⁴ is selected from (R¹³)_(p)-alkylene, (R¹³)_(p)-heteroalkylene, (R¹³)_(p)-arylene, and (R¹³)_(p)-heteroarylene, R¹⁵ is selected from (R¹⁴)_(p)-alkylene, (R¹⁴)_(p)-heteroalkylene, (R¹⁴)_(p)-arylene, and (R¹⁴)_(p)-heteroarylene, and p is selected from 0, 1, 2, 3, 4 and 5.

[0069] In any of the above embodiments unless otherwise inconsistent with a previous definition, in a further embodiment R⁶ is selected from C₁-C₁₅alkyl, C₁-C₁₅heteroalkyl, (C₆-C₁₀aryl)C₁-C₁₅alkylene, (C₆aryl)(C₆aryl)C₁-C₁₅alkylene, (C₂-C₆heteroaryl)C₁-C₁₅alkylene, (C₆-C₁₀aryl)C₁-C₁₅heteroalkylene, (heteroalkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene, (heteroalkyl)_(p)(C₂-C₆heteroarylene)C₁-C₁₅alkylene, and (heteroalkyl)_(p)(C₆arylene)(heteroalkylene)(C₆arylene)C₁-C₁₅alkylene.

[0070] In any of the above embodiments unless otherwise inconsistent with a previous definition, in a further embodiment R⁶ is an inorganic group having 1-8 atoms exclusively selected from boron, sulfur, phosphorous, silicon and hydrogen. Separately, in any of the above embodiments, R⁶ excludes inorganic group having 1-8 atoms exclusively selected from boron, sulfur, phosphorous, silicon and hydrogen.

[0071] In any of the above embodiments unless otherwise inconsistent with a previous definition, in a further embodiment R⁶ is hydrogen.

[0072] In any of the above embodiments unless otherwise inconsistent with a previous definition, in a further embodiment n is 0.

[0073] In any of the above embodiments unless otherwise inconsistent with a previous definition, in a further embodiment n is 1.

[0074] In any of the above embodiments unless otherwise inconsistent with a previous definition, in a further embodiment R³ is hydrogen; R⁴ and R⁵ are selected from (a) R⁴ is hydrogen and R⁵ is hydroxyl or protected hydroxyl and (b) R⁴ and R⁵ together form carbonyl; R⁶ is hydrogen; and n is 0.

[0075] In any of the above embodiments unless otherwise inconsistent with a previous definition, in a further embodiment R² is —OR⁹.

[0076] In any of the above embodiments unless otherwise inconsistent with a previous definition, in a further embodiment R² is —OCH₂CH₂Si(CH₃)₃.

[0077] In any of the above embodiments unless otherwise inconsistent with a previous definition, in a further embodiment R¹ is

[0078] In any of the above embodiments unless otherwise inconsistent with a previous definition, in a further embodiment R⁹ is a C₁-C₆ hydrocarbyl.

[0079] In any of the above embodiments unless otherwise inconsistent with a previous definition, in a further embodiment R⁹ is selected from n-propyl and —CH₂—CH═CH₂.

[0080] In any of the above embodiments unless otherwise inconsistent with a previous definition, in a further embodiment R¹ is

[0081] In any of the above embodiments unless otherwise inconsistent with a previous definition, in a further embodiment, R⁸ is hydrogen and R⁹ is C₁-C₆ hydrocarbyl.

[0082] In any of the above embodiments unless otherwise inconsistent with a previous definition, in a further embodiment, R⁹ is —CH₂—CH═CH₂.

[0083] In any of the above embodiments unless otherwise inconsistent with a previous definition, in a further embodiment the stereochemistry of the R¹ and C(═O)R² groups being as shown in formula Ia, with R¹ and C(═O)R² in a cis arrangement, both over the benzo ring substituted with —OR⁶

[0084] In any of the above embodiments unless otherwise inconsistent with a previous definition, in a further embodiment the stereochemistry of the R¹ and C(═O)R² groups being as shown in formula Ib, with R¹ and C(═O)R² in a trans arrangement, with only C(═O)R² over the benzo ring substituted with —OR⁶

[0085] In any of the above embodiments unless otherwise inconsistent with a previous definition, in a further embodiment the stereochemistry of the R¹ and C(═O)R² groups being as shown in formula Ic, with R¹ and C(═O)R² in a trans arrangement, with only R¹ over the benzo ring substituted with —OR⁶

[0086] In any of the above embodiments unless otherwise inconsistent with a previous definition, in a further embodiment the stereochemistry of the R¹ and C(═O)R² groups being as shown in formula Id, with R¹ and C(═O)R² in a cis arrangement, with neither of the R¹ nor C(═O)R² groups being over the benzo ring substituted with —OR⁶

[0087] In another embodiment, the present invention provides a composition 10 comprising a compound, or a combination of compounds, according to any one of the above-described embodiments, and a pharmaceutically acceptable carrier, adjuvant or incipient.

[0088] In another embodiment, the present invention provides a method for inhibiting a TNF-α mediated processes, comprising administering to a patient in need thereof, through a therapeutically or prophylactically acceptable manner, a therapeutically or pharmaceutically effective amount of a composition comprising a compound or a mixture of compounds according to any of the above-described embodiments. In one embodiment, the administering is selected from transdermal, oral, intravenous, intramuscular, vaginal, rectal, pulmonary, subcutaneous, sublingual and transmucosal administration.

[0089] In another embodiment, the present invention provides a method for treating an inflammation event, comprising administering to a patient in need thereof, through a therapeutically or prophylactically acceptable manner, a therapeutically or pharmaceutically effective amount of a composition comprising a compound or a mixture of compounds according to any of the above-described embodiments. In one embodiment, the administering is selected from transdermal, oral, intravenous, intramuscular, vaginal, rectal, pulmonary, subcutaneous, sublingual and transmucosal administration.

[0090] In another embodiment, the present invention provides a library of benzobicyclooctane compounds where said library comprises a plurality of compounds each having a structure of formula (I) as describe above, including inventive embodiments thereof as set forth above, where diversity is present among the R¹, R², R³, R⁴, R⁵, R⁶, and R⁷ groups.

[0091] In another embodiment, the present invention provides a process for preparing a combinatorial library of benzobicyclooctane compounds, wherein said library comprises a plurality of compounds of formula (I), including inventive embodiments thereof as set forth above, said process comprising the steps:

[0092] (a) providing a compound bound to a solid support according to formula (II)

[0093] wherein PG1 and PG2 refer to first and second protecting groups, respectively, where the first protecting group can be removed in the continued presence of the second protecting group, and the second protecting group can be removed in the continued presence of the linker, and (SS) refers to a solid support;

[0094] (b) removing the first protecting group but not the second protecting group, to provide a first deprotected product;

[0095] (c) reacting the first deprotected product with a plurality of amines of the formula HNRR′ to provide a plurality of compounds bound to a solid support, each according to formula (IIa)

[0096] where R and R′ are each independently selected from R⁹;

[0097] (d) removing the second protecting group from (IIa) to provide a second deprotected product;

[0098] (e) reacting the second deprotected product with a plurality of amines of the formula HNR″R′″ to provide a plurality of compounds bound to a solid support, each according to formula (IIb)

[0099] where R′ and R′″ are each independently selected from R⁹;

[0100] (f) removing the scaffold from the linker to provide a library of compounds according to formula (IIc)

[0101] These and other embodiments of the present invention are described in further detail below.

DETAILED DESCRIPTION OF THE INVENTION

[0102] Before providing a detailed description of the invention, a number of terms as used herein are defined as follows:

Definition of Terms

[0103] As used herein, the following terms have the indicated meanings.

[0104] Unless otherwise indicated, the term “a” refers to one or more than one of the indicated items. For example, “a compound” includes one and more than one compound.

[0105] “Alkyl” is a saturated or unsaturated, straight or branched, hydrocarbon chain. In various embodiments, the alkyl group has 1-18 carbon atoms, i.e., is a C1-C18 group, or is a C1-C12 group, a C1-C6 group, or a C1-C4 group. Independently, in various embodiments, the alkyl group has zero branches (i.e., is a straight chain), one branch, two branches, or more than two branches. Independently, in one embodiment, the alkyl group is saturated. In another embodiment, the alkyl group is unsaturated. In various embodiments, the unsaturated alkyl may have one double bond, two double bonds, more than two double bonds, and/or one triple bond, two triple bonds, or more than two triple bonds. Alkyl chains may be substituted or unsubstituted. In one embodiment, the alkyl chains are unsubstituted. In another embodiment, the alkyl chain is substituted, e.g., with 1 substituent (i.e., the alkyl group is monosubstituted), or 1-2 substituents, or 1-3 substituents, or 1-4 substituents, etc.

[0106] “Aryl” is an aromatic hydrocarbon ring system. The ring system may be monocyclic or fused polycyclic (e.g., bicyclic, tricyclic, etc.). In various embodiments, the monocyclic aryl ring is C5-C10, or C5-C7, or C5-C6, where these carbon numbers refer to the number of carbon atoms that make up the ring system. A C6 ring system, i.e., a phenyl ring, is a preferred aryl ring. In various embodiments, the polycyclic ring is a bicyclic aryl ring, where preferred bicyclic aryl rings are C8-C12, or C9-C10. A naphthyl ring, which has 10 carbon atoms, is a preferred polycyclic aryl ring. Aryl rings may be substituted or unsubstituted. In one embodiment, the aryl ring is unsubstituted. In another embodiment, the aryl ring is substituted with 1 substituent (i.e., the aryl ring is monosubstituted), or 1-2 substituents, or 1-3 substituents, or 1-4 substituents, etc.

[0107] “Carbocyclic aliphatic ring,” also referred to as carbocycle, is a saturated or unsaturated, monocyclic or polycyclic (e.g., bicyclic, tricyclic, etc.) hydrocarbon ring. Carbocyclic aliphatic rings are not aromatic. A polycyclic hydrocarbon ring may include fused, spiro or bridged ring structures. In various embodiments, the monocyclic carbocyclic aliphatic ring is a C3-C10, or a C4-C7, or a C5-C6 ring system. In various embodiments, the polycyclic carbocyclic aliphatic ring is a C6-C12, or a C9-C10 ring system. In one embodiment, the polycyclic ring is bicyclic. In another embodiment, the polycyclic ring is bicyclic or tricyclic. Carbocyclic aliphatic rings include cyclopropyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl. Carbocycles may be substituted or unsubstituted. In one embodiment, the carbocycle is unsubstituted. In another embodiment, the carbocycle is substituted with, e.g., 1 substituent (i.e., the alkyl group is monosubstituted), or 1-2 substituents, or 1-3 substituents, or 1-4 substituents, etc.

[0108] “Haloalkyl” is an alkyl chain substituted with one or more halogens. A preferred haloalkyl is trifluoromethyl.

[0109] “Heteroalkyl” is a saturated or unsaturated, straight or branched, chain containing carbon and at least one heteroatom. The heteroalkyl group may, in various embodiments, have one heteroatom, or 1-2 heteroatoms, or 1-3 heteroatoms, or 1-4 heteroatoms. Heteroalkyl chains may contain from 1 to 18 (i.e., 1-18) member atoms (carbon and heteroatoms) in the chain, and in various embodiments contain 1-12, or 1-6, or 1-4 member atoms. Independently, in various embodiments, the heteroalkyl group has zero branches (i.e., is a straight chain), one branch, two branches, or more than two branches. Independently, in one embodiment, the heteroalkyl group is saturated. In another embodiment, the heteroalkyl group is unsaturated. In various embodiments, the unsaturated heteroalkyl may have one double bond, two double bonds, more than two double bonds, and/or one triple bond, two triple bonds, or more than two triple bonds. Heteroalkyl chains may be substituted or unsubstituted. In one embodiment, the heteroalkyl chain is unsubstituted. In another embodiment, the heteroalkyl chain is substituted. A substituted heteroalkyl chain may have 1 substituent (i.e., be monosubstituted), or may have 1-2 substituents, or 1-3 substituents, or 1-4 substituents, etc. Exemplary heteroalkyl groups include esters (—C(═O)—OR) and ketones (—C(═O)—).

[0110] “Heteroaryl” is an aromatic ring system or a semi-aromatic system of rings or a pseudo aromatic ring or rings containing carbon and at least one heteroatom in at least one of the rings. The heteroaryl group may, in various embodiments, have one heteroatom, or 1-2 heteroatoms, or 1-3 heteroatoms, or 1-4 heteroatoms in the ring. The heteroaryl group may further include more than one ring system, which in various embodiments may include one heteroatom or 1-2 heteroatoms, or 1-3 heteroatoms, or 1 heteroatom in each ring system, or 1-4 heteroatoms in each ring system. The heteroaryl group which comprises more than one ring system may, in various embodiments have one or more than one of the ring systems aromatic. Heteroaryl rings may be monocyclic or polycyclic, where the polycyclic ring may contained fused, spiro or bridged ring junctions. In one embodiment, the heteroaryl is selected from monocyclic and bicyclic. Monocyclic heteroaryl rings may contain from about 5 to about 10 member atoms (carbon and heteroatoms), preferably from 5-7, and most preferably from 5-6 member atoms in the ring. Bicyclic heteroaryl rings may contain from about 8-12 member atoms, or 9-10 member atoms in the ring. The heteroaryl ring may be unsubstituted or substituted. In one embodiment, the heteroaryl ring is unsubstituted. In another embodiment, the heteroaryl ring is substituted. The substituted heteroaryl ring may contain 1 substituent, or 1-2 substituents, or 1-3 substituents, or 1-4 substituents, etc. Exemplary heteroaryl rings include benzofuran, benzothiophene, furan, imidazole, indole, isothiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, quinoline, thiazole and thiophene.

[0111] “Heteroatom” is a nitrogen, sulfur, oxygen or silicon atom. Groups containing more than one heteroatom may contain different heteroatoms.

[0112] “Heterocyclic aliphatic ring,” also referred to as “heterocyclyl”, is a saturated or unsaturated, monocyclic or polycyclic (e.g., bicyclic, tricyclic, etc.) ring containing carbon and at least one heteroatom. Heterocyclic aliphatic rings are not aromatic per se but may be pseudo-aromatic and/or readily be made aromatic through methods known in the art. The heterocyclic aliphatic ring may, in various embodiments, have one heteroatom, or 1-2 heteroatoms, or 1-3 heteroatoms, or 1-4 heteroatoms, etc. In one embodiment, the heterocyclic aliphatic ring is monocyclic, where the monocyclic ring may have 3-10, or 4-7, or 5-6 member atoms. In another- embodiment, the heterocyclic aliphatic ring is polycyclic, where in various embodiments, the ring may be bicyclic, or may be tricyclic, or may be either bicyclic or tricyclic. A polycyclic ring system may have one or more fused, spiro or bridged ring systems. The polycyclic heterocyclic aliphatic ring system may have 6-12, or 9-10 member atoms. The heterocyclic ring may be unsubstituted or substituted. In one embodiment, the heterocyclic ring is unsubstituted. In another embodiment, the heterocyclic ring is substituted. The substituted heterocyclic ring may contain 1 substituent, or 1-2 substituents, or 1-3 substituents, or 1-4 substituents, etc. Exemplary heterocyclic aliphatic rings include piperazyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl and piperidyl.

[0113] “Inorganic groups having 1-8 atoms exclusively selected from boron, sulfur, phosphorous, silicon and hydrogen” refers to, for example, borates, sulfates, phosphates, silicates, and acids thereof.

[0114] “Lower alkyl” is an alkyl chain comprised of 1-6, preferably 1-4 carbon atoms.

[0115] “Pharmaceutically acceptable salt” and “salts thereof” means organic or inorganic salts of the pharmaceutically important molecule. A pharmaceutically acceptable salt may involve the inclusion of another molecule such as an acetate ion, a succinate ion or other counterion. The counterion may be any organic or inorganic moiety that stabilizes the charge on the parent compound. Furthermore, a pharmaceutically important organic molecule may have more than one charged atom in its structure. Situations where multiple charged atoms are part of the molecule may have multiple counterions. Hence, the molecule of a pharmaceutically acceptable salt may contain one or more than one charged atoms and may also contain, one or more than one counterion. The desired charge distribution is determined according to methods of drug administration. Examples of pharmaceutically acceptable salts are well known in the art but, without limiting the scope of the present invention, exemplary presentations can be found in the Physician's Desk Reference, The Merck Index, The Pharmacopoeia and Goodman & Gilman's The Pharmacological Basis of Therapeutics.

[0116] “Substituents” replace a hydrogen atom with a non-hydrogen atom on an alkyl, heteroalkyl, aryl, heteroaryl, carbocycle, and/or heterocyclyl group as defined herein. Where the substituent contains a heteroatom, that heteroatom may be at any acceptable oxidation state for that particular atom, e.g., sulfur as part of a substituent may vary from an oxidation state of −2 to +8, and may be part of a complex or chelate as in a sulfoxide a mercapto-phosphine or metal chelated in a thia-crown ether. Suitable substituents that may be located on one or more of these groups include the following: hydroxy, alkoxy (i.e., alkyl-O—, e.g., methoxy, ethoxy, propoxy, butoxy, pentoxy), aryloxy (e.g., phenoxy, chlorophenoxy, tolyloxy, methoxyphenoxy, benzyloxy, alkyloxycarbonylphenoxy, acyloxyphenoxy), acyloxy (e.g., propionyloxy, benzoyloxy, acetoxy), carbamoyloxy, carboxy, mercapto, alkylthio, acylthio, arylthio (e.g., phenylthio, chlorophenylthio, alkylphenylthio, alkoxyphenylthio, benzylthio, alkyloxycarbonyl-phenylthio), sulfonamido (—N(R⁹)SO₂R⁹ or —SO₂NR⁹R⁹), amino (e.g., amino, mono- and di-C₁-C₃ alkanylamino, methylphenylamino, methylbenzylamino, C₁-C₃ alkanylamido, acylamino, carbamamido, ureido, guanidino, nitro, cyano and imino). Moreover, any substituent may have from 1-5 further substituents attached thereto.

[0117] “Amino” means a nitrogen atom substituted with up to 4 groups, for instance, 2 or 3 alkyl groups as defined above, or 1 or 2 alkyl groups and a hydrogen group, or with one or two aryl groups and one or two alkyl groups so that the total number of groups is 2 or 3, or with two or three aryl groups, or with two or more hydrogen atoms or with other the substitution required to complete the nitrogen's valence requirements. “Amino” further includes amino salts where the nitrogen is hypervalent, having four bonds and may or may not have a charge and a counterion. The counterion, when present, may be an external inorganic and/or organic counterion and/or may be an internal counterion. Inorganic counterions include, for example, anions such as halo anions and other non-metal anions. Examples of organic counterions include, for example, anionic organic moieties such as acetate, citrate and other anionic organic moieties. Thus, amino refers to quaternary ammonium groups, tertiary amines and salts thereof, secondary amines and salts thereof, and primary amines and salts thereof.

[0118] As used herein and in the appended claims a “library” means a large number of chemical derivatives used in screening for biological activity or other activity. In general a library will have greater than 20 members, preferably the library will have at least 50 members, more preferably the library will have at least 96 members and most preferably the library will have at least 1000 members.

[0119] As used herein and in the appended claims “scaffold” means a common chemical structure found within a library of organic compounds. Similarly, within a combinatorial chemical library the scaffold forms the basis for a diverse series of chemical derivatization, additions and subtractions. Importantly, regardless of the extent of the chemical derivatization performed on the scaffold, the product is within the scope of the combinatorial library.

[0120] “Inflammation event” or “inflammation” or “swelling” are synonymous terms that mean an abnormal enlargement of a portion or tissue of an animal. The abnormal enlargement may be the normal, expected result of another event, such as, for example, sepsis, fever, trauma, shock, or injury. Non-limiting examples of some of these events include sepsis due to renal or liver failure, fever secondary to systemic infection, localized fever secondary to local infection, blunt force trauma or emotional trauma having physical manifestations, shock secondary to trauma and/or other events causing a pooling of body fluids and an injury causing release of cellular fluids initiating the inflammation cascade.

[0121] As used herein, “commercially available chemicals” and the chemicals used in the Examples set forth herein may be obtained from standard commercial sources including Acros Organics (Pittsburgh Pa.), Aldrich Chemical (Milwaukee Wis., including Sigma Chemical and Fluka), Apin Chemicals Ltd. (Milton Park UK), Avocado Research (Lancashire U.K.), BDH Inc. (Toronto, Canada), Bionet (Cornwall, U.K.),Chemservice Inc. (West Chester Pa.), Crescent Chemical Co. (Hauppauge N.Y.), Eastman Organic Chemicals, Eastman Kodak Company (Rochester N.Y.), Fisher Scientific Co. (Pittsburgh Pa.), Fisons Chemicals (Leicestershire UK), Frontier Scientific (Logan Utah), ICN Biomedicals, Inc. (Costa Mesa Calif.), Key Organics (Cornwall U.K.), Lancaster Synthesis (Windham N.H.), Maybridge Chemical Co. Ltd. (Cornwall U.K.), Parish Chemical Co. (Orem Utah), Pfaltz & Bauer, Inc. (Waterbury Conn.), Polyorganix (Houston Tex.), Pierce Chemical Co. (Rockford Ill.), Riedel de Haen AG (Hannover, Germany), Spectrum Quality Product, Inc. (New Brunswick, N.J.), TCI America (Portland Oreg.), Trans World Chemicals, Inc. (Rockville Md.), and Wako Chemicals USA, Inc. (Richmond Va.).

[0122] As used herein, “compounds described in the chemical literature” may be identified though various reference books and databases. Suitable reference books and treatise that detail the synthesis of reactants useful in the preparation of compounds of the present invention, or provide references to articles that describe the preparation, include for example, “Synthetic Organic Chemistry”, John Wiley & Sons, Inc., New York; S. R. Sandler et al., “Organic Functional Group Preparations,” 2nd Ed., Academic Press, New York, 1983; H. O. House, “Modem Synthetic Reactions”, 2nd Ed., W. A. Benjamin, Inc. Menlo Park, Calif. 1972; T. L. Gilchrist, “Heterocyclic Chemistry”, 2nd Ed., John Wiley & Sons, New York, 1992; J. March, “Advanced Organic Chemistry: Reactions, Mechanisms and Structure”, 4th Ed., Wiley-Interscience, New York, 1992. Specific and analogous reactants may also be identified through the indices of known chemicals prepared by the Chemical Abstract Service of the American Chemical Society, which are available in most public and university libraries, as well as through on-line databases (the American Chemical Society, Washington, D.C., www.acs.org may be contacted for more details). Chemicals that are known but not commercially available in catalogs may be prepared by custom chemical synthesis houses, where many of the standard chemical supply houses (e.g., those listed above) provide custom synthesis services.

[0123] As used herein “suitable conditions” for carrying out a synthetic step are explicitly provided herein or may be discerned by reference to publications directed to methods used in synthetic organic chemistry. The reference books and treatise set forth above that detail the synthesis of reactants useful in the preparation of compounds of the present invention, will also provide suitable conditions for carrying out a synthetic step according to the present invention.

[0124] All other acronyms and abbreviations have the corresponding meaning as published in journals relative to the art of organic chemistry.

[0125] A. Compounds

[0126] In one aspect, the present invention provides benzobicyclooctane compounds of formula (I)

[0127] and optical isomers, diastereomers, enantiomers and pharmaceutically acceptable salts thereof in isolation (i.e., isolated from one another) or in mixture (i.e., two or more compounds in admixture with one another), where, independently at each location:

[0128] R¹ is selected from the following six formulae:

[0129] R² is —OR⁹ or —NR⁹R⁹;

[0130] R³ is selected from hydrogen, halogen, hydroxyl or protected hydroxyl, amino or protected amino, and C₁-C₈alkyl or C₁-C₈haloalkyl;

[0131] R⁴ and R⁵ are independently selected from R⁹, —OR⁹, —NR⁹R⁹ and —N═N—R⁹, or R⁴ and R⁵ may together form a group selected from ═O, ═CR⁸R⁸ and ═NR¹⁰, or R⁴ and R⁵ may together with the carbon to which they are both attached form a spiro carbocyclic or heterocyclic ring;

[0132] R⁶ is selected from hydrogen, inorganic groups having 1-8 atoms exclusively selected from boron, sulfur, phosphorous, silicon and hydrogen, and organic groups having 1-20 carbons and optionally containing 1-4 heteroatoms selected from nitrogen, oxygen and silicon;

[0133] R⁷ is selected from halogen, hydroxyl or protected hydroxyl, amino or protected amino, and C₁-C₈alkyl or C₁-C₈haloalkyl;

[0134] R⁸ is selected from hydrogen, alkyl (preferably C₁-C₈alkyl), aryl and heteroalkyl;

[0135] R⁹ is selected from hydrogen and organic groups having 1-30 carbons and optionally containing 1-4 heteroatoms selected from nitrogen, oxygen and silicon, with the proviso that two R⁹ groups both joined to a common atom may be joined together so as to form a ring with the common atom;

[0136] R¹⁰ is selected from —R⁹, —OR⁹, —NR⁹R⁹, —NH—C(O)R⁹; —NH—C(O)OR⁹ and —NH—C(S)NHR⁹; and

[0137] n is 0, 1, 2 or 3.

[0138] In one embodiment, when R⁶ is hydrogen and R⁴ and R⁵ together form ═O and R¹ is CO₂R⁹, then R² is not OCH₃. In one embodiment, R⁴ and R⁵ are both hydrogen, while in another embodiment R⁴ is not hydrogen when R⁵ is hydrogen.

[0139] In formula (1), the two wavy lines (one connected to R¹, the other connected to C(═O)R²) indicate that the invention provides any possible stereochemistry for the R¹ and C(═O)R² groups. In other words, the present invention provides benzobicyclooctanes having each of the four relative stereochemistries shown below as formulae (Ia), (Ib), (Ic) and (Id).

[0140] In individual aspects the present invention provides compounds of formulae Ia through Io, where each of Ia through Io is made up of one or more of the compounds of formula Ia, Ib, Ic and Id. An “x” in a box to the right of the designation Ia through Io indicates which of Ia, Ib, Ic and Id is contained within the designated formula. Thus, for instance, the compounds of formula Ij contain the compounds within formulae Ic and Id (as an “x” is present in the columns designated Ic and Id), but do not include the compounds of formula Ia or Ib (as no “x” appears in the columns designated Ia and Ib) in the row designated formula Ij. TABLE A Code Formula No. Ia Ib Ic Id Ia x Ib x Ic x Id x Ie x x If x x Ig x x Ih x x Ii x x Ij x x Ik x x x Il x x x Im x x x In x x x Io x x x x

[0141] Thus, as shown in Table A, in one aspect the present invention provides compounds of formula Ia, while in a separate aspect the present invention provides compounds of formula Ib; while in a still separate aspect the present invention provides compounds of formula Ic. In another aspect, the present invention provides compounds of formula Id, while in another aspect the present invention provides compounds of formula Ie (containing the set of compounds within formulae Ia and Ib), and in another aspect the present invention provides compounds of formula If (containing the set of compounds within formulae Ia and Ic). In still another aspect the present invention provides compounds of formula Ig, and in another aspect provides compounds of formula Ih, while in another aspect the invention provides compounds of formula Ii, and in yet another aspect the present invention provides compounds of formula Ij. In a separate aspect, the present invention provides compounds of formula Ik, while in another aspect the present invention provides compound of formula Il, and in still another aspect the invention provides compounds of formula Im. In addition, the present invention provides compounds of formula In, while in another aspect the present invention provides compounds of formula Io. Thus, using a convenient shorthand, it may be said that in various aspects the present invention provides benzybicyclooctane compounds of formulae: (Ia); (Ib); (Ic); (Id); (Ie); (If); (Ig); (Ih); (Ii); (Ij); (Ik); (II); (Im); (In); (Io). In each of the above-listed aspects, the compounds include optical isomers, diastereomers, enantiomers and pharmaceutically acceptable salts thereof in isolation or mixture, where, independently at each location, the substituents R¹, R¹ etc. are as defined herein.

[0142] In the compounds of the present invention, R¹ is selected from the following six formulae, identified as R1a, R1b, R1c, R1d, R1e and R1f as defined below in Table B. TABLE B

R1a R1b R1c

R1d R1e R1f

[0143] Thus, in compounds of the invention, R¹ may be one or more of R1a, R1b, R1c, R1d, R1e and R1f. Table C defines groups R1A through R1BJ, where each of R1A through R1BJ is composed of one or more of R1a, R1b, R1c, R1d, R1e and R1f. For example, as shown in Table C, R1A is defined as formula R1a but not any of R1b through R1f. As another example, R1G is defined as the sum of R1a and R1b, but does not include R1c through R1f. As a final example, R1BI is the sum of R1b through R1f, and excludes only R1a TABLE C R1 R1 a b c d e f A X B X C X D X E X F X G X X H X X I X X J X X K X X L X X M X X N X X O X X P X X Q X X R X X S X X T X X U X X V X X X W X X X X X X X Y X X X Z X X X AA X X X AB X X X AC X X X AD X X X AE X X X AF X X X AG X X X AH X X X AI X X X AJ X X X AK X X X AL X X X AM X X X AN X X X AO X X X AP X X X X AQ X X X X AR X X X X AS X X X X AT X X X X AU X X X X AV X X X X AW X X X X AX X X X X AY X X X X AZ X X X X BA X X X X BB X X X X BC X X X X BD X X X X X BE X X X X X BF X X X X X BG X X X X X BH X X X X X BI X X X X X BJ X X X X X X

[0144] Thus, in one aspect, the present invention provides compounds of formula (I) where R¹ is R1A. In another aspect, the invention provides compounds of formula (I) where R¹ is R1B. In another aspect, the invention provides compounds of formula (I) where R¹ is R1C. In another aspect, the invention provides compounds of formula (I) where R¹ is R1D. In another aspect, the invention provides compounds of formula (I) where R¹ is R1C. In another aspect, the invention provides compounds of formula (I) where R¹ is R1F. In other words, stated in a convenient shorthand nomenclature, in various aspects the present invention provides “Compounds of formula (I) where: R¹ is R1A; R¹ is R1B; R¹ is R1C; R¹ is R1D; R¹ is R1E; R¹ is R1F.”

[0145] Using this same shorthand nomenclature, in various aspects the present invention provides compounds of formula (I) where: R¹ is R1G; R¹ is R1H; R¹ is R1I; R¹ is R1J; R¹ is R1K; R¹ is R1L; R¹ is R1M; R¹ is R1N; R¹ is R1O; R¹ is R1P; R¹ is R1Q; is R1R; R¹ is R1S; R¹ is R1T; R¹ is R1U; R¹ is R1V; R¹ is R1W; R¹ is R1X; R¹ is R1Y; R¹ is R1Z; R¹ is R1AA; R¹ is R1AB; R¹ is, R1AC; R¹ is R1AD; R¹ is R1AE; R¹ is R1AF; R¹ is R1AG; R¹ is R1AH; R¹ is R1AI; R¹ is R1AJ; R¹ is R1AK; R¹ is R1AL; R¹ is R1AM; R¹ is R1AN; R¹ is R1AO; R¹ is R1AP; R¹ is R1AQ; R¹ is R1AR; R¹ is R1 AS; R¹ is R1AT; R¹ is R1AU; R¹ is R1AV; R¹ is R1AW; R¹ is R1AX; R¹ is R1AY; R¹is R1AZ; R¹ is R1BA; R¹ is R1BB; R¹ is R1BC; R¹ is R1BD; R¹ is R1BE; R¹ is R1BF; R¹ is R1BG; R¹ is R1BH; R¹ is R1BI; R¹ is R1BJ.

[0146] In separate aspects, the present invention provides compounds of formulae (Ia)-(Io) as defined in Table B wherein R¹ is selected from R1A through R1BJ as defined in Table C. Each of these aspects is given a unique identifier, X1 through X937 in Table D, where each of X1 through X937 is a separate and unique aspect of the present invention. In each of X1 through X937, R² is —OR⁹ or NR⁹R⁹. The present invention also provides aspects Y1 through Y937 as defined in Table E, which are analogous to aspects X1 through X937 in terms of formula (Ia)-(Io) and R¹, however in aspects Y1 through Y937 R² is limited to —OR⁹. The present invention also provides aspects Z1 through Z937 as defined in Table F, which are analogous to aspects X1 through X937 in terms of formula (Ia)-(Io) and R¹, however in aspects Z1 through Z937 R² is limited to —NR⁹R⁹. TABLE D R1 Ia Ib Ic Id Ie If Ig Ih Ii Ij Ik Il Im In Io A X1  X63  X125 X187 X249 X311 X373 X435 X497 X559 X621 X683 X745 X807 X869 B X2  X64  X126 X188 X250 X312 X374 X436 X498 X560 X622 X684 X746 X808 X870 C X3  X65  X127 X189 X251 X313 X375 X437 X499 X561 X623 X685 X757 X809 X871 D X4  X66  X128 X190 X252 X314 X376 X438 X500 X562 X624 X686 X748 X810 X872 E X5  X67  X129 X191 X253 X315 X377 X439 X501 X563 X625 X687 X749 X811 X873 F X6  X68  X130 X192 X254 X316 X378 X440 X502 X564 X626 X688 X750 X812 X874 G X7  X69  X131 X193 X255 X317 X379 X441 X503 X565 X627 X689 X751 X813 X875 H X8  X70  X132 X194 X256 X318 X380 X442 X504 X566 X628 X690 X752 X814 X876 I X9  X71  X133 X195 X257 X319 X381 X443 X505 X567 X629 X691 X753 X815 X877 J X10 X72  X134 X196 X258 X320 X382 X444 X506 X568 X630 X692 X754 X816 X878 K X11 X73  X135 X197 X259 X321 X383 X445 X507 X569 X631 X693 X755 X817 X870 L X12 X74  X136 X198 X260 X322 X384 X446 X508 X570 X632 X694 X756 X818 X880 M X13 X75  X137 X199 X261 X323 X385 X447 X509 X571 X633 X695 X757 X819 X881 N X14 X76  X138 X200 X262 X324 X386 X448 X510 X572 X634 X696 X758 X820 X882 O X15 X77  X139 X201 X263 X325 X387 X449 X511 X573 X635 X697 X759 X821 X883 P X16 X78  X140 X202 X264 X326 X388 X450 X512 X574 X636 X698 X760 X822 X884 Q X17 X79  X141 X203 X265 X327 X389 X451 X513 X575 X637 X699 X761 X823 X885 R X18 X80  X142 X204 X266 X328 X390 X452 X514 X576 X638 X700 X762 X824 X886 S X19 X81  X143 X205 X267 X329 X391 X453 X515 X577 X639 X701 X763 X825 X887 T X20 X82  X144 X206 X268 X330 X392 X454 X516 X578 X640 X702 X764 X826 X888 U X21 X83  X145 X207 X269 X331 X393 X455 X517 X579 X641 X703 X765 X827 X889 V X22 X84  X146 X208 X270 X332 X394 X456 X518 X580 X642 X704 X766 X828 X890 W X23 X85  X147 X209 X271 X333 X395 X457 X519 X581 X643 X705 X767 X829 X891 X X24 X86  X148 X210 X272 X334 X396 X458 X520 X582 X644 X706 X768 X830 X892 Y X25 X87  X149 X211 X273 X335 X397 X459 X521 X583 X645 X707 X769 X831 X893 Z X26 X88  X150 X212 X274 X336 X398 X460 X522 X584 X646 X708 X770 X832 X894 AA X27 X89  X151 X213 X275 X337 X399 X461 X523 X585 X647 X709 X771 X833 X895 AB X28 X90  X152 X214 X276 X338 X400 X462 X524 X586 X648 X710 X772 X834 X896 AC X29 X91  X153 X215 X277 X339 X401 X463 X525 X587 X649 X711 X773 X835 X897 AD X30 X92  X154 X216 X278 X340 X402 X464 X526 X588 X650 X712 X774 X836 X898 AE X31 X93  X155 X217 X279 X341 X403 X465 X527 X589 X651 X713 X775 X837 X899 AF X32 X94  X156 X218 X280 X342 X404 X466 X528 X590 X652 X714 X776 X838 X900 AG X33 X95  X157 X219 X281 X343 X405 X467 X529 X591 X653 X715 X777 X839 X901 AH X34 X96  X158 X220 X282 X344 X406 X468 X530 X592 X654 X716 X778 X840 X902 AI X35 X97  X159 X221 X283 X345 X407 X469 X531 X593 X655 X717 X779 X841 X903 AJ X36 X98  X160 X222 X284 X346 X408 X470 X532 X594 X656 X718 X780 X842 X904 AK X37 X99  X161 X223 X285 X347 X409 X471 X533 X595 X657 X719 X781 X843 X905 AL X38 X100 X162 X224 X286 X348 X410 X472 X534 X596 X658 X720 X782 X844 X906 AM X39 X101 X163 X225 X287 X349 X411 X473 X535 X597 X659 X721 X783 X845 X907 AN X40 X102 X164 X226 X288 X350 X412 X474 X536 X598 X660 X722 X784 X846 X908 AO X41 X103 X165 X227 X289 X351 X413 X475 X537 X599 X661 X723 X785 X847 X909 AP X42 X104 X166 X228 X290 X352 X414 X476 X538 X600 X662 X724 X786 X848 X910 AW X43 X105 X167 X229 X291 X353 X415 X477 X539 X601 X663 X725 X787 X849 X911 AR X44 X106 X168 X230 X292 X354 X416 X478 X540 X602 X664 X726 X788 X850 X912 AS X45 X107 X169 X231 X293 X355 X417 X479 X541 X603 X665 X727 X789 X851 X913 AT X46 X108 X170 X232 X294 X356 X418 X480 X542 X604 X666 X728 X790 X852 X914 AU X47 X109 X171 X233 X295 X357 X419 X481 X543 X605 X667 X729 X791 X853 X915 AV X48 X110 X172 X234 X296 X358 X420 X482 X544 X606 X668 X730 X792 X854 X916 AW X49 X111 X173 X235 X297 X259 X421 X483 X545 X607 X669 X731 X793 X855 X917 AX X50 X112 X174 X236 X298 X260 X422 X484 X546 X608 X670 X732 X794 X856 X918 AY X51 X113 X175 X237 X299 X261 X423 X485 X547 X609 X671 X733 X795 A857 X919 AZ X52 X114 X176 X238 X300 X362 X424 X486 X548 X610 X672 X734 X796 X858 X920 BA X53 X115 X177 X239 X301 X363 X425 X487 X549 X611 X673 X735 X797 X859 X921 BB X54 X116 X178 X240 X302 X364 X426 X488 X550 X612 X674 X736 X798 X860 X922 BC X55 X117 X179 X241 X303 X365 X427 X489 X551 X613 X675 X737 X799 X861 X923 BD X56 X118 X180 X242 X304 X366 X428 X490 X552 X614 X676 X738 X800 X862 X924 BE X57 X119 X181 X243 X305 X367 X429 X491 X553 X615 X677 X739 X801 X863 X925 BF X58 X120 X182 X244 X306 X368 X430 X492 X554 X616 X678 X740 X802 X864 X926 BG X59 X121 X183 X245 X307 X369 X431 X493 X555 X617 X679 X741 X803 X865 X927 BH X60 X122 X184 X246 X308 X370 X432 X494 X556 X618 X680 X742 X804 X866 X928 BI X61 X123 X185 X247 X309 X371 X433 X495 X557 X619 X681 X743 X805 X867 X929 BJ X62 X124 X186 X248 X310 X372 X434 X496 X558 X620 X682 X744 X806 X868 X930

[0147] TABLE E R1 Ia Ib Ic Id Ie If Ig Ih Ii Ij Ik Il Im In Io A Y1  Y63  Y125 Y187 Y249 Y311 Y373 Y435 Y497 Y559 Y621 Y683 Y745 Y807 Y869 B Y2  Y64  Y126 Y188 Y250 Y312 Y374 Y436 Y498 Y560 Y622 Y684 Y746 Y808 Y870 C Y3  Y65  Y127 Y189 Y251 Y313 Y375 Y437 Y499 Y561 Y623 Y685 Y747 Y809 Y871 D Y4  Y66  Y128 Y190 Y252 Y314 Y376 Y438 Y500 Y562 Y624 Y686 Y748 Y810 Y872 E Y5  Y67  Y129 Y191 Y253 Y315 Y377 Y439 Y501 Y563 Y625 Y687 Y749 Y811 Y873 F Y6  Y68  Y130 Y192 Y254 Y316 Y378 Y440 Y502 Y564 Y626 Y688 Y750 Y812 Y874 G Y7  Y69  Y131 Y193 Y255 Y317 Y379 Y441 Y503 Y565 Y627 Y689 Y751 Y813 Y875 H Y8  Y70  Y132 Y194 Y256 Y318 Y380 Y442 Y504 Y566 Y628 Y690 Y752 Y814 Y876 I Y9  Y71  Y133 Y195 Y257 Y319 Y381 Y443 Y505 Y567 Y629 Y691 Y753 Y815 Y877 J Y10 Y72  Y134 Y196 Y258 Y320 Y382 Y444 Y506 Y568 Y630 Y692 Y754 Y816 Y878 K Y11 Y73  Y135 Y197 Y259 Y321 Y383 Y445 Y507 Y569 Y631 Y693 Y755 Y817 Y879 L Y12 Y74  Y136 Y198 Y260 Y322 Y384 Y446 Y508 Y570 Y632 Y694 Y756 Y818 Y880 M Y13 Y75  Y137 Y199 Y261 Y323 Y385 Y447 Y509 Y571 Y633 Y695 Y757 Y819 Y881 N Y14 Y76  Y138 Y200 Y262 Y324 Y386 Y448 Y510 Y572 Y634 Y696 Y758 Y820 Y882 O Y15 Y77  Y139 Y201 Y263 Y325 Y387 Y449 Y511 Y573 Y635 Y697 Y759 Y821 Y883 P Y16 Y78  Y140 Y202 Y264 Y326 Y388 Y450 Y512 Y574 Y636 Y698 Y760 Y822 Y884 Q Y17 Y79  Y141 Y203 Y265 Y327 Y389 Y451 Y513 Y575 Y637 Y699 Y761 Y823 Y885 R1 Y18 Y80  Y142 Y204 Y266 Y328 Y390 Y452 Y514 Y576 Y638 Y700 Y762 Y824 Y886 S Y19 Y81  Y143 Y205 Y267 Y329 Y391 Y453 Y515 Y577 Y639 Y701 Y763 Y825 Y887 T Y20 Y82  Y144 Y206 Y268 Y330 Y392 Y454 Y516 Y578 Y640 Y702 Y764 Y826 Y888 U Y21 Y83  Y145 Y207 Y269 Y331 Y393 Y455 Y517 Y579 Y641 Y703 Y765 Y827 Y889 V Y22 Y84  Y146 Y208 Y270 Y332 Y394 Y456 Y518 Y580 Y642 Y704 Y766 Y828 Y890 W Y23 Y85  Y147 Y209 Y271 Y333 Y395 Y457 Y519 Y581 Y643 Y705 Y767 Y829 Y891 X Y24 Y86  Y148 Y210 Y272 Y334 Y396 Y458 Y520 Y582 Y644 Y706 Y768 Y830 Y892 Y Y25 Y87  Y149 Y211 Y273 Y335 Y397 Y459 Y521 Y583 Y645 Y707 Y769 Y831 Y893 Z Y26 Y88  Y150 Y212 Y274 Y336 Y398 Y460 Y522 Y584 Y646 Y708 Y770 Y832 Y894 AA Y27 Y89  Y151 Y213 Y275 Y337 Y399 Y461 Y523 Y585 Y647 Y709 Y771 Y833 Y895 AB Y28 Y90  Y152 Y214 Y276 Y338 Y400 Y462 Y524 Y586 Y648 Y710 Y772 Y834 Y896 AC Y29 Y91  Y153 Y215 Y277 Y339 Y401 Y463 Y525 Y587 Y649 Y711 Y773 Y835 Y897 AD Y30 Y92  Y154 Y216 Y278 Y340 Y402 Y464 Y526 Y588 Y650 Y712 Y774 Y836 Y898 AE Y31 Y93  Y155 Y217 Y279 Y341 Y403 Y465 Y527 Y589 Y651 Y713 Y775 Y837 Y899 AF Y32 Y94  Y156 Y218 Y280 Y342 Y404 Y466 Y528 Y590 Y652 Y714 Y776 Y838 Y900 AG Y33 Y95  Y157 Y219 Y281 Y343 Y405 Y467 Y529 Y591 Y653 Y715 Y777 Y839 Y901 AH Y34 Y96  Y158 Y220 Y282 Y344 Y406 Y468 Y530 Y592 Y654 Y716 Y778 Y840 Y902 AI Y35 Y97  Y159 Y221 Y283 Y345 Y407 Y469 Y531 Y593 Y655 Y717 Y779 Y841 Y903 AJ Y36 Y98  Y160 Y222 Y284 Y346 Y408 Y470 Y532 Y594 Y656 Y718 Y780 Y842 Y904 AK Y37 Y99  Y161 Y223 Y285 Y347 Y409 Y471 Y533 Y595 Y657 Y719 Y781 Y843 Y905 AL Y38 Y100 Y162 Y224 Y286 Y348 Y410 Y472 Y534 Y596 Y658 Y720 Y782 Y844 Y906 AM Y39 Y101 Y163 Y225 Y287 Y349 Y411 Y473 Y535 Y597 Y659 Y721 Y783 Y845 Y907 AN Y40 Y102 Y164 Y226 Y288 Y350 Y412 Y474 Y536 Y598 Y660 Y722 Y784 Y846 Y908 AO Y41 Y103 Y165 Y227 Y289 Y351 Y413 Y475 Y537 Y599 Y661 Y723 Y785 Y847 Y909 AP Y42 Y104 Y166 Y228 Y290 Y352 Y414 Y476 Y538 Y600 Y662 Y724 Y786 Y848 Y910 AW Y43 Y105 Y167 Y229 Y291 Y353 Y415 Y477 Y539 Y601 Y663 Y725 Y787 Y849 Y911 AR Y44 Y106 Y168 Y230 Y292 Y354 Y416 Y478 Y540 Y602 Y664 Y726 Y788 Y850 Y912 AS Y45 Y107 Y169 Y231 Y293 Y355 Y417 Y479 Y541 Y603 Y665 Y727 Y789 Y851 Y913 AT Y46 Y108 Y170 Y232 Y294 Y356 Y418 Y480 Y542 Y604 Y666 Y728 Y790 Y852 Y914 AU Y47 Y109 Y171 Y233 Y295 Y357 Y419 Y481 Y543 Y605 Y667 Y729 Y791 Y853 Y915 AV Y48 Y110 Y172 Y234 Y296 Y358 Y420 Y482 Y544 Y606 Y668 Y730 Y792 Y854 Y916 AW Y49 Y111 Y173 Y235 Y297 Y359 Y421 Y483 Y545 Y607 Y669 Y731 Y793 Y855 Y917 AX Y50 Y112 Y174 Y236 Y298 Y360 Y422 Y484 Y546 Y608 Y670 Y732 Y794 Y856 Y918 AY Y51 Y113 Y175 Y237 Y299 Y361 Y423 Y485 Y547 Y609 Y671 Y733 Y795 Y857 Y919 AZ Y52 Y114 Y176 Y238 Y300 Y362 Y424 Y486 Y548 Y610 Y672 Y734 Y796 Y858 Y920 BA Y53 Y115 Y177 Y239 Y301 Y363 Y425 Y487 Y549 Y611 Y673 Y735 Y797 Y859 Y921 BB Y54 Y116 Y178 Y240 Y302 Y364 Y426 Y488 Y550 Y612 Y674 Y736 Y798 Y860 Y922 BC Y55 Y117 Y179 Y241 Y303 Y365 Y427 Y489 Y551 Y613 Y675 Y737 Y799 Y861 Y923 BD Y56 Y118 Y180 Y242 Y304 Y366 Y428 Y490 Y552 Y614 Y676 Y738 Y800 Y862 Y924 BE Y57 Y119 Y181 Y243 Y305 Y367 Y429 Y491 Y553 Y615 Y677 Y739 Y801 Y863 Y925 BF Y58 Y120 Y182 Y244 Y306 Y368 Y430 Y492 Y554 Y616 Y678 Y740 Y802 Y864 Y926 BG Y59 Y121 Y183 Y245 Y307 Y369 Y431 Y493 Y555 Y617 Y679 Y741 Y803 Y865 Y927 BH Y60 Y122 Y184 Y246 Y308 Y370 Y432 Y494 Y556 Y618 Y680 Y742 Y804 Y866 Y928 BI Y61 Y123 Y185 Y247 Y309 Y371 Y433 Y495 Y557 Y619 Y681 Y743 Y805 Y867 Y929 BJ Y62 Y124 Y186 Y248 Y310 Y372 Y434 Y496 Y558 Y620 Y682 Y744 Y806 Y868 Y930

[0148] TABLE F R1 Ia Ib Ic Id Ie If Ig Ih Ii Ij Ik Il Im In Io A  Z1  Z63 Z125 Z187 Z249 Z311 Z373 Z435 Z497 Z559 Z621 Z683 Z745 Z807 Z869 B  Z2  Z64 Z126 Z188 Z250 Z312 Z374 Z436 Z498 Z560 Z622 Z684 Z746 Z808 Z870 C  Z3  Z65 Z127 Z189 Z251 Z313 Z375 Z437 Z499 Z561 Z623 Z685 Z747 Z809 Z871 D  Z4  Z66 Z128 Z190 Z252 Z314 Z376 Z438 Z500 Z562 Z624 Z686 Z748 Z810 Z872 E  Z5  Z67 Z129 Z191 Z253 Z315 Z377 Z439 Z501 Z563 Z625 Z687 Z749 Z811 Z873 F  Z6  Z68 Z130 Z192 Z254 Z316 Z378 Z440 Z502 Z564 Z626 Z688 Z750 Z812 Z874 G  Z7  Z69 Z131 Z193 Z255 Z317 Z379 Z441 Z503 Z565 Z627 Z689 Z751 Z813 Z875 H  Z8  Z70 Z132 Z194 Z256 Z318 Z380 Z442 Z504 Z566 Z628 Z690 Z752 Z814 Z876 I  Z9  Z71 Z133 Z195 Z257 Z319 Z381 Z443 Z505 Z567 Z629 Z691 Z753 Z815 Z877 J Z10  Z72 Z134 Z196 Z258 Z320 Z382 Z444 Z506 Z568 Z630 Z692 Z754 Z816 Z878 K Z11  Z73 Z135 Z197 Z259 Z321 Z383 Z445 Z507 Z569 Z631 Z693 Z755 Z817 Z879 L Z12  Z74 Z136 Z198 Z260 Z322 Z384 Z446 Z508 Z570 Z632 Z694 Z756 Z818 Z880 M Z13  Z75 Z137 Z199 Z261 Z323 Z385 Z447 Z509 Z571 Z633 Z695 Z757 Z819 Z881 N Z14  Z76 Z138 Z200 Z262 Z324 Z386 Z448 Z510 Z572 Z634 Z696 Z758 Z820 Z882 O Z15  Z77 Z139 Z201 Z263 Z325 Z387 Z449 Z511 Z573 Z635 Z697 Z759 Z821 Z883 P Z16  Z78 Z140 Z202 Z264 Z326 Z388 Z450 Z512 Z574 Z636 Z698 Z760 Z822 Z884 Q Z17  Z79 Z141 Z203 Z265 Z327 Z389 Z451 Z513 Z575 Z637 Z699 Z761 Z823 Z885 R Z18  Z80 Z142 Z204 Z266 Z328 Z390 Z452 Z514 Z576 Z638 Z700 Z762 Z824 Z886 S Z19  Z81 Z143 Z205 Z267 Z329 Z391 Z453 Z515 Z577 Z639 Z701 Z763 Z825 Z887 T Z20  Z82 Z144 Z206 Z268 Z330 Z392 Z454 Z516 Z578 Z640 Z702 Z764 Z826 Z888 U Z21  Z83 Z145 Z207 Z269 Z331 Z393 Z455 Z517 Z579 Z641 Z703 Z765 Z827 Z889 V Z22  Z84 Z146 Z208 Z270 Z332 Z394 Z456 Z518 Z580 Z642 Z704 Z766 Z828 Z890 W Z23  Z85 Z147 Z209 Z271 Z333 Z395 Z457 Z519 Z581 Z643 Z705 Z767 Z829 Z891 X Z24  Z86 Z148 Z210 Z272 Z334 Z396 Z458 Z520 Z582 Z644 Z706 Z768 Z830 Z892 Y Z25  Z87 Z149 Z211 Z273 Z335 Z397 Z459 Z521 Z583 Z645 Z707 Z769 Z831 Z893 Z Z26  Z88 Z150 Z212 Z274 Z336 Z398 Z460 Z522 Z584 Z646 Z708 Z770 Z832 Z894 AA Z27  Z89 Z151 Z213 Z275 Z337 Z399 Z461 Z523 Z585 Z647 Z709 Z771 Z833 Z895 AB Z28  Z90 Z152 Z214 Z276 Z338 Z400 Z462 Z524 Z586 Z648 Z710 Z772 Z834 Z896 AC Z29  Z91 Z153 Z215 Z277 Z339 Z401 Z463 Z525 Z587 Z649 Z711 Z773 Z835 Z897 AD Z30  Z92 Z154 Z216 Z278 Z340 Z402 Z464 Z526 Z588 Z650 Z712 Z774 Z836 Z898 AE Z31  Z93 Z155 Z217 Z279 Z341 Z403 Z465 Z527 Z589 Z651 Z713 Z775 Z837 Z899 AF Z32  Z94 Z156 Z218 Z280 Z342 Z404 Z466 Z528 Z590 Z652 Z714 Z776 Z838 Z900 AG Z33  Z95 Z157 Z219 Z281 Z343 Z405 Z467 Z529 Z591 Z653 Z715 Z777 Z839 Z901 AH Z34  Z96 Z158 Z220 Z282 Z344 Z406 Z468 Z530 Z592 Z654 Z716 Z778 Z840 Z902 AI Z35  Z97 Z159 Z221 Z283 Z345 Z407 Z469 Z531 Z593 Z655 Z717 Z779 Z841 Z903 AJ Z36  Z98 Z160 Z222 Z284 Z346 Z408 Z470 Z532 Z594 Z656 Z718 Z780 Z842 Z904 AK Z37  Z99 Z161 Z223 Z285 Z347 Z409 Z471 Z533 Z595 Z657 Z719 Z781 Z843 Z905 AL Z38 Z100 Z162 Z224 Z286 Z348 Z410 Z472 Z534 Z596 Z658 Z720 Z782 Z844 Z906 AM Z39 Z101 Z163 Z225 Z287 Z349 Z411 Z473 Z535 Z597 Z659 Z721 Z783 Z845 Z907 AN Z40 Z102 Z164 Z226 Z288 Z350 Z412 Z474 Z536 Z598 Z660 Z722 Z784 Z846 Z908 AO Z41 Z103 Z165 Z227 Z289 Z351 Z413 Z475 Z537 Z599 Z661 Z723 Z785 Z847 Z909 AP Z42 Z104 Z166 Z228 Z290 Z352 Z414 Z476 Z538 Z600 Z662 Z724 Z786 Z848 Z910 AW Z43 Z105 Z167 Z229 Z291 Z353 Z415 Z477 Z539 Z601 Z663 Z725 Z787 Z849 Z911 AR Z44 Z106 Z168 Z230 Z292 Z354 Z416 Z478 Z540 Z602 Z664 Z726 Z788 Z850 Z912 AS Z45 Z107 Z169 Z231 Z293 Z355 Z417 Z479 Z541 Z603 Z665 Z727 Z789 Z851 Z913 AT Z46 Z108 Z170 Z232 Z294 Z356 Z418 Z480 Z542 Z604 Z666 Z728 Z790 Z852 Z914 AU Z47 Z109 Z171 Z233 Z295 Z357 Z419 Z481 Z543 Z605 Z667 Z729 Z791 Z853 Z915 AV Z48 Z110 Z172 Z234 Z296 Z358 Z420 Z482 Z544 Z606 Z668 Z730 Z792 Z854 Z916 AW Z49 Z111 Z173 Z235 Z297 Z359 Z421 Z483 Z545 Z607 Z669 Z731 Z793 Z855 Z917 AX Z50 Z112 Z174 Z236 Z298 Z360 Z422 Z484 Z546 Z608 Z670 Z732 Z794 Z856 Z918 AY Z51 Z113 Z175 Z237 Z299 Z361 Z423 Z485 Z547 Z609 Z671 Z733 Z795 Z857 Z919 AZ Z52 Z114 Z176 Z238 Z300 Z362 Z424 Z486 Z548 Z600 Z672 Z734 Z796 Z858 Z920 BA Z53 Z115 Z177 Z239 Z301 Z363 Z425 Z487 Z549 Z611 Z673 Z735 Z797 Z859 Z921 BB Z54 Z116 Z178 Z240 Z302 Z364 Z426 Z488 Z550 Z612 Z674 Z736 Z798 Z860 Z922 BC Z55 Z117 Z179 Z241 Z303 Z365 Z427 Z489 Z551 Z613 Z675 Z737 Z799 Z861 Z923 BD Z56 Z118 Z180 Z242 Z304 Z366 Z428 Z490 Z552 Z614 Z676 Z738 Z800 Z862 Z924 BE Z57 Z119 Z181 Z243 Z305 Z367 Z429 Z491 Z553 Z615 Z677 Z739 Z801 Z863 Z925 BF Z58 Z120 Z182 Z244 Z306 Z368 Z430 Z492 Z554 Z616 Z678 Z740 Z802 Z864 Z926 BG Z59 Z121 Z183 Z245 Z307 Z369 Z431 Z493 Z555 Z617 Z679 Z741 Z803 Z865 Z927 BH Z60 Z122 Z184 Z246 Z308 Z370 Z432 Z494 Z556 Z618 Z680 Z742 Z804 Z866 Z928 BI Z61 Z123 Z185 Z247 Z309 Z371 Z433 Z495 Z557 Z619 Z681 Z743 Z805 Z867 Z929 BJ Z62 Z124 Z186 Z248 Z310 Z372 Z434 Z496 Z558 Z620 Z682 Z744 Z806 Z868 Z930

[0149] In each of the above-listed aspects, the compounds include optical isomers, diastereomers, enantiomers and pharmaceutically acceptable salts thereof in isolation or mixture, where, independently at each location, the substituents R¹, R² etc. are as defined herein.

[0150] Thus, for example, in one embodiment, the present invention provides a compound, or a mixture including a compound, wherein the stereochemistry of the R¹ and C(═O)R² groups are as shown in formula Ia, with R¹ and C(═O)R² in a cis arrangement, both over the benzo ring substituted with —OR⁶

[0151] In another exemplary embodiment, the present invention provides a compounds, or a mixture including a compound, wherein the stereochemistry of the R¹ and C(═O)R² groups are as shown in formula Ib, with R¹ and C(═O)R² in a trans arrangement, with only C(═O)R² over the benzo ring substituted with —OR⁶

[0152] In yet another exemplary embodiment, the present invention provides a compound, or a mixture including a compound, having the stereochemistry of the R¹ and C(═O)R² groups as shown in formula Ic, with R¹and C(═O)R² in a trans arrangement, with only R¹ over the benzo ring substituted with —OR⁶

[0153] Another exemplary embodiment of the present invention provides a benzobicyclooctane compound, or a mixture containing a benzobicyclooctane compound, wherein the stereochemistry of the R¹ and C(═O)R² groups are as shown in formula Id, with R¹ and C(═O)R² in a cis arrangement, with neither of the R¹ nor C(═O)R² groups being over the benzo ring substituted with —OR⁶

[0154] In one embodiment, the present invention provides a compound of formula (I) wherein R¹ is selected from the following four formulae, i.e., R¹ is R1AX:

[0155] In one embodiment, the present invention provides a compound of formula (I) wherein R¹ is R1AX; R⁸ is selected from hydrogen and C₁-C₁₅alkyl; and R⁹ is selected from hydrogen, heteroalkyl, C₁-C₁₅alkyl, (heteroaryl)C₁-C₁₅alkylene, (C₆-C₁₀aryl)C₁-C₁₅alkylene, C₆-C₁₀aryl fused to C₁-C₁₅alkylene, (alkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene, (C₆-C₁₀aryl)(C₆-C₁₀arylene)C₁-C₁₅alkylene, (C₁-C₁₅alkyl)_(p)(heteroarylene)C₁-C₁₅alkylene, and (heteroalkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene, or two R⁹ groups bonded to a common nitrogen of R¹ may be joined together to form a 5-8 membered heterocycle including the common nitrogen, where this 5-8 membered heterocycle may be substituted with 0-5 groups selected from alkyl and heteralkyl, where p is selected from 1, 2, 3, 4 and 5.

[0156] In one embodiment, the present invention provides a compound of formula I wherein R¹ is R1A and R⁸ and R⁹ are each independently selected from R¹¹, R¹², R¹³, R¹⁴ and R¹⁵ where R¹¹ is selected from alkyl, heteroalkyl, aryl and heteroaryl; R¹² is selected from (R¹¹)_(p)-alkylene, (R¹¹)_(p)-heteroalkylene, (R¹¹)_(p)-arylene and (R¹¹)_(p)-heteroarylene; R¹³ is selected from (R¹²)_(p)-alkylene, (R¹²)_(p)-heteroalkylene, (R¹²)_(p)-arylene, and (R¹²)_(p)-heteroarylene; R¹⁴ is selected from (R¹³)_(p)-alkylene, (R¹³)_(p)-heteroalkylene, (R¹³)_(p)-arylene, and (R¹³)_(p)-heteroarylene, R¹⁵ is selected from (R¹⁴)_(p)-alkylene, (R¹⁴)_(p)-heteroalkylene, (R¹⁴)_(p)-arylene, and (R¹⁴)_(p)-heteroarylene, and p is selected from 0, 1, 2, 3, 4 and 5. Optionally, R⁹ is selected from heteroalkyl, C₁-C₁₅alkyl, (C₆-C₁₀aryl)C₁-C₁₅alkylene, (C₆-C₁₀aryl) (C₆-C₁₀arylene)C₁-C₁₅alkylene, (C₁-C₁₅alkyl)_(p)(heteroarylene)C₁-C₁₅alkylene, and C₆-C₁₀aryl fused to C₁-C₁₅alkylene.

[0157] In one embodiment, the present invention provides a compound of formula (I) wherein R¹ is R1C and R⁸ and R⁹ are each independently selected from hydrogen, R¹¹, R¹², R¹³, R¹⁴ and R¹⁵ where R¹¹ is selected from alkyl, heteroalkyl, aryl and heteroaryl; R¹² is selected from (R¹¹)_(p)-alkylene, (R¹¹)_(p)-heteroalkylene, (R¹¹)_(p)-arylene and (R¹¹)_(p)-heteroarylene; R¹³ is selected from (R¹²)_(p)-alkylene, (R¹²)_(p)-heteroalkylene, (R¹²)_(p)-arylene, and (R¹²)_(p)-heteroarylene; R¹⁴ is selected from (R¹³)_(p)-alkylene, (R¹³)_(p)-heteroalkylene, (R¹³)_(p)-arylene, and (R¹³)_(p)-heteroarylene, R¹⁵ is selected from (R¹⁴)_(p)-alkylene, (R¹⁴)_(p)-heteroalkylene, (R¹⁴)_(p)-arylene, and (R¹⁴)_(p)-heteroarylene, and p is selected from 0, 1, 2, 3, 4 and 5. Optionally, R⁸ is selected from hydrogen and C₁-C₁₅alkyl; and R⁹ is selected from hydrogen, heteroalkyl, C₁-C₁₅alkyl, (C₆-C₁₀aryl)C₁-C₁₅alkylene, (heteroaryl)C₁-C₁₅alkylene, and (heteroalkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene, or the two R⁹ groups joined to a common nitrogen of R¹ may be joined together to form a 5-8 membered heterocycle including the common nitrogen.

[0158] In one embodiment, the present invention provides a compound of formula (I) wherein R¹ is R1E and R⁹ is selected from hydrogen, RK¹, R¹², R¹³, R¹⁴ and R¹⁵ where R¹¹ is selected from alkyl, heteroalkyl, aryl and heteroaryl; R¹² is selected from (R¹¹)_(p)-alkylene, (R¹¹)_(p)-heteroalkylene, (R¹¹)_(p)-arylene and (R¹¹)_(p)-heteroarylene; R¹³ is selected from (R¹²)_(p)-alkylene, (R¹²)_(p)-heteroalkylene, (R¹²)_(p)-arylene, and (R¹²)_(p)-heteroarylene; R¹⁴ is selected from (R¹³)_(p)-alkylene, (R¹³)_(p)-heteroalkylene, (R¹³)_(p)-arylene, and (R¹³)_(p)-heteroarylene, R¹⁵ is selected from (R¹⁴)_(p)-alkylene, (R¹⁴)_(p)-heteroalkylene, (R¹⁴)_(p)-arylene, and (R¹⁴)_(p)-heteroarylene, and p is selected from 0, 1, 2, 3, 4 and 5. Optionally, R⁹ is selected from hydrogen, heteroalkyl, C₁-C₁₅alkyl, (heteroaryl)C₁-C₁₅alkylene, and (heteroalkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene.

[0159] In one embodiment, the present invention provides a compound of formula (I) wherein R¹ is R1F and R⁹ is selected from hydrogen, R¹¹, R¹², R¹³, R¹⁴ and R¹⁵ where R¹¹ is selected from alkyl, heteroalkyl, aryl and heteroaryl; R¹² is selected from (R¹¹)_(p)-alkylene, (R¹¹)_(p)-heteroalkylene, (R¹¹)_(p)-arylene and (R¹¹)_(p)-heteroarylene; R¹³ is selected from (R¹²)_(p)-alkylene, (R¹²)_(p)-heteroalkylene, (R¹²)_(p)-arylene, and (R¹²)_(p)-heteroarylene; R¹⁴ is selected from (R¹³)_(p)-alkylene, (R¹³)_(p)-heteroalkylene, (R¹³)_(p)-arylene, and (R¹³)_(p)-heteroarylene, R¹⁵ is selected from (R¹⁴)_(p)-alkylene, (R¹⁴)_(p)-heteroalkylene, (R¹⁴)_(p)-arylene, and (R¹⁴)_(p)-heteroarylene, and p is selected from 0, 1, 2, 3, 4 and 5. Optionally, R⁹ is selected from hydrogen, heteroalkyl, C₁-C₁₅alkyl, (heteroaryl)C₁-C₁₅alkylene, (C₆-C₁₀aryl)C₁-C₁₅alkylene, (alkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene, or the two R⁹ groups of R¹ may be joined together to form a 5-8 membered heterocycle including the common nitrogen, where this 5-8 membered heterocycle may be substituted with 0-5 groups selected from alkyl and heteralkyl.

[0160] In one embodiment, the present invention provides a compound of formula (I) wherein R² is —OR⁹, i.e., aspects Y1 through Y937. Optionally, R⁹ of —OR⁹ of R² is selected from hydrogen, R¹¹, R¹², R¹³, R¹⁴ and R¹⁵ where R¹¹ is selected from alkyl, heteroalkyl, aryl and heteroaryl; R¹² is selected from (R¹¹)_(p)-alkylene, (R¹¹)_(p)-heteroalkylene, (R¹¹)_(p)-arylene and (R¹²)_(p)-heteroarylene; R¹³ is selected from (R¹²)_(p)-alkylene, (R¹²)_(p)-heteroalkylene, (R¹²)_(p)-arylene, and (R¹²)_(p)-heteroarylene; R¹⁴ is selected from (R¹³)_(p)-alkylene, (R¹³ ⁾ _(p)-heteroalkylene, (R¹³)_(p)-arylene, and (R¹³)_(p)-heteroarylene, R¹⁵is selected from (R¹⁴ ⁾ _(p)-alkylene, (R¹⁴)_(p)-heteroalkylene; (R¹⁴)_(p)-arylene, and (R¹⁴)_(p)-heteroarylene, and p is selected from 0, 1, 2, 3, 4 and 5. In a further optional embodiment, R⁹ of —OR⁹ of R² is selected from hydrogen, heteroalkyl, C₁-C₁₅alkyl, (C₆-C₁₀aryl)(C₆-C₁₀arylene)C₁-C₁₅alkylene, (C₁-C₁₅alkyl)_(p)(heteroarylene)C₁-C₁₅alkylene, (C₁-C₁₅alkyl)_(p)(heteroarylene)heteroalkylene, (heteroalkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene, and (C₁-C₁₅alkyl)_(p)(C₆-C₁₀arylene)hetero-alkylene. In a further embodiment, R⁹ of —OR⁹ of R² is selected from a heteroalkyl group having 1-10 carbons and 1-4 heteroatoms selected from nitrogen, oxygen, silicon and sulfur, where —CH₂CH₂Si(CH₃)₃ is a preferred heteroaklyl within this group.

[0161] In one embodiment, the present invention provides a compound of formula (I) wherein R² is —NR⁹R⁹. Optionally, R⁹ of —NR⁹R⁹ of R² is independently selected from hydrogen, R¹¹, R¹², R¹³, R¹⁴ and R¹⁵ where R¹¹ is selected from alkyl, heteroalkyl, aryl and heteroaryl; R¹² is selected from (R¹¹)_(p)-alkylene, (R¹¹)_(p)-heteroalkylene, (R¹¹)_(p)-arylene and (R¹¹)_(p)-heteroarylene; R¹³ is selected from (R¹²)_(p)-alkylene, (R¹²)_(p)-heteroalkylene, (R¹²)_(p)-arylene, and (R¹²)_(p)-heteroarylene; R¹⁴ is selected from (R¹³)_(p)-alkylene, (R¹³)_(p)-heteroalkylene, (R¹³)_(p)-arylene, and (R¹³)_(p)-heteroarylene, R¹⁵ is selected from (R¹⁴)_(p)-alkylene, (R¹⁴)_(p)-heteroalkylene, (R¹⁴)_(p)-arylene, and (R¹⁴)_(p)-heteroarylene, and p is selected from 0, 1, 2, 3, 4 and 5. In a further optional embodiment, R⁹ of —NR⁹R⁹ of R² is selected from hydrogen, heteroalkyl, C₁-C₁₅alkyl, (heteroaryl)C₁-C₁₅alkylene, (heteroalkyl)_(p)(aryl)heteroalkylene, (heteroalkyl)_(p)(aryl)C₁-C₁₅alkylene, and (C₁-C₁₅alkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene.

[0162] In one embodiment, the present invention provides a compound of formula (I) wherein R³ is hydrogen.

[0163] In two embodiments, the present invention provides a compound of formula (I) wherein R⁴ and R⁵ are independently selected from: hydrogen, —R⁹, —OR⁹, and —NR⁹R⁹, or R⁴ and R⁵ may together with the carbon to which they are both attached form a spiro carbocyclic or heterocyclic ring; and wherein R⁴ and R⁵ are each hydrogen. In one embodiment, the present invention provides a compound of formula (I) wherein at least one of R⁴ and R⁵ is selected from C₁-C₁₅alkyl, heteroalkyl, and C₆-C₁₀aryl. In one embodiment, the present invention provides a compound of formula (I) wherein one of R⁴ and R⁵ is hydrogen and the other of R⁴ and R⁵ is selected from hydrogen, —OR⁹, —NR⁹R⁹ and —N═N—R⁹ where the R⁹ is selected from hydrogen, R¹¹, R¹², R¹³, R¹⁴ and R¹⁵ where R¹¹ is selected from alkyl, heteroalkyl, aryl and heteroaryl; R¹² is selected from (R )_(p)-alkylene, (R¹¹)_(p)-heteroalkylene, (R¹¹)_(p)-arylene and (R¹¹)_(p)-heteroarylene; R¹³ is selected from (R¹²)_(p)-alkylene, (R¹²)-heteroalkylene, (R¹²)_(p)-arylene, and (R¹²)_(p)-heteroarylene; R¹⁴ is selected from (R¹³) -alkylene, (R¹³)_(p)-heteroalkylene, (R¹³)_(p)-arylene, and (R¹³)_(p)-heteroarylene, R¹⁵ is selected from (R¹⁴)_(p)-alkylene, (R¹⁴)_(p)-heteroalkylene, (R¹⁴)_(p)-arylene, and (R¹⁴)_(p)-heteroarylene, and p is selected from 0, 1, 2, 3, 4 and 5. Optionally, R⁹ of —OR⁹, —NR⁹R⁹ and —N═N—R⁹ from R⁴ and R⁵ is selected from hydrogen, C₆-C₁₀aryl, heteroalkyl, C₁-C₁₅alkyl, and (C₁-C₁₅alkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene. In one embodiment, the present invention provides a compound of formula (I) wherein R⁴ and R⁵ together with the carbon to which they are both attached form a 3-6-membered spiro carbocyclic or heterocyclic ring. In one embodiment, the present invention provides a compound of formula (I) wherein R⁴ and R⁵ together form ═O. In one embodiment, the present invention provides a compound of formula (I) wherein R⁴ and R⁵ together form ═NR¹⁰ and R¹⁰ is —OR⁹ where R⁹ is selected from hydrogen, C₆-C₁₀aryl, C₁-C₈alkyl, heteroalkyl, (C₆-C₁₀aryl)heteroalkyl, (C₆-C₁₀aryl)C₁-C₁₅alkylene, (heteroalkyl)_(p)(heteroarylene)C₁-C₁₅alkylene, (heteroalkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene, and (C₁-C₁₅alkyl)_(p)(C₆-C₁₀arylene)heteroalkylene. In one embodiment, the present invention provides a compound of formula (I) wherein R⁴ and R⁵ together form ═NR¹⁰ and R¹⁰ is —N(R⁹)(R⁹) where R⁹ is selected from hydrogen, C₁-C₈alkyl, heteroalkyl, C₆-C₁₀aryl, (C₆-C₁₀aryl)heteroalkylene, (heteroalkyl)_(p)C₆-C₁₀arylene, (C₁-C₁₅alkyl)_(p)C₆-C₁₀arylene, (heteroalkyl)_(p)(C₆-C₁₀arylene)heteroalkylene, (C₁-C₁₅alkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene, and (C₁-C15alkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅heteroalkylene. In one embodiment, the present invention provides a compound of formula (I) wherein R⁴ and R⁵ together form ═CR⁸R⁸, and one of R⁸ is hydrogen while the other R⁸ is selected from hydrogen, C₁-C₈alkyl and heteroalkyl.

[0164] In one embodiment, the present invention provides a compound of formula (I) wherein R⁶ is hydrogen. In another embodiment, the present invention provides a compound of formula (I) wherein R⁶ is selected from R¹¹, R¹², R¹³, R¹⁴ and R¹⁵ where R¹¹ is selected from alkyl, heteroalkyl, aryl and heteroaryl; R¹² is selected from (R¹¹)_(p)-alkylene, (R¹¹)_(p)-heteroalkylene, (R¹¹)_(p)-arylene and (R¹¹)_(p)-heteroarylene; R¹³ is selected from (R¹²)_(p)-alkylene, (R¹²)_(p)-heteroalkylene, (R¹²)_(p)-arylene, and (R¹²)_(p)-heteroarylene; R¹⁴ is selected from (R¹³)_(p)-alkylene, (R¹³)_(p)-heteroalkylene, (R¹³)_(p)-arylene, and (R¹³)_(p)-heteroarylene, R¹⁵ is selected from (R¹⁴)_(p)-alkylene, (R¹⁴)_(p)-heteroalkylene, (R¹⁴)_(p)-arylene, and (R¹⁴)_(p)-heteroarylene, and p is selected from 0, 1, 2, 3, 4 and 5. In another embodiment, R⁶ is selected from C₁-C₁₅alkyl, C₁-C₁₅heteroalkyl, (C₆-C₁₀aryl)C_(1-C) ₁₅alkylene, (C₆aryl)(C₆aryl)C₁-C₁₅alkylene, (C₂-C₆heteroaryl)C₁-C₁₅alkylene, (C₆-C₁₀aryl)C₁-C₁₅heteroalkylene, (heteroalkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene, (heteroalkyl)_(p)(C₂-C₆heteroarylene)C₁-C₁₅alkylene, and (heteroalkyl)_(p)(C₆arylene)heteroalkylene)(C₆arylene)C₁-C₁₅alkylene. In one embodiment of the present invention, R⁶ is as defined above with the proviso that R⁶ is not lower alkyl, e.g., is not C₁-C₆ so that —OR⁶ is not C₁-C₆alkoxy.

[0165] In one embodiment, the present invention provides a compound of formula (I) wherein R⁸ is hydrogen.

[0166] In one embodiment, the present invention provides a compound of formula (1) wherein n is 0. In another embodiment, the present invention provides a compound of formula (I) wherein n is 1. In another embodiment, the present invention provides a compound of formula (I) wherein n is 0 or 1.

[0167] In one embodiment, the present invention provides a compound of formula (I) wherein —R¹ is trans to —C(O)R², ie., compounds of formula (Ib) and (Ic), also referred to herein as compounds of formula (Ih).

[0168] In one embodiment, the present invention provides a compound of formula (I) wherein —R¹ is cis to —C(O)R², i.e., compounds of formula (Ia) and (Id), also referred to herein as compounds of formula (Ig).

[0169] In one embodiment, the present invention provides a compound of formula (I) wherein R³ is hydrogen; R⁴ and R⁵ are selected from (a) R⁴ is hydrogen and R⁵ is hydroxyl or protected hydroxyl and (b) R⁴ and R⁵ together form carbonyl; R⁶ is hydrogen; and n is 0. In one embodiment R² is —OR⁹ where a preferred R² group is —OCH₂CH₂Si(CH₃)₃.

[0170] In one embodiment R¹ is

[0171] where optionally R⁹ is a C₁-C₆ hydrocarbyl, such as, in one embodiment, n-propyl and —CH₂—CH═CH₂.

[0172] In one embodiment R¹ is

[0173] where optionally R⁸ is hydrogen and R⁹ is C₁-C₆ hydrocarbyl, such as, in one embodiment, R⁹ is —CH₂—CH═CH₂.

[0174] B. Preparation of Benzobicyclooctane Compounds

[0175] The benzobicyclooctanes of this invention may be prepared according to Schemes 1-4. In these Schemes, “PG” denotes a protecting group. Suitable protecting groups are set forth in, for example, Greene and Wuts, Protective Groups in Organic Synthesis, 2d Edition, John Wiley & Sons, New York, 1991.

[0176] In Scheme 1, the starting material (not shown) for 1 may be prepared by the Diels-Alder reaction of 2,7-dihydroxynaphthalene with maleic anhydride (see, e.g., Singh, A. K.; Yadar, S.; Bhattacharjee, G., J. Indian Chemical Soc. 1990, 67, 818; and Takeda, K.; Hagishita, S.; Sugiura, M.; Kitahonoki, K.; Ban, I.; Miyazaki, S.; Kuriyama, K., Tetrahdedron 1970, 26, p. 1435). The resulting anhydride may be opened with a suitable alcohol, e.g., trimethylsilylethanol, to give the 9-protected and the 10-protected benzobicyclooctane, 1 (only the 9-ester is depicted).

[0177] In Scheme 1, chemical steps a, b, c, d, and e represent the following reaction conditions.

[0178] (a) is a chemical reaction wherein the free acid of 1 is transformed into the reactive intermediate 2. Suitable conditions for this type of reaction involve treating 1 with a suitable activating agent, e.g. diphenylphosphoryl azide, in the presence of a suitable base, e.g., an organoamine such as diisopropylethylamine (DIEA), in an appropriate solvent, e.g., tetrahydrofuran (THF), at a suitable reaction temperature, e.g., at ambient temperature. Alternatively, formation of an active ester via a suitable coupling agent and hydroxy compound, e.g., 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCl) and 1-hydroxybenzotriazole (HOBt), under the same conditions produce 2, suitable for use in steps b or c. In either process, X is a leaving group that activates the adjoining carbonyl group.

[0179] (b) is a chemical reaction in which the activated acid 2 forms the ester 3. Suitable conditions for this type of reaction involve treating 2 with a suitable alcohol (R⁹OH), e.g., n-propanol, in the presence of a suitable catalyst, e.g., 4-dimethylaminopyridine (DMAP), in an appropriate solvent, e.g., THF, at an appropriate temperature, e.g., ambient temperature. In alcohols of formula R⁹OH, R⁹ is an organic group having 1-30 carbons and optionally containing 1-4 heteroatoms selected from nitrogen, oxygen, silicon and sulfur, with the provision that two R⁹ groups both joined to a common atom may be joined together so as to form a ring with the common atom. In one embodiment, R⁹ is selected from R¹¹, R¹², R¹³, R¹⁴ and R¹⁵ where R¹¹ is selected from alkyl, heteroalkyl, aryl and heteroaryl; R¹² is selected from (R¹¹)_(p)-alkylene, (R¹¹)_(p)-heteroalkylene, (R¹¹)_(p)-arylene and (R¹¹)_(p)-heteroarylene; R¹³ is selected from (R¹²)_(p)-alkylene, (R¹²)_(p)-heteroalkylene, (R¹²)_(p)-arylene, and (R¹²)_(p)-heteroarylene; R¹⁴ is selected from (R¹³)_(p)-alkylene, (R¹³)_(p)-heteroalkylene, (R¹³)_(p)-arylene, and (R¹³)_(p)-heteroarylene, R¹⁵ is selected from (R¹⁴)_(p)-alkylene, (R¹⁴)_(p)-heteroalkylene, (R¹⁴)_(p)-arylene, and (R¹⁴)_(p)-heteroarylene, and p is selected from 0, 1, 2, 3, 4 and 5. Optionally, R⁹ is selected from heteroalkyl, C₁-C₁₅alkyl, (C₆-C₁₀aryl)C₁-C₁₅alkylene, (C₆-C₁₀aryl)(C₆-C₁₀arylene)C₁-C₁₅alkylene, (C₁-C₁₅alkyl)_(p)(heteroarylene)C₁-C₁₅alkylene, and C₆-C₁₀aryl fused to C₁-C₁₅alkylene. Numerous suitable alcohols of formula R⁹OH are either commercially available chemicals or are compounds described in the chemical literature.

[0180] (c) is a chemical reaction in which 2 is coupled with an amine to give the amide 4. Suitable conditions for this type of reaction involve treating 2 with a suitable amine (R⁹R⁹NH), e.g., di(n-pentyl)amine, and a suitable base (if required), e.g., DIEA, in the presence of a suitable catalyst, e.g., DMAP, in an appropriate solvent, e.g., THF, at ambient temperature. In amines of formula R⁹R⁹NH, R⁹ is selected from hydrogen and organic groups having 1-30 carbons and optionally containing 1-4 heteroatoms selected from nitrogen, oxygen, silicon and sulfur, with the proviso that the two R⁹ groups may be joined together so as to form a ring with the nitrogen to which they are both attached. In one embodiment, R⁹ is selected from hydrogen, R¹¹, R¹², R¹³, R¹⁴ and R¹⁵ where R¹¹ is selected from alkyl, heteroalkyl, aryl and heteroaryl; R¹² is selected from (R¹¹)_(p)-alkylene, (R¹¹)_(p)-heteroalkylene, (R¹¹)_(p)-arylene and (R¹¹)_(p)-heteroarylene; R¹³ is selected from (R¹²)_(p)-alkylene, (R¹²)_(p)-heteroalkylene, (R¹²)_(p)-arylene, and (R¹²)_(p)-heteroarylene; R¹⁴ is selected from (R¹³)_(p)-alkylene, (R¹³)_(p)-heteroalkylene, (R¹³)_(p)-arylene, and (R¹³)_(p)-heteroarylene, R¹⁵ is selected from (R¹⁴)_(p)-alkylene, (R¹⁴)_(p)-heteroalkylene, (R¹⁴)_(p)-arylene, and (R¹⁴)_(p)-heteroarylene, and p is selected from 0, 1, 2, 3, 4 and 5. Optionally, R⁹ is selected from hydrogen, heteroalkyl, C₁-C₁₅alkyl, (heteroaryl)C₁-C₁₅alkylene, and (heteroalkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene. Numerous suitable amines of formula R⁹R⁹NH are either commercially available chemicals or are compounds described in the chemical literature.

[0181] (d) is a chemical reaction in which 2 is an acyl azide and is converted to the corresponding isocyanate prior to reaction with an alcohol (R⁹OH as defined above) to yield carbamate 5. Suitable conditions for this type of reaction involve first heating 2 in suitable solvent, e.g., refluxing dioxane, and then treating the resulting isocyanate with a suitable alcohol R⁹OH, e.g., n-propanol, in the absence or presence of a suitable catalyst, e.g., DMAP.

[0182] (e) is a chemical reaction in which 2 is an acyl azide and is converted to the isocyanate prior to reacting with an amine (R⁹R⁹NH as defined above), to yield urea 6. Suitable conditions for this type of reaction involve first heating 2 in a suitable solvent, e.g., refluxing dioxane, and then treating the resulting isocyanate with a suitable amine (R⁹R⁹NH), e.g., morpholine or tyramine.

[0183] In Scheme 2, chemical steps f, g and h represent the following reaction conditions.

[0184] (f) is a chemical reaction in which the protecting group of 3 is removed to give 7. When, for example, PG is trimethylsilylethyl, it may be removed by exposure to a suitable fluoride source, e.g., tetrabutylammonium fluoride (TBAF), in a suitable solvent, e.g., anhydrous THF. Alternatively, suitable deprotection conditions involve performing an acidolysis in, e.g., TFA/H₂O, 9/1 (v/v). Other conditions for removing protecting groups are set forth in Greene and Wuts, Protective Groups in Organic Synthesis, 2d Edition, John Wiley & Sons, New York, 1991.

[0185] (g) is a chemical reaction in which 7 is coupled to an alcohol to give 8. Suitable conditions for this type of reaction involve treating 7 with a suitable alcohol, e.g., dimethylbutanol, a coupling reagent such as O-(N-Succinimidyl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TSTU), a suitable base, e.g., an organoamine such as N-methylmorpholine (NMM), in the presence of a suitable catalyst, e.g., DMAP, in an appropriate solvent, e.g., 5% dimethylformamide (DMF) in THF.

[0186] (h) is a chemical reaction in which 7 is coupled with an amine HNR⁹R⁹ to give 9. Suitable conditions for this type of reaction involve treating 7 with a suitable coupling reagent such as O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU), a suitable base, e.g., an organoamine such as NMM, in the presence of a suitable catalyst, e.g., DMAP, in an appropriate solvent, e.g., THF.

[0187] In Scheme 3, chemical steps i, j, k, l and m represent the following reaction conditions.

[0188] (i) is a chemical reaction in which the ketone group of 3 is derivatized with an organohydrazine or organohydroxylamine to give 10. Suitable conditions for performing this type of reaction involve treating the ketone with a suitable hydrazine or hydroxylamine, e.g., methyl hydrazine or O-phenyl-hydroxylamine, in a suitable solvent, e.g., methanol.

[0189] (j) is a chemical reaction in which the ketone group of 3 is reduced to give alcohols 11 and 12. Suitable conditions for performing this type of reaction involve treating the ketone with a suitable reducing agent, e.g., NaBH4, in a suitable solvent, e.g., methanol. Other suitable reducing conditions are set forth in well known books and treatises. The resulting stereoisomers 11 and 12 may be separated from one another by, e.g., column chromatography.

[0190] (k) is a chemical reaction in which the ketone of group of 3 undergoes reductive amination to give amines 13 and 14. Suitable conditions for performing this type of reaction involve treating the ketone with a suitable amine (HNR⁹R⁹), e.g., dimethylamine, a suitable reducing agent, e.g., NaBH₃CN, in the presence of a mild acid, e.g., acetic acid, in a suitable solvent, e.g., methanol. Other suitable reductive amination conditions are set forth in well known books and treatises. The resulting stereoisomers 13 and 14 may be separated from one another by, e.g., column chromatography.

[0191] (l) is a chemical reaction in which the phenolic group of 3 is alkylated to give 15. Suitable conditions for performing this type of reaction involve treating 3 with a suitable alkyl halide, e.g., N,N-diethyl-2-chloroacetamide, in the presence of a suitable inorganic base, e.g., CS₂CO₃, in a suitable solvent, e.g., dimethoxyethane (DME) or DMF. Other suitable alkyl halides of formula R⁶-X are well known in the art, where X is halide, and R⁶ is selected from R¹¹, R¹², R¹³, R¹⁴ and R¹⁵ where R¹¹ is selected from alkyl, heteroalkyl, aryl and heteroaryl; R¹² is selected from (R¹¹)_(p)-alkylene, (R¹¹)_(p)-heteroalkylene, (R¹¹)_(p)-arylene and (R¹¹)_(p)-heteroarylene; R¹³ is selected from (R¹²)_(p)-alkylene, (R¹²)_(p)-heteroalkylene, (R¹²)_(p)-arylene, and (R¹²)_(p)-heteroarylene; R¹⁴ is selected from (R¹³)_(p)-alkylene, (R¹³)_(p)-heteroalkylene, (R¹³)_(p)-arylene, and (R¹³)_(p)-heteroarylene, R¹⁵ is selected from (R¹⁴)_(p)-alkylene, (R¹⁴)_(p)-heteroalkylene, (R¹⁴)_(p)-arylene, and (R¹⁴)_(p)-heteroarylene, and p is selected from 0, 1, 2, 3, 4 and 5, and optionally is selected from C₁-C₁₅alkyl, C₁-C₁₅heteroalkyl, (C₆-C₁₀aryl)C₁-C₁₅alkylene, (C₆aryl)(C₆aryl)C₁-C₁₅alkylene, (C₂-C₆heteroaryl)C₁-C₁₅alkylene, (C₆-C₁₀aryl)C₁-C₁₅heteroalkylene, (heteroalkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene, (heteroalkyl)_(p)(C₂-C₆heteroarylene)C₁-C₁₅alkylene, and (heteroalkyl)_(p)(C₆arylene)(heteroalkylene)(C₆arylene)C₁-C₁₅alkylene. Numerous suitable alkyl halides are either commercially available chemicals or are compounds described in the chemical literature.

[0192] (m) is a chemical reaction in which the phenolic group of 3 is alkylated to give 15. Suitable conditions for performing this type of reaction involve treating 3 with an organic compound having a suitably activated hydroxyl group in a suitable solvent, such as THF. For example, allyl 4-hydroxymethylbenzoate may be activated by exposure to a phosphine, e.g., triphenylphosphine, and a suitable azo compound, e.g., diethylazodicarboxylate (DEAD). Other suitable compounds having an activated hydroxyl group may be readily prepared from the corresponding alcohol of the formula R⁶-OH where R⁶ is an organic group. Alcohols of the formula R⁶-OH are well known in the art, including alcohols wherein R⁶ is selected from R¹¹, R¹², R¹³, R¹⁴ and R¹⁵ where R¹¹ is selected from alkyl, heteroalkyl, aryl and heteroaryl; R¹² is selected from (R¹¹)_(p)-alkylene, (R¹¹)_(p)-heteroalkylene, (R¹¹)_(p)-arylene and (R¹¹)_(p)-heteroarylene; R¹³ is selected from (R¹²)_(p)-alkylene, (R¹²)_(p)-heteroalkylene, (R¹²)_(p)-arylene, and (R¹²)_(p)-heteroarylene; R¹⁴ is selected from (R¹³)_(p)-alkylene, (R¹³)_(p)-heteroalkylene, (R¹³)_(p)-arylene, and (R¹³)_(p)-heteroarylene, R¹⁵ is selected from (R¹⁴)_(p)-alkylene, (R¹⁴)_(p)-heteroalkylene, (R¹⁴)_(p)-arylene, and (R¹⁴)_(p)-heteroarylene, and p is selected from 0, 1, 2, 3, 4 and 5, and optionally is selected from C₁-C₁₅alkyl, C₁-C₁₅heteroalkyl, (C₆-C₁₀aryl)C_(1-C) ₁₅alkylene, (C₆aryl)(C₆aryl)C₁-C₁₅alkylene, (C₂-C₆heteroaryl)C₁-C₁₅alkylene, (C₆-C₁₀aryl)C₁-C₁₅heteroalkylene, (heteroalkyl)_(p)(C₆ -C₁₀arylene)C₁-C₁₅alkylene, (heteroaklyl)_(p)(C₂-C₆heteroarylene)C₁-C₁₅alkylene, and (heteroalkyl)_(p)(C₆arylene)(heteroalkylene)(C₆arylene)C₁-C₁₅alkylene. Numerous suitable alcohols are either commercially available chemicals or are compounds described in the chemical literature.

[0193] In Scheme 4, chemical steps n, o, p and q represent the following reaction conditions.

[0194] (n) is a chemical reaction wherein the ester-carbamate 5 (prepared in, e.g., Scheme 1) is transformed into the corresponding ester-amine 16. Suitable conditions for this type of reaction involve treating 5 under reducing conditions, e.g., H₂, on a suitable catalyst or solid support, e.g., palladium, in the presence of a suitable solvent, e.g. ethanol.

[0195] (o) is a chemical reaction wherein the ester-amine 16 is acylated to form the corresponding ester-amide 17. Suitable conditions for this type of reaction involve treating 16 with an acylating agent, generally denoted as R⁹—C(═O)—X where R⁹ represents R⁹ as set forth in compounds of formula R1a, and X is a leaving group, e.g., chloride. The acylation reaction is suitably conducted in the presence of an amine, such as a secondary or tertiary amine, e.g., diisopropylethylamine (DIEA).

[0196] (p) is a chemical reaction wherein the ester-1° amine 16 is transformed into an ester-2°amine 18. Suitable conditions for this type of reaction involve treating 16 with an aldehyde of the formula R⁸—CHO, in the presence of a reducing agent, e.g., NaCNBH₃. In Scheme 4, the designation “R⁸” is used to denote the “R⁸” group as found in, for example, compound of formula R1a. Compounds of formula R⁸—CHO wherein R⁸ is selected from alkyl, aryl and heteroalkyl are well known in the chemical literature, and are available from commercial suppliers of chemicals. The ester-2°amine 18 is a suitable intermediate in the preparation of compounds of formula 19, which are also compounds of formula R1a.

[0197] (q) is a chemical reaction wherein the ester-2°amine 18 is transformed into an ester-amide 19. Suitable conditions for this type of reaction involve treating 18 with an acylating agent, generally denoted as R⁹—C(═O)—X, where R⁹ is used in Scheme 4 to denote “R⁹” in, for example, compounds of formula R1a, and X is a leaving group, e.g., chloride. The acylation reaction is suitably conducted in the presence of an amine, such as a secondary or tertiary amine, e.g., diisopropylethylamine (DIEA). Compounds of the formula R⁹—C(═O)—X are readily prepared from the corresponding carboxylic acid of the formula R⁹—C(═O)—OH by treatment with, e.g., thionyl chloride.

[0198] Numerous compounds of the formula R⁹—C(═O)—OH wherein R⁹ is an organic group having 1-30 carbons and optionally containing 1-4 heteroatoms selected from nitrogen, oxygen and silicon are well known in the chemical literature, and/or may be obtained from many commercial suppliers of chemicals. Furthermore, many compounds of formula R⁹—C(═O)—OH wherein R⁹ is selected from R¹¹, R¹², R¹³, R¹⁴ and R¹⁵ where R¹¹ is selected from alkyl, heteroalkyl, aryl and heteroaryl; R¹² is selected from (R¹¹)_(p)-alkylene, (R¹¹)_(p)-heteroalkylene, (R¹¹)_(p)-arylene and (R¹¹)_(p)-heteroarylene; R¹³ is selected from (R¹²)_(p)-alkylene, (R¹²)_(p)-heteroalkylene, (R¹²)_(p)-arylene, and (R¹²)_(p)-heteroarylene; R¹⁴ is selected from (R¹³)_(p)-heteroalkylene, (R¹³)_(p)-arylene, and (R¹³)_(p)-heteroarylene, R¹⁵ is selected from (R¹⁴)_(p)-alkylene, (R¹⁴)_(p)-heteroalkylene, (R¹⁴)_(p)-arylene, and (R¹⁴)_(p)-heteroarylene, and p is selected from 0, 1, 2, 3, 4 and 5, are well known in the chemical literature and/or may be obtained from commercial suppliers of chemicals. Furthermore, many compounds of formula R⁹—C(═O)—OH wherein R⁹ is selected from heteroalkyl, C₁-C₁₅alkyl, (heteroaryl)C₁-C₁₅alkylene, (C₆-C₁₀aryl)C₁-C₁₅alkylene, C₆-C₁₀aryl fused to C₁-C₁₅alkylene, (alkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene, (C₆-C₁₀aryl)(C₆-C₁₀arylene)C₁-C₁₅alkylene, (C₁-C₁₅alkyl)_(p)(heteroarylene)C₁-C₁₅alkylene, and (heteroalkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene, are well known in the chemical literature and/or may be obtained from commercial suppliers of chemicals. Furthermore, many compounds of formula R⁹—C(═O)—OH wherein R⁹ is selected from heteroalkyl, C₁-C₁₅alkyl, (C₆-C₁₀aryl)C₁-C₁₅alkylene, (heteroaryl)C₁-C₁₅alkylene, and (heteroalkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene, are well known in the chemical literature and/or may be obtained from commercial suppliers of chemicals. Furthermore, many compounds of formula R⁹—C(═O)—OH wherein R⁹ is selected from heteroalkyl, C₁-C₁₅alkyl, (C₆-C₁₀aryl)C_(-C) ₁₅alkylene, (C₆-C₁₀aryl)(C₆-C₁₀arylene)C₁-C₁₅alkylene, (C₁-C₁₅alkyl)_(p)(heteroarylene)C₁-C₁₅alkylene, and C₆-C₁₀aryl fused to C₁-C₁₅alkylene are well known in the chemical literature and/or may be obtained from commercial suppliers of chemicals. Furthermore, many compounds of formula R⁹—C(═O)—OH wherein R⁹ is selected from heteroalkyl, C₁-C₁₅alkyl, (C₆-C₁₀aryl)C₁-C₁₅alkylene, (C₆-C₁₀aryl)(C₆-C₁₀arylene)C₁-C₁₅alkylene, (C₁-C₁₅alkyl)_(p)-(heteroarylene)C₁-C₁₅alkylene, and C₆-C₁₀aryl fused to C₁-C₁₅alkylene are well known in the chemical literature and/or may be obtained from commercial suppliers of chemicals. Furthermore, many compounds of formula R⁹—C(═O)—OH wherein R⁹ is selected from heteroalkyl, C₁-C₁₅alkyl, (heteroaryl)C₁-C₁₅alkylene, and (heteroalkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene are well known in the chemical literature and/or may be obtained from commercial suppliers of chemicals. Furthermore, many compounds of formula R⁹—C(═O)—OH wherein R⁹ is selected from heteroalkyl, C₁-C₁₅alkyl, (heteroaryl)C₁-C₁₅alkylene, (C₆-C₁₀aryl)C₁-C₁₅alkylene, (alkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene, are well known in the chemical literature and/or may be obtained from commercial suppliers of chemicals. These carboxylic acids may be used in the preparation of compounds of the present invention.

[0199] One skilled in the art of organic synthesis would readily understand that the chemical steps disclosed above may be performed in a variety of sequences to produce bicyclooctanes of this invention. For instance, the compound of Example 2 undergoes step (h) to give the compound of Example 4. This compound in turn undergoes step (m) to give the bicyclooctane of Example 5.

[0200] The present invention provides benzobicyclooctane compounds wherein R³ may or may not be hydrogen, and independently, R⁷ may replace a hydrogen either 0, 1, 2 or 3 times on the “benzo” portion of the benzobicyclooctane compound. Compounds wherein R³ is hydrogen and n is 0 are readily prepared from (unsubstituted) 2,7-dihydroxynaphthalene, as shown in Schemes 1, 2, 3 and 4. Compounds wherein R³ is not hydrogen, and/or n is not 0, are readily prepared from the corresponding substituted 2,7-dihydroxynaphthalene. For example, a benzobicyclooctane compound of the invention wherein R³ is methyl and n is 1 with R⁷ being a methyl group may be prepared from a dimethyl substituted 2,7-dihydroxynaphthalene, e.g., 2,7-dihydroxy-3,6-dimethylnaphthalene as shown in Scheme 5. Commercial supply houses, custom chemical supply houses, and published synthetic methods provide access to a large number of substituted 2,7-dihydroxynaphthalene compounds that may be used in preparing compounds of the present invention.

[0201] Furthermore, benzobicyclooctane compounds wherein R³ is not equal to hydrogen and/or n is 1, 2 or 3 may be used in the synthetic transformations shown in Schemes 1, 2, 3 and/or 4, in lieu of the hydrogen-substituted benzobicyclooctane depicted in those Schemes, to provide compounds of the present invention. For instance, the benzobicyclooctane produced by the Diels-Alder reaction of maleic anhydride and 2,7-dihydroxy-3,6-dimethylnaphthalene as shown in Scheme 5 may be treated to open up the anhydride and form the corresponding acid/ester. Exemplary treatment conditions are DMAP with trimethylsilylethanol (see, e.g., Example 1 as described herein), which provides the corresponding carboxylic acid/trimethylsilylethylene ester as shown in Scheme 5, where this acid/ester is a representative compound of formula 1 as shown in Schemes 1, 2, 3 and 4.

[0202] In one aspect, the present invention provides benzobicyclooctane compounds wherein R⁶ is hydrogen or an organic group having 1-20 carbons, wherein the organic group may optionally include 1-4 heteroatoms selected from nitrogen, oxygen, silicon and sulfur. Schemes 1, 2, 3 and 4 illustrate synthetic methodology using a benzobicyclooctane compound wherein R⁶ is hydrogen. However, the same methodology may be employed with benzobicyclooctane compounds wherein R⁶ is an organic group.

[0203] Alternatively, a compound of the invention may be prepared according to Schemes 1, 2, 3 and 4, having desired R¹, R², R³, R⁴, R⁵ and R⁷ groups, with R⁶ being hydrogen. The R⁶ hydrogen may be replaced with an organic group having 1-20 carbons and optionally having 1-4 heteroatoms selected from nitrogen, oxygen, silicon and sulfur, as shown in steps 1 or m of Scheme 3. This later approach is illustrated in several Examples as set forth herein (see, e.g., Examples 5, 10, 33 (describing General Procedure F for converting R⁶═H to R⁶=organic group), 35 (describing General Procedure G) 36-43 and 45 (employing General Procedure F), and 44, 46-52 (employing General Procedure G) and 87-88. See also Examples 7, 8 and 34 wherein the R⁶ group is replaced with a different R₆ group). Accordingly, in view of the present disclosure, those of ordinary skill in the art can prepare compounds of the present invention wherein R⁶ is hydrogen or an organic group.

[0204] Benzobicyclooctane compounds of the invention wherein R⁶ is an inorganic group having 1-8 atoms exclusively selected from boron, sulfur, phosphorous, silicon and hydrogen, may readily be prepared from the corresponding phenolic compound, i.e., compounds wherein R⁶ is H. Methodology to convert alcohols to, e.g., sulfates, sulfonates, phosphates, phosphonates, borates, and boronates, where these groups are exemplary inorganic R⁶ groups, are well known in the art, and may be employed in the preparation of compounds of the present invention. For clarification, it will be noted that groups including heteroatoms as well as carbon atoms, e.g., —O—B(OR)₂ and —S(O)₂R where R is an organic group, are included within the scope of heteroalkyls as defined herein.

[0205] The present invention provides various stereoisomers of benzobicyclooctanes, in isolated form or as mixtures of stereoisomers, and in particular provides the diastereomers shown as Formulae Ia, Ib, Ic and Id. Any of these four diastereomers can be prepared according to the present invention. The Diels-Alder reaction of 2,7-dihydroxynaphthalene and maleic acid typically forms two diastereomers, shown as structures A and B in Scheme 6.

[0206] The diastereomers A and B can be separated from one another by, for example, chromatography, and then each can be reacted individually with trimethylsilyl ethanol to provide a mixture of the corresponding two cis acid-esters (C and D), as shown in Scheme 7a starting from diastereomer A, or the corresponding two trans acid-esters (E and F), as shown in Scheme 7b starting from diastereomer B.

[0207] The diastereomers C and D may be separated from one another by, for example, chromatography. Likewise, the diastereomers E and F can be separated from one another by, for example, chromatography. Each of the diastereomers C, D, E and F may be reacted under conditions to give either the trans or cis products. For example, as shown in Scheme 8a, diastereomer C may be reacted to form the trans diastereomer G or the cis diastereomer H where X is —OR (diester) or —NRR (ester amide). Likewise, diastereomer D may be reacted to form cis and trans products as shown in Scheme 8b.

[0208] C. Libraries

[0209] In one aspect, the present invention provides a library of benzobicyclooctane compounds. In one aspect the library includes, i.e., comprises, a plurality of compounds each having a structure of formula (I), while in another aspect the library consists of a plurality of compounds each having a structure of formula (I)

[0210] where each of R¹, R², R³, R⁴, R⁵, R⁶, and R⁷ have been defined above, including narrower embodiments thereof and set forth above, and diversity is present among the R¹, R², R³, R⁴, R⁵, R⁶, and R⁷ groups.

[0211] A library according to the present invention may be prepared by combinatorial synthetic techniques, where such a library is referred to herein as a combinatorial library. An exemplary combinatorial approach to preparing a library of the present invention is a solid-phase technique, where the benzobicyclooctane scaffold is covalently attached to a solid support. An exemplary solid-phase combinatorial technique includes the following steps:

[0212] (a) providing a compound bound to a solid support according to formula

[0213] wherein PG1 and PG2 refer to first and second protecting groups, respectively, where the first protecting group can be removed in the continued presence of the second protecting group, and the second protecting group can be removed in the continued presence of the linker, and (SS) refers to a solid support;

[0214] (b) removing the first protecting group but not the second protecting group, to provide a first deprotected product;

[0215] (c) reacting the first deprotected product with a plurality of amines of the formula HNRR′ to provide a plurality of compounds bound to a solid support, each according to formula (IIa)

[0216] where R and R′ are each independently selected from R⁹;

[0217] (d) removing the second protecting group from (IIa) to provide a second deprotected product;

[0218] (e) reacting the second deprotected product with a plurality of amines of the formula HNR″R′″ to provide a plurality of compounds bound to a solid support, each according to formula (IIb)

[0219] where R″ and R′″ are each independently selected from R⁹; and

[0220] (f) removing the benzobicyclooctane compounds from the linker to provide a library of compounds according to formula (IIc)

[0221] In various embodiments of this method: PG1 is —CH₂—CH═CH₂; and/or wherein PG2 is —CH₂CH₂—Si(CH₃)₃; and/or linker is

[0222] , or PG1 is —CH2—CH═CH2 while PG2 is —CH₂CH₂—Si(CH₃)₃ and while linker is

[0223] In various embodiments, additionally or alternatively: removing the first protecting group but not the second protecting group, to provide a first deprotected product according to step (b), is accomplished by reacting (II) with Pd(PPh₃)₄ and N-methylaniline; and/or removing the second protecting group from (IIa) to provide a second deprotected product according to step (d) is accomplished by treating (IIa) with tetrabutylammonium fluoride solution; and/or removing the linker to provide a library of compounds according to formula (IIc) is accomplished by treating (IIb) with aqueous trifluoroacetic acid.

[0224] In various embodiments, additionally or alternatively, the library prepares compounds wherein R³ is H, R⁴ and R⁵ collectively form ═O, and n is zero.

[0225] C. Pharmaceutical Compositions

[0226] In another aspect, the present invention provides a composition containing a benzobicyclooctane compound of formula (I) in admixture with a pharmaceutically acceptable adjuvant, carrier, diluent or excipient, i.e., the present invention provides a pharmaceutical composition containing a compound of formula (I). In other aspects, the present invention provides a composition containing a benzobicyclooctane compound according to each of embodiments, X1-X930, Y1-Y930 and Z1-Z930 in admixture with a pharmaceutically acceptable adjuvant, carrier, diluent or excipient. The pharmaceutical composition may contain optional ingredient(s) if desired.

[0227] The pharmaceutical compositions of the present invention may be in any form which allows for the composition to be administered to a patient. Typical routes of administration include, without limitation, oral, topical, parenteral, sublingual, rectal, vaginal, and intranasal. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. Pharmaceutical composition of the invention are formulated so as to allow the active ingredients contained therein to be bioavailable upon administration of the composition to a patient. Compositions that will be administered to a patient take the form of one or more dosage units, where for example, a tablet may be a single dosage unit, and a container of benzobicyclooctane in aerosol form may hold a plurality of dosage units.

[0228] The composition may be in the form of a solid, liquid or gas (aerosol). In one aspect, the carrier(s) are particulate, so that the compositions are, for example, in tablet or powder form. The carrier(s) may be liquid, with the compositions being, for example, an oral syrup or injectable liquid. In addition, the carrier(s) may be gaseous, so as to provide an aerosol composition useful in, e.g., inhalatory administration.

[0229] When intended for oral administration, the composition is preferably in either solid or liquid form, where semi-solid, semi-liquid, suspension and gel forms are included within the forms considered herein as either solid or liquid.

[0230] As a solid composition for oral administration, the composition may be formulated into a powder, granule, compressed tablet, pill, capsule, chewing gum, wafer or the like form. Such a solid composition will typically contain one or more inert diluents or edible carriers. In addition, one or more of the following adjuvants may be present: binders such as carboxymethylcellulose, ethyl cellulose, microcrystalline cellulose, gum tragacanth or gelatin; excipients such as starch, lactose or dextrins, disintegrating agents such as alginic acid, sodium alginate, Primogel, corn starch and the like; lubricants such as magnesium stearate or Sterotex; glidants such as colloidal silicon dioxide; sweetening agents such as sucrose or saccharin, a flavoring agent such as peppermint, methyl salicylate or orange flavoring, and a coloring agent.

[0231] When the composition is in the form of a capsule, e.g., a gelatin capsule, it may contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol or a fatty oil.

[0232] The composition may be in the form of a liquid, e.g., an elixir, syrup, solution, emulsion or suspension. The liquid may be for oral administration or for delivery by injection, as two examples. When intended for oral administration, preferred composition contain, in addition to the present compounds, one or more of a sweetening agent, preservatives, dye/colorant and flavor enhancer. In a composition intended to be administered by injection, one or more of a surfactant, preservative, wetting agent, dispersing agent, suspending agent, buffer, stabilizer and isotonic agent may be included.

[0233] The liquid pharmaceutical compositions of the invention, whether they be solutions, suspensions or other like form, may include one or more of the following adjuvants: sterile diluents such as water for injection, saline solution, preferably physiological saline, Ringer's solution, isotonic sodium chloride, fixed oils such as synthetic mono or digylcerides which may serve as the solvent or suspending medium, polyethylene glycols, glycerin, propylene glycol or other solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic. Physiological saline is a preferred adjuvant. An injectable pharmaceutical composition is preferably sterile.

[0234] A liquid compositions intended for either parenteral or oral administration should contain an amount of the inventive compound such that a suitable dosage will be obtained. Typically, this amount is at least 0.01% of a compound of the invention in the composition. When intended for oral administration, this amount may be varied to be between 0.1 and about 70% of the weight of the composition. Preferred oral compositions contain between about 4% and about 50% of the active vanadium(V) complex. Preferred compositions and preparations according to the present invention are prepared so that a parenteral dosage unit contains between 0.01 to 1% by weight of active compound.

[0235] The pharmaceutical composition may be intended for topical administration, in which case the carrier may suitably comprise a solution, emulsion, ointment or gel base. The base, for example, may comprise one or more of the following: petrolatum, lanolin, polyethylene glycols, bee wax, mineral oil, diluents such as water and alcohol, and emulsifiers and stabilizers. Thickening agents may be present in a pharmaceutical composition for topical administration. If intended for transdermal administration, the composition may include a transdermal patch or iontophoresis device. Topical formulations may contain a concentration of the inventive compound of from about 0.1 to about 10% w/v (weight per unit volume).

[0236] The composition may be intended for rectal administration, in the form, e.g., of a suppository which will melt in the rectum and release the drug. The composition for rectal administration may contain an oleaginous base as a suitable nonirritating excipient. Such bases include, without limitation, lanolin, cocoa butter and polyethylene glycol.

[0237] The composition may include various materials which modify the physical form of a solid or liquid dosage unit. For example, the composition may include materials that form a coating shell around the active ingredients. The materials which form the coating shell are typically inert, and may be selected from, for example, sugar, shellac, and other enteric coating agents. Alternatively, the active ingredients may be encased in a gelatin capsule.

[0238] The composition in solid or liquid form may include an agent which binds to the benzobicyclooctane compounds of the invention and thereby assists in the delivery of the active compound. Suitable agents which may act in this capacity include a monoclonal or polyclonal antibody, a protein or a liposome.

[0239] Materials used in preparing the pharmaceutical compositions should be pharmaceutically pure and non-toxic in the amounts used. It will be evident to those of ordinary skill in the art that the optimal dosage of the active ingredient(s) in the pharmaceutical composition will depend on a variety of factors. Relevant factors include, without limitation, the type of subject (e.g., human), the particular form of the active ingredient, the manner of administration and the composition employed.

[0240] The pharmaceutical composition of the present invention may consist of gaseous dosage units, e.g., it may be in the form of an aerosol. The term aerosol is used to denote a variety of systems ranging from those of colloidal nature to systems consisting of pressurized packages. Delivery may be by a liquefied or compressed gas or by a suitable pump system which dispenses the active ingredients. Aerosols of compounds of the invention may be delivered in single phase, bi-phasic, or tri-phasic systems in order to deliver the active ingredient(s). Delivery of the aerosol includes the necessary container, activators, valves, subcontainers, and the like, which together may form a kit. Preferred aerosols may be determined by one skilled in the art, without undue experimentation.

[0241] Whether in solid, liquid or gaseous form, the pharmaceutical composition of the present invention may contain one or more known pharmacological agents used in the treatment of inflammation.

[0242] The pharmaceutical compositions may be prepared by methodology well known in the pharmaceutical art. For example, a composition intended to be administered by injection can be prepared by combining a benzobicyclooctane compounds of formula (I) with water so as to form a solution. A surfactant may be added to facilitate the formation of a homogeneous solution or suspension. Surfactants are compounds that non-covalently interact with the benzobicyclooctane compound so as to facilitate dissolution or homogeneous suspension of the compound in the aqueous delivery system.

[0243] D. Biological Applications

[0244] The present invention provides benzobicyclooctanes, compositions containing a benzobicyclooctane, and methods of using benzobicyclooctane compounds to inhibit cellular events involving TNF-α or IL-8. Thus, in one aspect, the present invention provides a method to modulate binding of TNF-α to cell receptors, and/or modulate the consequential intracellular events comprising administering to a subject in a need thereof an effective amount of a benzobicyclooctane compounds of formula (I). The inhibition of TNF-α induced apoptosis and of NFκB activation is one means of preventing and/or treating autoimmune and inflammatory diseases including, but not limited to, rheumatoid arthritis, inflammatory bowel disease, psoriasis, atherosclerosis, asthma, reperfusion injury, ischemia, sepsis, graft vs. host disease, adult respiratory distress syndrome, multiple sclerosis, and a host of severe invasive infections such as fulminant hepatitis, AIDS and bacterial meningitis, and allergic inflammation-of the lungs and airways.

[0245] Thus, in one aspect, the present invention provides a method of inhibiting TNF-α induced apoptosis comprising administering to a subject in a need thereof an effective amount of a benzobicyclooctane compounds of formula (I). In another aspect, the present invention provides a method of inhibiting NFκB activation comprising administering to a subject in a need thereof an effective amount of a benzobicyclooctane compounds of formula (I). In another aspect, the present invention provides a method of inhibiting, preventing, treating, or preventing and/or treating autoimmune and inflammatory diseases including, but not limited to, rheumatoid arthritis, Inflammatory Bowel Disease (IBD), psoriasis, atherosclerosis, asthma, reperfusion injury, ischemia, sepsis, graft vs. host disease, Adult Respiratory Distress Syndrome (ARDS), and multiple sclerosis, comprising administering to a subject in a need thereof an effective amount of a benzobicyclooctane compounds of formula (I). In another aspect, the present invention provides a method of inhibiting, preventing, treating, or preventing and/or treating severe invasive infections such as fulminant hepatitis comprising administering to a subject in a need thereof an effective amount of a benzobicyclooctane compounds of formula (I).

[0246] In another aspect, the present invention provides a method for the inhibition of IL-8 or other CXC chemokines binding to CXCR1 and/or CXCR2 receptors comprising administering an effective amount of a compound of formula (I) to a subject in need thereof. In another aspect, the present invention provides a method for reducing the levels of IL-8 within a subject comprising administering to a subject in need thereof an effective amount of a compound of formula (I). In another aspect, the present invention provides a method for treating, preventing, or treating and/or preventing one or more of inflammatory and autoimmune diseases such as Inflammatory Bowel Disease (IBD), psoriasis, rheumatoid arthritis, Acute Respiratory Distress Syndrome (ARDS), cancer, atherosclerosis, reperfusion injury, and graft vs. host disease, comprising administering to a subject in need thereof an effective amount of a compound of formula (I).

[0247] The present invention provides a method for inhibiting TNF-α mediated processes, comprising administering to a patient in need thereof, through a therapeutically or prophylactically acceptable manner, a therapeutically or pharmaceutically effective amount of a composition comprising a compound of formula (I). Administering may be by, for example, transdermal, oral, intravenous, intramuscular, vaginal, rectal, pulmonary, subcutaneous, sublingual and transmucosal administration.

[0248] The present invention provides a method for treating an inflammation event, comprising administering to a patient in need thereof, through a therapeutically or prophylactically acceptable manner, a therapeutically or pharmaceutically effective amount of the compound of formula (I). Administering may be selected from transdermal, oral, intravenous, intramuscular, vaginal, rectal, pulmonary, subcutaneous, sublingual and transmucosal administration.

[0249] The “effective amount” or “therapeutically effective amount” of a compound of the present invention will depend on the route of administration, the type of mammal being treated, and the physical characteristics of the specific mammal under consideration. These factors and their relationship to determining this amount are well known to skilled practitioners in the medical arts. This amount and the method of administration can be tailored to achieve optimal efficacy but will depend on such factors as weight, diet, concurrent medication and other factors which those skilled in the medical arts will recognize.

[0250] In addition, this invention provides a method for identifying a binding partner to a compound of formula (I), wherein the method comprises immoblizing proteins known to be involved in the TNF-a signaling pathway onto a suitable carrier; and passing a solution of said compounds in isolation or mixture over said proteins and analyzing for compound:protein complex formation using surface plasmon resonance (SPR) in a manner similar to that reported by Karlsson, R et al. Biosensor Analysis of Drug-Target Interactions: Direct and Competitive Binding Assays for Investigation of Interactions Between Thrombin and Thrombin Inhibitors. Anal. Biochem. 2000, 278(1), 1-13. For other examples of identifying small molecule-protein interactions using SPR see the Biacore website: http://www.biacore.com

[0251] In addition, this invention provides a method for identifying a binding partner to a compound of formula (I), wherein the method comprises (in a manner similar to that reported by Shimizu, N et al. High Performance Affinity Beads for Identifying Drug Receptors. Nature Biotechnology, 2000, 18(8), 877-881) providing said compound(s) bound to a solid support to provide solid phase compounds; contacting a cell or cell components with said solid phase compounds in isolation or mixture; removing uncomplexed cellular material, for example by gentle washing with aqueous buffer, from said solid phase compounds; and recovering said binding partner from the solid phase compounds.

[0252] As to each publication or patent referenced herein, that publication or patent is incorporated herein by reference in its entirety for all purposes.

[0253] From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

[0254] The following examples are offered by way of illustration, and not by way of limitation.

EXAMPLES

[0255] Abbreviations and acronyms used in the examples include: AcOH, acetic acid; APCI-MS, atmospheric pressure chemical ionization mass spectroscopy; DBU, 1,8-diazabicyclo[5.4.0]undec-7-ene; DEAD, diethylazodicarboxylate; DIEA, diisopropylethylamine;-DMAP, 4-N,N-dimethylaminopyridine; DME, 1,2-dimethoxyethane; DMF, dimethylformamide; DMSO, dimethyl sulfoxide; DPPA, diphenylphosphorylazide; ESI-MS, electrospray ionization mass spectroscopy; FAB-MS, fast atom bombardment mass spectroscopy; FTIR, Fourier transform infrared spectroscopy; HATU, O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate; HPLC, high pressure liquid chromatography; HRMS, high resolution mass spectroscopy; LC-MS, liquid chromatography-mass spectroscopy; NMA, N-methylaniline; NMM, N-methylmorpholine; NMP, N-methylpyrrolidinone; NMR, nuclear magnetic resonance spectroscopy; TBAF, tetrabutylammonium fluoride; TFA, trifluoroacetic acid; THF, tetrahydrofuran; TSTU, O-(N-Succinimidyl)-1,1,3,3-tetramethyluronium tetrafluoroborate; rt, room temperature; h, hour; min, minute; eq, equivalents.

Example 1 Synthesis of 4-hydroxy-11-oxo-tricyclo[6.2 .2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 9-(2-trimethylsilylethyl) ester

[0256]

[0257] A. 4-Hydroxy-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid anhydride

[0258] A solution of dihydroxynaphthalene (500 g, 3.125 mol) and maleic anhydride (765 g, 7.815 mol, 2.5 eq) in 1 L 1:1 1,2-dichlorobenzene:toluene were heated at 110° C. for 3 days. The reaction mixture was then cooled to 90° C., 1.5 L ethyl acetate added, and then further cooled to room temperature overnight. The mixture was then cooled over ice after another 0.5 L ethyl acetate was added and left stirring for 2 hours. The resultant solid was isolated by filtration, washed with 2×200 mL cold ethyl acetate and dried in oven at 40° C. to provide 130 g of the anhydride as a beige solid (16% yield). ¹H NMR (acetone-d₆) 7.33 (d, J=8.2 Hz, 1H), 6.97 (d, J=2.3 Hz, 1H), 6.85 (dd, J=8.1, 2.4 Hz, 4.05 (d, J=3.9 Hz, 1H), 3.98 (dd, J=6.0, 2.9 Hz, 1H), 3.88 (dd, J=10.2, 3.9 Hz, 1H), 3.70 (dd, J=10.2, 2.7 Hz, 1H), 2.39 (br s, 2H). HRMS for MH⁺259.0600 (theoretical 259.0606).

[0259] B. 4-Hydroxy-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 9-(2-trimethylsilanylethyl) ester, 1

[0260] DMAP (0.96 g, 7.9 mmol, 10 mol %) and trimethylsilyl-ethanol (12.43 mL, 0.087 mol, 1.1 eq) were added to a stirred suspension of the anhydride from step A (20.5 g, 0.079 mol) in 200 mL acetonitrile and heated to reflux for 7 hours. By HPLC there was some starting material present and the two regioisomers of the opened anhydride were present in a 1:1 ratio. The reaction mixture was cooled and dicyclohexylamine (15.71 mL, 0.079 mol) was added dropwise. A precipitate formed instantaneously but was left overnight. The resulting white salt (40.73 g, 93%) was filtered, suspended in water, acidified with 2 M HCl and extracted with ethyl acetate. An emulsion formed, but was removed by filtration before the layers could be separated, and the organic layer was dried and evaporated in vacuo to give a mixture of the regioisomeric acid-esters as a beige foam (25.59 g, 93%). A hazy solution of the solids (25.59 g, 0.068 mol) in 150 mL isopropanol was treated with isopropylamine (5.79 mL, 0.068 mol) and left stirring overnight. The precipitate was isolated by filtration yielding a white solid (12.44 g, 42% yield) as a 86/17 mixture of diastereomers. This solid was slurried in 48 mL isopropanol for 1.5 hours giving a second white solid (10.69 g) as a 93/7 mixture of diasteroemers. This salt was cracked as described above to give a white foam (6.76 g) which was then triturated in 33 mL 20% diethyl ether/toluene at −20° C. The resulting white solid was collected by filtration and washed with 10 mL cold solvent. This afforded 1 as a white solid (4.59 g, 300% overall yield from the anhydride) of 98.2% purity by HPLC. ¹H NMR (acetonitrile-d₃) 7.12 (d, J=8.0 Hz, 1H), 6.76 (d, J=2.5 Hz, 1H), 6.72 (dd, J=8.0, 2.5 Hz, 1H), 4.20-4.06 (m, 2H), 3.65 (d, J=3 Hz, 1H), 3.61 (br s, 1H), 3.22 (br d, J=11.0 Hz, 1H), 2.93 (br s, 1H), 2.85 (dd, J=18.3, 2.3 Hz, 1H), 2.04 (br d, IH), 0.99-0.93 (m, 2H), 0.03 (s, 9H). MS for MNa⁺ 399.4. Elemental analysis for C₁₉H₂₄O₆Si, Theoretical: C, 60.62; H, 6.43. Found: C, 60.61; H,6.58.

Example 2 Synthesis of (4-hydroxy-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-(2-trimethylsilanyl-ethyl) ester)

[0261]

[0262] DMAP (0.5 g, 4 mmol, 10 mol %) and trimethylsilylethanol (6.6 mL, 5.45 g, 46 mmol) were added to a stirred suspension of the anhydride (10.83 g, 42 mmol) from Example 1.A in 400 mL acetonitrile and heated to reflux for 6 h. The volatiles were evaporated, and the resulting foam was chromatographed on silica gel (20% acetonitrile/dichloromethane with 2% AcOH). Appropriate fractions were combined and dichloromethane and toluene were used to remove residual AcOH. Repeated trituration of the less polar product with ethyl ether provided 4.9 g (31%) of the title compound. ¹H NMR (acetonitrile-d₃) 7.13 (d, J=8.0 Hz, 1H), 6.75 (d, J=2.2 Hz, 1H), 6.72 (dd, J=8.0, 2.5 Hz, 1H), 4.17-4.11 (m, 2H), 3.64-3.62 (m, 1H), 3.60 (d, J=3.0 Hz, 1H), 3.22 (dd, J=11.8, 3.0 Hz, 1H), 2.97 (dt, J=11.8, 2.2 Hz, 1H), 2.87 (dd, J=18.7, 2.2 Hz, 1H), 2.08 (ddd, J=18.4, 3.3, 2.5 Hz, 1H), 1.00-0.95 (m, 2H), 0.04 (s, 9H). MS 399.4 (MNa⁺). Elemental for C₁₉H₂₄O₆Si: Theoretical, C, 60.62; H, 6.43. Found: C, 60.58; H, 6.57. In addition, repeated trituration of the more polar product provided 5.0 g (32%) of acid 1.

Example 3 Synthesis of (9,10 cis)-10-allyloxycarbonylamino-4-hydroxy-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9-(2-Trimethylsilanyl-ethyl) ester

[0263]

[0264] To a solution of acid 1 (196 mg, 0.52 mmol) in THF (25 mL) was added DPPA (230 μL, 1.05 mmol), triethylamine (150 μL, 1.08 mmol), and allyl alcohol (360 μL, 5.3 mmol). The mixture was heated to reflux and held for 15 h. Upon cooling, the mixture was concentrated in vacuo, and the residue chromatographed, initially with 30% ethyl acetate/hexane followed by a second chromatography using 15% ethyl acetate/dichloromethane to afford a total of 65.8 mg (30%) of the title compound. ESI-MS m/z 454 (MNa⁺).

Example 4 Synthesis of 5-hydroxy-10-{methyl-[(2,4,6-trimethoxy-benzylcarbamoyl)-methyl]-carbamoyl}-12-oxo-tricyclo[6.2.2.0²,⁷]dodeca-2(7),3,5-triene-9-(2-trimethylsilanyl-ethyl) ester

[0265]

[0266] A. Sarcosine-2,4,6-trimethoxybenzylamide

[0267] To a solution of N-Fmoc-sarcosine (5 g, 16 mmol) in dichloromethane (160 mL) containing 3A molecular sieves was added NMM (6 mL, 5.52 g, 55 mmol), HATU (7.33 g, 19 mmol) and 2,4,6-trimethoxybenzylamine hydrochloride (4.5 g, 19.2 mmol). The resulting reaction mixture was allowed to stir at rt overnight. The sieves were filtered, the volatiles evaporated and ethyl acetate was added. Acid wash (0.1 N HCl, 3×300 mL) followed by sodium bicarbonate (5% solution, 1×300 mL) provided a solid precipitate, which was collected, washed with ethyl acetate, collected and air dried. The organic layer was concentrated to dryness to give a residue which was triturated with ethyl acetate to provide an additional amount of the Fmoc derivative of 101: amount recovered 7.5 g (95%). ¹H NMR (CDCl₃) 7.77-7.27 (m, 8H), 6.35 (br s, 1H), 6.05 (br s, 2H), 4.49-4.05 (m, 5H), 3.93 (s, 2H), 3.74 (s, 9H), 2.99 (s, 3H). FAB-MS m/z 513 (MNa⁺), 491 (MH⁺).

[0268] The isolated N-Fmoc-sarcosine-2,4,6-trimethoxybenzylamide (6.5 g, 13 mmol) was suspended in 25% pyrrolidine/chloroform (100 mL) and allowed to stir at rt for 50 min. The volatiles were then evaporated to give a pale yellow solid. Column chromatography (10% methanol/dichloromethane) provided the desired product 101 upon trituration with ethyl ether, wt. 3.1 g (88%). ¹H NMR (CDCl₃) 6.13 (d, 2H), 4.48 (d, J=5.5 Hz, 2H), 3.82 (s, 9H), 3.24 (s, 2H), 2.40 (s, 3H). Elemental for C₁₃H₂₀N₂O₄: Theoretical, C, 58.19; H, 7.51; N, 10.44. Found: C, 58.09; H, 7.66; N, 10.18.

[0269] B. 5-Hydroxy-10-{methyl-[(2,4,6-trimethoxy-benzylcarbamoyl)-methyl]-carbamoyl}-12-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9-(2-trimethylsilanyl-ethyl) ester

[0270] To a solution of the carboxylic acid from Example 2 (4.5 g, 11.8 mmol) in dichloromethane (25 mL) was added NMM (3.2 mL, 2.9 g, 29 mmol), HATU (5.3 g, 13.9 mmol), 3A molecular sieves and sarcosine-2,4,6-trimethoxybenzylamide (3.1 g). The resulting solution was allowed to stir at rt under nitrogen overnight. The volatiles were then evaporated, ethyl acetate (300 mL) was added and the organic layer was washed with 0.1 N HCl (2×150 mL), 5% NaHCO₃ solution (1×100 mL) and brine (1×100 mL). The organic layer was dried (MgSO₄), filtered and the volatiles were evaporated to give a yellow foam. Column chromatography (90% ethyl acetate/hexane) provided the desired product, wt. 3.5 g (49%). ¹H NMR (CDCl₃) 7.05-6.70 (m, 3H), 6.48 (t, 1H), 6.12, 6.05 (2s, 2H), 4.56-4.40 (m, 2H), 4.20-2.71 (m, 21H), 2.20-2.07 (m, 1H), 1.00-0.90 (m, 2H), 0.02 (s, 9H). Elemental for C₃₂H₄₂N₂O₉Si: Theoretical, C, 60.16; H, 7.04; N, 4.25. Found: C, 60.29; H, 6.93; N, 4.18.

Example 5 Synthesis of 2,4,6-trimethoxy-benzylcarbamoyl)-methyl]-carbamoyl}-1-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-trien-4-yloxymethyl)-benzoic acid allyl ester

[0271]

[0272] A. Allyl 4-Hydroxymethylbenzoate

[0273] To a solution of 4-hydroxymethylbenzoic acid (0.5 g, 3.3 mmol) in CHCl₃ (10 mL) was added allyl bromide (0.6 mL, 0.84 g, 6.9 mmol) and diisopropylethylamine (1.3 mL, 0.96 g, 7.5 mmol). The resulting reaction mixture was allowed to reflux under nitrogen for 2.5 h. Upon cooling to rt, dichloromethane (50 mL) was added and the organic layer was washed with 0.1 N HCl (3×30 mL), 5% NaHCO₃ solution (1×30 mL) and brine (1×30 mL). Upon drying (MgSO₄), filtration of the drying agent and concentration, the resulting oily residue was chromatographed on silica gel (30% ethyl acetate/hexane) to give 440 mg (70%) of a colorless oil. ₁H NMR (CDCl₃) 8.06 (d, J=8.2 Hz, 2H), 7.44 (d, J=8.2 Hz, 2H), 6.11-5.98 (m, 11H), 5.42 (dd, J=17.2, 1.5 Hz, 11H), 5.30 (dd, J=10.4, 1.2 Hz, 1H), 4.83 (dd, J=5.6, 1.2 Hz, 2H), 4.78 (s, 2H), 1.80 (br s, 1H). MS 192 (M⁺).

[0274] B. 5-(4-Allyloxycarbonyl-benzyloxy)-10-{methyl-[(2,4,6-trimethoxy-benzylcarbamoyl)-methyl]-carbamoyl}-11-oxo-tricyclo [6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9-carboxylic acid-(2-trimethylsilanyl-ethyl) ester

[0275] To a cooled solution (ice bath) of allyl 4-hydroxymethylbenzoate (0.62 g, 3.2 mmol) and the compound prepared in Example 4 (1.33 g, 2 mmol) in anhydrous THF (40 mL) was added PPh₃ (1.34 g, 5.1 mmol) and DEAD (0.8 mL, 0.88 g, 5.1 mmol). The resulting reaction mixture was allowed to warm to room temperature and then allowed to reflux under N₂ for 0.5 h. Column chromatography of the concentrated residue (90% ethyl acetate/hexane) provided the title compound as a white foamy material, wt. 0.98 g (58%). ¹H NMR (CDCl₃) 8.09 (d, J=8.2 Hz, 2H), 7.49 (d, J=8. 0 Hz, 2H), 7.16-6.46 (m, 4H), 6.11-5.98 (m, 3H), 5.42 (d, J=17.2 Hz, 1H), 5.30 (d, J=10.4 Hz, 1H), 5.11 (s, 2H), 5.83 (d, J=5.6 Hz, 2H), 4.56-4.37 (m, 2H), 4.17-3.9 (m, 2H), 3.81-3.70 (m, 12H), 3.55-2.05 (m, 8H), 0.97-0.89 (m, 2H), 0.02 (s, 9H). Elemental for C₄₃H₅₂N₂O¹¹Si: Theoretical, C, 64.48; H, 6.54; N, 3.50. Found: C, 64.18; H. 6.67; N, 3.28.

Example 6 Synthesis of 4-(10-dipentylcarbamoyl-9-{methyl-[(2,4,6-trimethoxy-benzylcarbamoyl)-methyl]-carbamoyl}-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-trien-4-yloxymethyl)-benzoic acid allyl ester

[0276]

[0277] To a solution of the diester prepared in Example 5 (0.5 g, 0.62 mmol) in anhydrous THF (14 mL) was added a 1.0 M solution of TBAF (1.0 mL, 1 mmol). The reaction mixture was allowed to stir at rt for 1.75 h, after which ethyl acetate (200 mL) was added. The organic layer was then washed with 0.1 N HCl (2×50 mL), brine (2×50 mL), dried (MgSO₄), filtered and concentrated to give a colorless oil. The free acid was dissolved in dichloromethane (12 mL) and HATU (0.29 g, 0.76 mmol); NMM (0.17 mL, 0.16 g, 1.55 mmol) and dipentylamine (.15 mL, 0.12 g, 0.7 mmol) were added. The resulting reaction mixture was then allowed to stir at rt under N₂ for 3 days, after which dichloromethane (300 mL) was added. The organic layer was then washed with 0.1 N HCl (2×100 mL), 55 solution of NaHCO₃ (2×50 mL), water (2×50 mL), brine (1×50 mL), dried (MgSO₄), filtered and the volatiles were evaporated to give a colorless oil. Column chromatography (5% methanol/dichloromethane) provided the desired product, wt. 303 mg (58%). ¹H NMR (CDCl₃) 8.08 (d, J=8.2 Hz, 2H), 7.50 (d, J=8.3 Hz, 2H), 7.18-6.72 (m, 3H), 6.11-5.98 (m, 3H), 5.41 (dd, J=17.2, 1.3 Hz, 1H), 5.30 (apt t, J=6.0, 4.4 Hz, 1H), 5.11 (s, 2H), 4.83 (d, J=5.6 Hz, 2H), 4.53-4.35 (m, 2H), 4.02 (d, J=15.4 Hz, 1H), 3.85-2.80 (m, 23H), 2.16 (d, J=18.5 Hz, 1H), 1.60-1.10 (m, 12H), 0.94-0.86 (m, 6H). Elemental for C₄₈H₆₁N₃O₁₀.methanol: Theoretical, C, 67.49; H, 7.51; N, 4.82. Found: C, 67.68; H, 7.45; N, 4.63.

Example 7 Synthesis of 4-(10-dipentylcarbamoyl-9-{methyl-[(2,4,6-trimethoxy-benzylcarbamoyl)-methyl]-carbamoyl}-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-trien-4-yloxymethyl)-benzoic acid

[0278]

[0279] A solution of allyl ester prepared in Example 6 (0.28 g, 0.33 mmol), tetrakis(triphenylphosphine) palladium (0) (27 mg, 23 μmol) and N-methylaniline (75 μL, 74 mg, 0.69 mmol) in dichloromethane (3.5 mL) was allowed to stir at rt for 1 h. The reaction mixture was then diluted with dichloromethane (50 mL) and washed with 0.1 N HCl solution (2×20 mL) and brine (2×20 mL). Upon drying (MgSO₄), filtration of the drying agent and concentration, the resulting oily residue was chromatographed on silica gel (5% methanol/dichloromethane) to provide the desired product as a white solid, wt. 160 mg (60%). ¹H NMR (CDCl₃) 8.14, 7.92 (2 d, J=8.0, 7.8 Hz, 2H), 7.54 (d, J=7.9 Hz, 2H), 7.31-6.89 (m, 4H), 6.12 (s, 2H), 5.15, 5.06 (2 br s, 2H), 4.57-4.39 (m, 2H), (m, 2H), 4.08 (J=15.5 Hz, 1H), 3.91-3.52 (m, 13H), 3.30-2.86 (m, 7H), 2.38 (s, 2H), 2.20 (d, J=18.4 Hz, 1H), 159-0.80 (m, 18H). MS (ESI +ve) 800 (MH⁺), 822 (MNa⁺). Elemental for C₄₅H₅₇N₃O₁₀. methanol: Theoretical, C, 66.41; H, 7.39; N, 5.05. Found: C, 66.28; H, 7.22; N, 4.83.

Example 8 Synthesis of 4-[4-(2-dimethylcarbamoyl-pyrrolidine-1-carbonyl)-benzyloxy]-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-dipentylamide 10-{methyl-[(2,4,6-trimethoxy-benzylcarbamoyl)-methyl]-amide}

[0280]

[0281] A solution of the acid prepared in Example 7 (67 mg, 84 μmol), HATU (38 mg, 100 μmol), NMM (22 μL, 20 mg, 0.2 mmol) and H-prolinedimethylamide (15 mg, 0.1 mmol) in dichloromethane (1.0 mL) was allowed to stir at rt overnight. The reaction mixture was then diluted with dichloromethane (30 mL) and washed with 0.1 N HCl solution (2×20 mL), 5% NaHCO₃ solution (1×25 mL) and brine (1×25 mL). Upon drying (MgSO₄), filtration of the drying agent and concentration, the resulting oily residue was chromatographed on silica gel (5% methanol/dichloromethane) to provide the diastereomeric mixture as a white solid, wt. 54 mg (70%). ¹H NMR (CDCl₃) 7.61 (d, J=8.0 Hz), 7.43 (d, J=8.0 Hz), 7.38 (s), 7.15(d, J=8.0 Hz), 7.02-6.78 (m), 6.11 (s), 6.09 (s), 5.06 (s), 5.02 (s), 4.52-4.33 (m), 4.04-3.88 (m), 3.86-3.67 (m), 3.57-3.49 (m), 3.27-3.06 (m), 2.99 (s), 2.85 (s), 2.82 (s), 2.76 (d, J=10.6 Hz), 2.53 (d, J=9.1 Hz), 2.31-1.80 (m) 1.60-1.10 (m), 0.91 (t, J=5.8 Hz), 0.87 (t, J=6.0 Hz). ESI-MS m/z 925 (MH⁺), 947 (MNa⁺).

Example 9 Synthesis of 4-hydroxy-11-oxo-tricyclo [6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-(2,4-dimethyoxy-benzyl) ester 9-(2-trimethylsilanyl-ethyl) ester

[0282]

[0283] To a solution of acid 1 (2.83 g, 7.5 mmol), prepared in Example 1, 2,4-dimethoxybenzylalcohol (1.65 g, 9.8 mmol) and DMAP (0.1 g, 0.8 mmol) in dichloromethane (50 mL) was added DIEA (2.8 mL, 2.1 g, 16 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (2.2 g, 11.5 mmol). The resulting reaction mixture was allowed to stir at rt for 24 h, after which time it was concentrated to dryness, redissolved in ethyl acetate (300 mL) and washed with 0.1 N HCl solution (2×100 mL), 5% NaHCO₃ solution (1×100 mL) and brine (1×100 mL). Upon drying (MgSO₄), filtration of the drying agent and concentration, the resulting oily residue was chromatographed on silica gel (35% ethyl acetate/hexane) to provide 370 mg (10%) of the trans bis-ester. ¹H NMR (CDCl₃) 7.10 (dd, J=8.1, 2.9 Hz, 2H), 6.69 (dd, J=8.0, 2.4 Hz, 1H), 6.48-6.42 (m, 2H), 6.33 (d, J=2.4 Hz, 1H), 5.30-5.22 (br s, 1H), 5.03 (dd, J=37.1, 11.8 Hz, 2H), 4.27-4.21 (m, 2H), 3.91 (d, J=2.2 Hz, 1H), 3.83 (s, 3H), 3.80 (s, 3H), 3.76-3.73 (m, 1H), 3.69 (dd, J=5.8, 2.2 Hz, 1H), 3.28-3.22 (m, 1H), 2.40 (dd, J=18.9, 2.0 Hz, 1H), 2.10 (dm, 1H), 1.04-0.99 (m, 2H), 0.01 (s, 9H). FAB-MS m/z 526 (M⁺).

Example 10 Synthesis of 4-methoxy-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-(2,4-dimethoxy-benzyl) ester 9-(2-trimethylsilanyl-ethyl) ester

[0284]

[0285] To a solution of the phenol prepared in Example 9 (70 mg, 0.13 mmol) in anhydrous THF (5 mL) was added cesium carbonate (48 mg, 0.14 mmol) and methyl iodide (45 μL, 103 mg, 0.7 mmol). The resulting reaction mixture was allowed to stir at rt under N₂ for 22 h. The reaction mixture was then diluted with ethyl acetate (20 mL) and washed with 0.1 N HCl solution (2×10 mL), 5% NaHCO₃ solution (1×10 mL) and brine (1×10 mL). Upon drying (MgSO₄), filtration of the drying agent and concentration, the resulting oily residue was chromatographed on silica gel (1% methanol/dichloromethane) to provide 35 mg (49%) of the methyl ether. ¹H NMR (CDCl₃) 7.18 (d, J=8.2 Hz, 1H), 7.11 (d, J=8.2 Hz, 1H), 6.77 (dd, J=8.2, 2.5 Hz, 1H), 6.58 (d, J=2.4 Hz, 1H), 6.49-6.41 (m, 2H), 5.02 (dd, J=24.7, 11.8 Hz, 2H), 4.28-4.22 (m, 2H), 3.98 (d, J=2.2 Hz, 1H), 3.83 (s, 3H), 3.80 (s, 3H), 3.78-3.75 (m, 1H), 3.72 (s, 3H), 3.71-3.69 (m, 1H), 3.28-3.26 (m, 1H), 2.41 (dd, J]19.0, 2.1 Hz, 1H), 2.11 (dm, 1H), 1.05-0.99 (m, 2H), 0.06 (s, 9H). FAB-MS m/z 540 (M⁺).

Example 11 Synthesis of 10-(2,4-dimethoxy-benzylcarbamoyl)-4-hydroxy-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9-(2-trimethylsilanyl-ethyl) ester

[0286]

General Procedure A for the Synthesis of 4-Hydroxy-10-amido Derivatives

[0287] To a solution of the cis acid ester 1 (0.5 mmol) and molecular sieves (3A) in THF (2 mL) was added diisopropylethylamine (2.8 mmol) and diphenylphosphoryl azide (0.7 mmol). The solution was allowed to stir at rt under nitrogen for 3-4 h, after which time a selected amine (1.5-2 mol equivalents) and DMAP (2 mol equivalents) were added and the resulting reaction mixture was allowed to stir overnight. Dilution with ethyl acetate (25 mL), followed by washes with 1 N HCl (2×25 mL), 5% NaHCO₃ solution (2×25 mL) and brine (1×25 mL) provided a pale yellow solution, which was dried (MgSO₄), filtered and concentrated to dryness. Column chromatography provided the desired product.

[0288] The title compound was prepared as in general procedure A, above. Column chromatography (10% acetonitrile/dichloromethane) provided 35% of the title compound. ¹H NMR (acetonitrile-d₃) 7.14 (br s, 1H), 7.11 (d, J=8.2 Hz, 1H), 7.05 (br s, 1H), 7.02 (d, J=8.2 Hz, 1H), 6.65 (dd, J=8.0, 2.5 Hz, 1H), 6.53 (dd, J=8.4, 2.3 Hz, 2H), 6.44 (dd, J=8.4 2.3 Hz, 1H), 4.25-4.16 (m, 4H), 3.81, 3.77 (2 s, 6H), 3.74 (app. q, J=2.4 Hz, 1H), 3.69 (d, J=1.9 Hz, 1H), 3.39 (dd, J=6.3, 1.9 Hz, IH), 3.20 (dt, J=6.3, 2.2 Hz, 1H), 2.37 (dd, J=19.0, 2.2 Hz, 1H), 2.03 (dq, J=19.0, 3.0, 2.2 Hz, IH), 1.01-0.96 (m, 2H), 0.04 (s, 9H). ¹³C NMR (acetonitrile-d₃) 209.20, 174.55, 171.38, 161.73, 159.66, 157.60, 135.53, 134.32, 130.69, 126.08, 120.02, 115.50, 114.98, 105.26, 99.43, 64.48, 57.56, 56.30, 56.10, 46.27, 43.91, 39.42, 39.01, 38.41, 17.96, −1.43. FAB-MS m/z 540 (MH⁺). Elemental for C₂₈H₃₅NO₇Si: Theoretical, C, 63.98; H, 6.71; N, 2.66. Found: C, 63.77; H, 6.86; N, 2.63.

Example 12 Synthesis of 10-dipentylcarbamoyl-4-hydroxy-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9-(2-trimethylsilanyl-ethyl) ester

[0289]

[0290] The title compound was prepared as in general procedure A in Example 11. Column chromatography (5% acetonitrile/dichloromethane) provided 23% of the title compound. ¹H NMR (acetonitrile-d₃) 7.12 (d, J=8.0 Hz, 1H), 6.98 (br s, 1H), 6.67 (dd, J=8.0, 2.5 Hz, 1H), 6.53 (d, J=2.5 Hz, 1H), 4.62-4.23 (m, 2H), 3.76-3.73 (m, 1H), 3.36 (dd, J=6.6, 1.7 Hz, 1H), 3.56-3.19 (m, 5H), 2.97-2.88 (m, 1H), 2.47 (dd, J=18.8, 2.1 Hz, 1H), 2.04 (dt, J=19.0, 2.6 Hz, 1H), 1.69-1.15 (m, 12H), 1.02-0.97 (m, 2H), 0.92, 0.88 (2 t, J=5.9, 5.6Hz, 6H), 0.03 (s, 9H). ¹³C NMR (acetonitrile-d₃) 208.83, 174.55, 170.74, 157.60, 135.21, 134.56, 125.88, 115.47, 114.94, 64.27, 57.27, 48.65, 46.87, 46.77, 40.21, 38.98, 38.25, 29.94, 29.86, 29.75, 28.34, 23.30, 23.26, 18.10, 14.44, −1.46. FAB-MS m/z 516 (MH⁺). Elemental for C₂₉H₄₅NO₅Si: Theoretical, C, 67.53; H, 8.79; N, 2.72. Found: C, 67.36; H, 9.00; N, 2.73.

Example 13 Synthesis of 4-hydroxy-11-oxo-tricyclo [6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0291]

[0292] A mixture of the product from Example 1 (1.46 g, 3.88 mmol), TSTU (1.40 g 4.65 mmol), DIEA (3.2 mL, 18.4 mmol) were dissolved in THF (15 mL) and stirred under N₂ for 5 h. The solution was then treated with DMAP (0.58 g, 4.7 mmol) and n-propanol (7.5 mL) and stirred an additional 19 h. The reaction was quenched with 0.2 M HCl (aq) and diluted with 150 mL ethyl acetate. The phases were separated and the organic was washed with 5% NaHCO₃ (aq) and brine. The organic layer was separated, dried (Na₂SO₄) and concentrated to 2.0 g of light yellow oil. Silica chromatography (ethyl acetate/hexanes) afforded 1.0 g (62%) of the title compound. ¹H NMR (CDCl₃) 7.12 (d, J=8 Hz, 1H), 6.70 (dd, J=2.5, 8 Hz, 1H), 6.64 (d, J=2.5 Hz, 1H), 5.26 (s, 1H), 4.25 (dd, J=7, 9 Hz, 2H), 3.98-3.93 (m, 3H), 3.74 (d, J=2.5 Hz, 1H), 3.65 (dd, J=2.2, 5.8 Hz, 1H), 3.2 (dd, J=2, 5 Hz, 1H), 2.41 (dd, J=2, 19 Hz, 1H), 2.16 (dd, J=2, 21 Hz, 1H), 1.57 (dd, J=7, 14 Hz, 2H), 1.05 (ddd, J=7, 7, <1 Hz, 2H), 0.87 (t, J=7, 7 Hz, 3H), 0.04 (s, 9H); ESI-MS m/z 417 (M−H)⁻.

Example 14 Synthesis of 4-hydroxy-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-(2-cyclohexyloxy-ethyl) ester 9-(2-trimethylsilanyl-ethyl) ester

[0293]

General Procedure B for the Synthesis of Trans Bis-esters 3

[0294] To a solution of the cis acid ester 1 (0.27 mmol) and molecular sieves (3A) in THF (1.0 mL) was added DIEA (1.4 mmol) and DPPA (0.37 mmol). The solution was allowed to stir at rt under nitrogen for 3-4 h, after which time a selected alcohol (2.5 mol equivalents) and DMAP (2 mol equivalents) were added and the resulting reaction mixture was allowed to stir overnight. Dilution with ethyl acetate (25 mL), followed by washes with 1 N HCl (2×25 mL), 5% NaHCO₃ solution (2x25 mL) and brine (1×25 mL) provided a pale yellow solution, which was dried (MgSO₄), filtered and concentrated to dryness. Column chromatography provided the desired product.

[0295] The title compound was prepared as described in general procedure B using 2-cyclohexyloxyethanol. Column chromatography (7% acetonitrile/dichloromethane) provided a 30% yield of the title compound. ¹H NMR (acetonitrile-d₃) 7.15 (d, J=8.0 Hz, 1H), 7.01 (br s, 1H), 6.74-6.69 (m, 2H), 4.32-4.19 (m, 2H), 4.14-4.05 (m, 2H), 3.84 (d, J=2.2 Hz, 1H), 3.73 (app. q, J=2.7 Hz, 1H), 3.60 (dd, J=6.0, 2.2 Hz, 1H), 3.56-3.53 (m, 2H), 3.27-3.20 (m, 1H), 3.09 (dt, J=6.0, 2.3 Hz, 1H), 2.36 (dd, J=19.0, 2.5 Hz, 1H), 2.06 (ddd, J=l9.0, 3.2, 2.1 Hz, 1H), 1.87-1.75 (m, 2H), 1.74-1.64 (m, 2H), 1.56-1.46 (m, 1H), 1.34-1.12 (m, 5H), 1.06-1.00 (m, 2H), 0.05 (s, 9H). ¹³C NMR (acetonitrile-d₃) 208.86, 173.97, 172.62, 157.71, 135.64, 134.36, 126.38, 115.77, 115.03, 78.49, 66.37, 65.95, 64.74, 55.95, 47.07, 43.78, 39.32, 38.30, 33.03, 26.63, 24.84, 18.01, −1.42. FAB-MS m/z 502 (M⁺). Elemental for C₂₇H₃₈O₇Si: Theoretical, C, 64.51; H, 7.62. Found: C, 64.47; H, 7.76.

Example 15 Synthesis of 4-hydroxy-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-(2-pyridin-2-yl-ethyl) ester 9-(2-trimethylsilanyl-ethyl) ester

[0296]

[0297] The title compound was prepared as described in general procedure B using 2-(2-hydroxyethyl)-pyridine. Column chromatography (neat ethyl acetate) provided 48% of the title compound. ¹H NMR (acetonitrile-d3) 8.49 (ddd, J=4.7, 1.7, 1.1 Hz, 1H), 7.68 (td, J=7.7, 1.9 Hz, 1H), 7.23-7.18 (m, 2H), 7.14 (d, J=8.2 Hz, 1H), 6.72 (dd, J=8.0, 2.5 Hz, 1H), 6.57 (d, J=2.5 Hz, 1H), 4.42-4.15 (2 m, 4H), 3.72-3.68 (m, 2H), 3.53 (dd, J=6.0, 2.2 Hz, 1H), 3.04-2.99 (m, 3H), 2.33 (dd, J=19.0, 2.2 Hz, 1H), 2.03 (ddd, J=19.0, 3.2, 2.1 Hz, 1H), 1.03-0.97 (m, 2H), 0.04 (s, 9H). ¹³C NMR (acetonitrile-d₃) 208.85, 173.90, 172.50, 159.30, 157.78, 150.50, 137.92, 135.53, 134.23, 126.38, 124.73, 123.06, 115.82, 114.95, 65.40, 64.68, 55.86, 46.87, 43.75, 39.22, 38.30, 37.71, 17.95, −1.42. FAB-MS m/z 482 (MH⁺). Elemental for C₂₆H₃₁NO₆Si: Theoretical, C, 64.84; H, 6.49; N, 2.91. Found: C, 64.63; H, 6.43; N, 2.70.

Example 16 Synthesis of 4-hydroxy-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-(3-fluoro-benzyl) ester 9-(2-trimethylsilanyl-ethyl) ester

[0298]

[0299] The title compound was prepared as described in general procedure B using 3-fluorobenzyl alcohol. Column chromatography (1% methanol/dichloromethane) provided a 56% yield of the title compound. ¹H NMR (acetonitrile-d₃) 7.41-7A34 (m, 1H), 7.16 (d, J=8.2 Hz, 1H), 7.11-7.02 (m, 3H), 6.98 (br s, 1H), 6.72 (dd, J=8.2, 2.5 Hz, 1H), 6.61 (d, J=2.5 Hz, 1H), 5.03 (s, 2H), 4.27-4.22 (m, 2H), 3.86 (d, J=2.2 Hz, 1H), 3.74 (dd, J=5.2, 2.5 Hz, 1H), 3.67 (dd, J=6.0, 2.2 Hz, 1H), 3.12 (dt, J=6.0, 2.3 Hz, 1H), 2.38 (dd, J=19.0, 2.2 Hz, 1H), 2.06 (ddd, J=l9.1, 3.3, 2.2 Hz, 1H), 1.03-0.97 (m, 2H), 0.04 (S, 9H). ¹³C NMR (acetonitrile-d₃) 208.68, 173.91, 172.49, 165.58, 162.35, 157.72, 140.06, 139.95, 135.46, 134.36, 131.72, 131.62, 126.43, 124.97, 124.94, 116.26, 115.99, 115.91, 115.82, 115.61, 114.97, 67.07, 64.74, 55.81, 47.06, 43.81, 39.19, 38.27, 17.96, −1.45. FAB-MS m/z 484 (M⁺). Elemental for C₂₆H₂₉FO₆Si: Theoretical, C, 64.44; H, 6.03. Found: C, 64.47; H, 6.13.

Example 17 Synthesis of 4-hydroxy-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-(2-pyrrolidin-1-yl-ethyl) ester 9-(2-trimethylsilanyl-ethyl) ester

[0300]

[0301] The title compound was prepared as described in general procedure B using 1-(2-hydroxyethyl)-pyrrolidine. Column chromatography (10% methanol/dichloromethane) provided 39% of the title compound. ¹H NMR (acetonitrile-d₃) 7.17-7.13 (m, 1H), 6.73-6.68 (m, 2H), 4.29-4.21 (m, 2H), 4.08 (t, J=5.8 Hz, 2H), 3.83 (d, J=2.2 Hz, 1H), 3.72 (dd, J=5.5, 2.8 Hz, 1H), 3.57 (dd, J=6.0, 2.2 Hz, 1H), 3.11 (dt, J=6.0, 2.3 Hz, 1H), 2.63 (td, J=5.6, 2.5 Hz, 2H), 2.51-2.45 (m, 4H), 2.35 (dd, J=19.0, 2.2 Hz, 1H), 2.05 (ddd, J=19.0, 3.2, 2.1 Hz, 1H), 1.73-1.68 (m, 4H), 1.05-1.00 (m, 2H), 0.05 (s, 9H). ¹³C NMR (acetonitrile-d₃) 208.89, 174.00, 172.59, 157.89, 135.58, 134.18, 126.41, 126.34, 115.83, 115.09, 114.94, 65.13, 64.69, 55.92, 55.10, 55.04, 54.93, 46.99, 43.79, 43.72, 39.27, 38.33, 24.31, 24.11, 17.99, −1.42. FAB-MS m/z 474 (MH⁺).

Example 18 Synthesis of 4-hydroxy-11-oxo-tricyclo [6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-dodecyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0302]

[0303] The title compound was prepared as described in general procedure B using n-dodecanol. Column chromatography (1% methanol/dichloromethane) provided 50% of the title compound. ¹H NMR (acetonitrile-d3) 7.15 (d, J=8.0 Hz, 1H), 7.00 (br s, 1H), 6.71 (dd, J=8.0, 2.5 Hz, 1H), 6.67 (d, J=2.5 Hz, 1H), 4.28-4.22 (m, 2H), 4.04-3.91 (m, 2H), 3.83 (d, J=2.2 Hz, 1H), 3.72 (dd, J=5.4, 2.6 Hz, 1H), 3.57 (dd, J=5.9, 2.3 Hz, 1H), 3.09 (dt, J=6.0, 2.4 Hz, 1H), 2.37 (dd, J=l9.0, 2.5 Hz, 1H), 2.05 (ddd, J=19.0, 3.1, 2.1 Hz, 1H), 1.56-1.44 (m, 2H), 1.28 (br s, 18H), 1.05-1.00 (m, 2H), 0.88 (t, J=6.6 Hz, 3H), 0.05 (s, 9H). ¹³C NMR (acetonitrile-d₃) 208.88, 174.01, 172.64, 157.75, 135.65, 134.36, 126.39, 115.75, 114.92, 66.38, 64.68, 55.98, 47.05, 43.87, 39.27, 38.32, 32.78, 30.52, 30.49, 30.44, 30.35, 30.21, 30.03, 29.41, 26.69, 23.50, 18.01, 14.50, −1.40. ESI-MS m/z 567.3 (MNa⁺). Elemental for C₃₁H₄₈O₆Si: Theoretical, C, 68.34; H, 8.88. Found: C, 68.22; H, 8.98.

Example 19 Synthesis of 4-hydroxy-11-oxo-tricyclo [6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-allyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0304]

[0305] The title compound was prepared as described in general procedure B using allyl alcohol. Column chromatography (7% acetonitrile/dichloromethane) provided 39% of the title compound. ¹H NMR (acetonitrile-d₃) 7.16 (d, J=8. 0 Hz, 1H), 7.02 (br S, 1H), 6.72 (dd, J=8.0, 2.5 Hz, 1H), 6.69 (d, J=2.5 Hz, 1H), 5.92-5.81 (m, 1H), 5.28-5.17 (m, 2H), 4.56-4.43 (m, 2H), 4.33-4.19 (m, 2H), 3.87 (d, J=2.2 Hz, 1H), 3.74 (dd, J=5.4, 2.6 Hz, 1H), 3.64 (dd, J=5.9, 2.3 Hz, 1H), 3.12 (dt, J=5.9, 2.5 Hz, IH), 2.37 (dd, J=19.0, 2.2 Hz, 1H), 2.06 (ddd, J=l9.0, 3.3, 2.2 Hz, 1H), 1.06-1.00 (m, 2H), 0.05 (s, 9H). ¹³C NMR (acetonitrile-d₃) 208.79, 173.96, 172.37, 157.71, 135.58, 134.36, 133.51, 126.44, 118.75, 115.79, 114.95, 66.75, 64.72, 55.92, 47.01, 43.81, 39.22, 38.31, 17.98, −1.43. FAB-MS m/z 416 (M⁺). Elemental for C₂₂H₂₈O₆Si: Theoretical, C, 63.44; H, 6.78. Found: C, 63.19; H, 6.97.

Example 20 Synthesis of 10-azidocarbonyl-4-hydroxy-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9-(2-trimethylsilanyl-ethyl) ester

[0306]

[0307] To a solution of 1 (584 mg, 1.51 mmol) in THF (15.6 mL) was added triethylamine (0.864 mL, 6.14 mmol) and DPPA (0.384 mL, 1.79 mmol). After 6.5 h the reaction was diluted with ethyl acetate and 1% HCl. The layers were separated and the organic layer washed with 5% NaHCO₃, H₂O, and brine, then dried (Na₂SO₄) and concentrated. Flash chromatography (25% ethyl acetate/hexane) afforded the trans acyl azide 2 (218 mg, 36%). FTIR (NaCl, cm⁻¹): 3435, 2960, 2907, 2152, 2129, 1803, 1735, 1728. ¹H NMR (CDCl₃): 7.15 (d) 1H), 6.7 (m, 2H), 4.23 (m, 2H), 3.94 (d, 1H), 3.77 (dd, 1H), 3.68 (dd, 1H), 3.20 (ddd, 1H), 2.40 (dd, 1H), 2.15 (ddd, 1H), 0.10 (s, 9).

Example 21 Synthesis of 4-hydroxy-11-oxo-10-propoxycarbonylamino-tricyclo[6.2.2.0²⁷]dodeca-2(7),3,5-triene-9-(2-trimethylsilanyl-ethyl) ester

[0308]

General Procedure C for Synthesis of 10-Alkoxycarbonylamino Derivatives

[0309] A 0.1 M solution of the acyl azide 2 in dioxane was refluxed for 1 h to generate the isocyanate. A selected alcohol was added in large excess and the solution heated for 4-20 h. The solution was cooled, and the crude product isolated by concentration in vacuo or by extraction. Chromatography on SiO₂ afforded the product.

[0310] The title compound was prepared as described in general procedure C employing propyl alcohol. Chromatography with 10% to 30% ethyl acetate/hexane afforded the title compound in 11% overall yield. FAB-MS m/z 434 (MH⁺).

Example 22 Synthesis of 4-hydroxy-10-(5-methyl-isoxazol-3-yl-methoxycarbonylamino)-11-OXO-tricyclo[.6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9-(2-trimethylsilanyl-ethyl) ester

[0311]

General Procedure D for Synthesis of 10-Alkoxycarbonylamino Derivatives

[0312] A 0.1 M solution of the acyl azide 2 in dioxane was refluxed for 1 h to generate the isocyanate. The alcohol (1.2-2 eq) was added followed by DMAP and the solution refluxed until complete, typically 12-20 h. The crude product was isolated by extraction.

[0313] The title compound was prepared as described in general procedure D employing 5-methylisoxazole-3-methanol, and with the following modifications. A solution of the acyl azide (200 mg, ˜0.36 mol) in dioxane (3.6 mL) was heated to reflux for 30 min. The reaction was cooled to rt and 171 mg of 5-methylisoxazole-3-methanol was added. The reaction was returned to reflux for 15 h, then cooled to rt. The reaction was quenched with aqueous ammonium chloride and diluted with ethyl acetate. The phases were partitioned, and the organic layer was separated and washed with 5% aqueous NaHCO₃, then brine. The solution was dried (Na₂SO₄) and concentrated to dryness. Chromatography with 5% to 40% ethyl acetate/hexane afforded the title compound in 4% overall yield. ¹H NMR (CDCl₃) 7.12 (d, 1H), 6.71 (dd, 1H), 6.56 (d, 1H), 5.81 (s, 1H), 5.49 (s, 1H), 4.97 (dd, 2H), 4.25 (dd, 2H), 3.95 (d, 1H), 3.75 (m, 2H), 3.48 (s, 1H), 3.25-3.23 (m, 1H), 2.41 (s, 3H), 2.38 (dd, 1H), 2.25 (dd, 1H), 1.03 (dd, 2H), 0.05 (s, 9H).

Example 23 Synthesis of 4-hydroxy-10-isopropoxycarbonylamino-11-oxo-tricyclo[6.2.2.0^(2,7) ]dodeca-2(7),3,5-triene-9-(2-trimethylsilanyl-ethyl) ester

[0314]

[0315] The title compound was prepared as described in general procedure C employing isopropyl alcohol. Chromatography with 30% ethyl acetate/hexane afforded a 53% yield of product. ESI-MS m/z 456 (MNa⁺).

Example 24 Synthesis of 10-cyclopentyloxycarbonylamino-4-hydroxy-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9-(2-trimethylsilanyl-ethyl) ester

[0316]

[0317] The title compound was prepared as in general procedure C employing cyclopentanol. Chromatography with 30% ethyl acetate/hexane afforded a 64% yield of product. ESI-MS m/z 482 (MNa⁺).

Example 25 Synthesis of (9, 10 trans)-10-allyloxycarbonylamino-4-hydroxy-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9-(2-trimethylsilanyl-ethyl) ester

[0318]

[0319] The title compound was prepared as in general procedure C employing allyl alcohol. Chromatography with 40% ethyl acetate/hexane afforded a 44% yield of product. ESI-MS m/z 454 (MNa⁺).

Example 26 Synthesis of 4-hydroxy-10-(indan-2-yloxycarbonylamino)-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9-(2-trimethylsilanyl-ethyl) ester

[0320]

[0321] The title compound was prepared as in general procedure D employing 2-indanol. Chromatography with 30% ethyl acetate/hexane afforded 17% yield of product. ESI-MS m/Z 530 (MNa⁺).

Example 27 Synthesis of 10-(3-allyl-ureido)-4-hydroxy-11-oxo-tricyclo [6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9-(2-trimethylsilanyl-ethyl) ester

[0322]

General Procedure E for The Synthesis of 10-Ureido Derivatives

[0323] A 0.1 M solution of the acyl azide 2 in dioxane was refluxed for 0.5 h. Upon cooling the appropriate amine was added and the solution stirred at ambient temperature for 1-4 h. Ethyl acetate and 1% HCl were added and the layers separated. The organic layer was washed with 5% NaHCO₃, H₂O, brine, dried (Na₂SO₄) and concentrated in vacuo. Flash chromatography afforded the urea.

[0324] The title compound was prepared as described in general procedure E employing 3.6 eq of allylamine. The crude product was chromatographed on SiO₂ to afford a 27% yield of the urea. ESI-MS m/z 453 (MNa⁺).

Example 28 Synthesis of 4-hydroxy-10-{3-[2-(4-hydroxy-phenyl)-ethyl]-ureido}-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3, 5-triene-9-(2-trimethylsilanyl-ethyl) ester

[0325]

[0326] The title compound was prepared as described in general procedure E employing 2.2 eq of tyramine. The crude product was chromatographed with 50% ethyl acetate/hexane to 65% ethyl acetate/hexane gradient to afford an 18% yield of the urea. ESI-MS m/z 533 (MNa⁺).

Example 29 Synthesis of 4-hydroxy-10-[(morpholine-4-carbonyl)-amino]-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9-(2-trimethylsilanyl-ethyl) ester

[0327]

[0328] The title compound was prepared as described in general procedure E employing 3.3 eq of morpholine. The crude product was chromatographed with 70% ethyl acetate/methylene chloride to afford a 50% yield of the urea. ESI-MS m/z 483 (MNa⁺).

Example 30 Synthesis of 10-(3-tert-butyl-ureido)-4-hydroxy-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9-(2-trimethylsilanyl-ethyl) ester

[0329]

[0330] The title compound was prepared as described in general procedure E employing 3 eq of tert-butylamine. The crude product was chromatographed with 35% ethyl acetate/hexane to 45% ethyl acetate/hexane gradient to afford a 57% yield of the urea. ESI-MS m/z 469 (MNa⁺).

Example 31 Synthesis of 10-[3-(2,4-dimethoxy-benzyl)-ureido]-4-hydroxy-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9-(2-trimethylsilanyl-ethyl) ester

[0331]

[0332] The title compound was prepared as described in general procedure E employing 1.5 eq of 2,4-dimethoxybenzylamine. The crude product was chromatographed with 60% ethyl acetate/hexane to afford a 16% yield of the urea. ESI-MS m/z 563 (MNa⁺).

Example 32 Synthesis of 4-hydroxy-10-(3-naphthalen-1-ylmethyl-ureido)-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7)3,5-triene-9-(2-trimethylsilanyl-ethyl) ester

[0333]

[0334] The title compound was prepared as described in general procedure E employing 2 eq of 1-naphthalene methylamine. The crude product was chromatographed with 50% ethyl acetate/hexane to afford a 47% yield of the urea. ESI-MS m/z 531 (MH⁺).

Example 33 Synthesis of 4-(4-allyloxycarbonyl-benzyloxy)-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9, 10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0335]

General Procedure F for the Synthesis of 4-Alkoxy Derivatives

[0336] To a 0.1 M solution of the benzobicyclooctane phenol (1 eq), prepared in Example 13, in tetrahydrofuran was added triphenylphosphine and the appropriate alcohol. The solution was cooled to 0° C. and DEAD was added. The cooling bath was removed, the solution stirred at ambient temp for 5 min then heated at reflux until reaction was complete, typically 20-30 min. After cooling, the solution was diluted with ethyl acetate, water was added and the layers separated. The organic layer was washed with brine, dried (Na₂SO4), and concentrated in vacuo. Chromatography on SiO₂ afforded the aryl ether.

[0337] The title compound was prepared as described in general procedure F employing 2.5 eq triphenyphosphine, 1.9 eq of allyl-4-(hydroxymethyl)-benzoate, and 2.5 eq of DEAD. Chromatography with 15% ethyl acetate/hexane followed by a second chromatography with 25% ethyl acetate/hexane afforded a 54% yield of aryl ether. ESI-MS m/z 615 (MNa⁺).

Example 34 Synthesis of 4-[4-(2-dimethylcarbamoyl-pyrrolidine-1-carbonyl)-benzyloxy]-11-oxo-tricyclo [6.2.2.02,7]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0338]

[0339] A. 4-(4-Carboxy-benzyloxy)-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0340] To a solution of the allyl ester prepared in Example 33 in methylene chloride was added N-methylaniline (40 μL, 0.37 mmol) followed by tetrakis(triphenylphosphine)palladium(0) (21 mg, 0.02 mmol). The reaction was stirred for 20 min, diluted with ethyl acetate, and 2% HCl added. The layers were separated and the organic layer was washed with 1% HCl, H₂O, brine, dried (Na₂SO₄), and concentrated in vacuo. Chromatography with 65% ethyl acetate/methylene chloride to 95% ethyl acetate/dichloromethane afforded a 60% yield of product. ESI-MS m/z 551 (M−H)³¹ .

[0341] B. 4-[4-(2-Dimethylcarbamoyl-pyrrolidine-1-carbonyl)-benzyloxy]-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0342] To a solution of the acid (51.1 mg), N-methylmorpholine (30 μL), and proline dimethylamide (17.5 mg, 0.12 mmol) in methylene chloride (0.7 mL) was added HATU (46 mg, 0.12 mmol). The solution was stirred for 6 h, diluted with ethyl acetate, and quenched with 3% HCl. The layers were separated and the organic layer washed with 1% HCl, 5% NaHCO₃, H₂O, brine, dried (Na₂SO₄), and concentrated in vacuo. Chromatography with 100% ethyl acetate—5% methanol/methylene chloride gradient afforded the product contaminated with tetramethyl urea. An ethereal solution of the mixture was washed with H₂O (10×), dried (Na₂SO₄) and concentrated to afford 29.6 mg (46%) of the titled product as a 1/1 mixture of diasteroemers. ESI-MS m/z 677 (MH⁺).

Example 35 Synthesis of 4-diethylcarbamoylmethoxy-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-Trimethylsilanyl-ethyl) ester

[0343]

General procedure G for the synthesis of 4-Alkoxy Derivatives

[0344] To a 0.2 M solution of the phenol prepared as in Example 13 (1 eq) in DME or DMF was added alkyl halide and cesium carbonate (Cs₂CO₃). The solution was stirred at ambient temperature until complete, normally 1-12 h. The reaction was diluted with ethyl acetate, 1% HCl was added and the layers separated. The organic layer was washed with 5% NaHCO₃, brine, dried (Na₂SO₄) and concentrated in vacuo. Chromatography on SiO₂ afforded the aryl ether.

[0345] The title compound was prepared as described in general procedure G employing DME, 1.5 eq of N,N-diethyl-2-chloroacetamide and 2.0 eq of cesium carbonate. Chromatography with 3% ethyl acetate/methylene chloride to 10% ethyl acetate/methylene chloride gradient afforded a 26% yield of product. ESI-MS m/z 554 (MNa⁺).

Example 36 Synthesis of 4-(4-nitro-benzyloxy)-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9, 10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0346]

[0347] The title compound was prepared as described in general procedure F employing 2.3 eq PPh₃, 2.0 eq. nitrobenzyl alcohol and 2.3 eq DEAD. Chromatography with 10% ethyl acetate/hexane afforded the title compound in 30% yield. ESI-MS m/z 576 (MNa⁺).

Example 37 Synthesis of 4-(biphenyl-4-ylmethoxy)-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9, 10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0348]

[0349] The title compound was prepared as described in general procedure F employing 1.7 eq PPh₃, 1.7 eq. biphenylmethanol and 1.7 eq DEAD. Chromatography with 10% ethyl acetate/hexane afforded the title compound in 47% yield. ESI-MS m/Z 607 (MNa⁺).

Example 38 Synthesis of 4-(2-naphthalen-2-yl-ethoxy)-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl)

[0350]

[0351] The title compound was prepared as described in general procedure F employing 2.3 eq PPh₃, 2.0 eq. naphthaleneethanol and 2.3 eq DEAD. Chromatography with 5% ethyl acetate/hexane afforded the title compound in 46% yield. ESI-MS m/z 595 (MNa⁺).

Example 39 Synthesis of 4-(3-fluoro-benzyloxy)-11-oxo-tricyclo[6.2.2.0 ^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0352]

[0353] The title compound was prepared as described in general procedure F employing 2.3 eq PPh₃, 2.0 eq. 3-fluorobenzyl alcohol and 2.3 eq DEAD. Chromatography with 5% ethyl acetate/hexane afforded the title compound in 50% yield. ESI-MS m/z 549 (MNa⁺).

Example 40 Synthesis of 11-Oxo-4-(3-phenyl-propoxy)-tricyclo [6.2.2.0^(2,7)]dodeca-2(7),-3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0354]

[0355] The title compound was prepared as described in general procedure F employing 2.3 eq PPh₃, 2.0 eq. 3-phenyl-1-propanol and 2.3 eq DEAD. Chromatography with 5% ethyl acetate/hexane afforded the title compound in 40% yield. ESI-MS m/z 559 (MNa⁺).

Example 41 Synthesis of 11-Oxo-4-(2-pyridin-2-yl-ethoxy)-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0356]

[0357] The title compound was prepared as described in general procedure F employing 2.3 eq PPh₃, 2.0 eq. 2-(2-hydroxyethyl) pyridine and 2.3 eq DEAD. Chromatography with 20% ethyl acetate/dichloromethane afforded the title compound in 36% yield. ESI-MS m/z 546 (MNa⁺).

Example 42 Synthesis of 4-(2-methoxy-ethoxy)-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0358]

[0359] The title compound was prepared as described in general procedure F employing 2.3 eq PPh₃, 2.0 eq. 2-methoxyethanol and 2.3 eq DEAD. Chromatography with 18% ethyl acetate/hexane, then 15% acetone/hexane afforded the title compound in 50% yield. ESI-MS m/z 499 (MNa⁺), 515 (MK⁺).

Example 43 Synthesis of 4-cyclopentyloxy-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0360]

[0361] The title compound was prepared as described in general procedure F employing 2.3 eq PPh₃, 2.0 eq. cyclopentanol and 2.3 eq DEAD. Chromatography with 10% ethyl acetate/hexane afforded the title compound in 36% yield. ESI-MS m/z 509 (MNa⁺).

Example 44 Synthesis of 4-(3-cyano-propoxy)-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0362]

[0363] The title compound was prepared as described in general procedure G employing DMF, 1.5 eq 4-bromobutyronitrile and 2.0 eq Cs₂CO₃. Chromatography with 20% ethyl acetate/hexane afforded the title compound in 82% yield. ESI-MS m/z 508 (MNa⁺).

Example 45 Synthesis of 4-(5-methyl-isoxazol-3-ylmethoxy)-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0364]

[0365] The title compound was prepared as described in general procedure F employing 2.3 eq PPh₃, 2.0 eq. 5-methylisoxazole-3-methanol and 2.3 eq DEAD. Chromatography with 20% ethyl acetate/dichloromethane afforded the title compound in 36% yield. ESI-MS m/z 536 (MNa⁺).

Example 46 Synthesis of 4-ethoxy-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0366]

[0367] The title compound was prepared as described in general procedure G employing DMF, 1.5 eq iodoethane and 2.0 eq Cs₂CO₃. Chromatography with 10% ethyl acetate/hexane afforded the title compound in 40% yield. ESI-MS m/z 469 (MNa⁺).

Example 47 Synthesis of 4-methoxy-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0368]

[0369] The title compound was prepared as described in general procedure G employing DMF, 3.0 eq iodomethane and 2.0 eq Cs₂CO₃. Chromatography with 15% ethyl acetate/hexane afforded the title compound in 54% yield. ESI-MS m/z 455 (MNa⁺).

Example 48 Synthesis of 4-allyloxy-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0370]

[0371] The title compound was prepared as described in general procedure G employing DMF, 3.0 eq 1,3-diiodopropane and 1.0 eq Cs₂CO₃. Chromatography with 10% ethyl acetate/hexane afforded the title compound in 8% yield. ESI-MS m/z 481 (MNa⁺).

Example 49 Synthesis of 11-oxo-4-(pyridin-3-ylmethoxy)-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9, 10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0372]

[0373] The title compound was prepared as described in general procedure G employing DMF, 2.0 eq 3-picolylchloride hydrochloride and 4.0 eq Cs₂CO₃. Chromatography with 40% ethyl acetate/hexane afforded the title compound in 75% yield. ESI-MS m/z 532 (MNa⁺).

Example 50 Synthesis of 11-oxo-4-(pyridin-2-ylmethoxy)-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0374]

[0375] The title compound was prepared as described in general procedure G employing DMF, 2.0 eq 2-picolylchloride.HCl and 4.0 eq Cs₂CO₃. Chromatography with 15% ethyl acetate/hexane afforded the title compound in 72% yield. ESI-MS m/z 532 (MNa⁺).

Example 51 Synthesis of 4-tert-butoxycarbonylmethoxy-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0376]

[0377] The title compound was prepared as described in general procedure G employing DMF, 1.1 eq oftert-butylbromo acetate, and 1.5 eq of Cs₂CO₃. Chromatography with 20% ethyl acetate/hexane afforded the title compound in 89% yield. ESI-MS m/z 555 (MNa⁺).

Example 52 Synthesis of 4-(dimethoxy-phosphoryloxy)-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0378]

[0379] The title compound was prepared as described in general procedure G employing DMF, 1.5 eq dimethylchlorophosphate and 2.0 eq Cs₂CO₃. Chromatography with 40% ethyl acetate/hexane afforded the title compound in 19% yield. ESI-MS m/z 549 (MNa⁺).

Example 53 Synthesis of 11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0380]

[0381] A. 11-Oxo-4-trifluoromethanesulfonyloxy-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0382] To a 0.3 M solution of the propyl ester of Example 13 in dichloromethane was added DIEA (2 eq) and N-phenyltrifluoromethanesulfonimide (1.1 eq). The reaction was stirred for 18 h at rt, then diluted with dichloromethane, quenched with aqueous ammonium chloride. The phases were partitioned, and the organic layer was separated and washed with 5% aqueous NaHCO₃. The solution was dried (Na₂SO₄), concentrated to dryness and chromatographed with 20% to 30% ethyl acetate/hexane.

[0383] B. 11-Oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0384] A 0.155 M solution of the purified triflate in DMF was treated with Pd(OAc)₂ (0.048 eq), 1,1′-Bis(diphenylphosphino)ferrocene (0.054 eq), triethylamine (7.7 eq) and formic acid (8.5 eq). The reaction was heated to 90° C. for 2 days, then diluted with dichloromethane and quenched with aqueous ammonium chloride. The phases were partitioned, and the organic layer was separated, washed with brine, then dried (Na₂SO₄). Chromatography with 30% ethyl acetate/hexane afforded the title compound in 59% yield. ¹H NMR (CDCl₃) 7.27 (dd, 2H), 7.23-7.15 (m, 2H), 4.26 (ddd, 2H), 4.04 (d, 1H), 3.96 (ddd, 2H), 3.80 (dd, 1H), 3.69 (dd, 1H), 3.23 (ddd, 1H), 2.43 (dd, 1H), 2.13 (ddd, 1H), 1.57 (dd, 2H), 1.61-1.54 (m, 4H), 1.03 (ddd, 2H), 0.88 (t, 3H), 0.04 (s, 9H).

Example 54 Synthesis of 4-hydroxy-11-(methyl-hydrazono)-tricyclo[6.2.2.0²⁷]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0385]

General Procedure H for the Synthesis of 11-Imino Derivatives

[0386] To a solution of the product of Example 13 (1 eq, 0.12-0.3 M) in methanol is added a selected amino derivative. Sodium acetate may be used as acid scavenger in the case where the nucleophile is added as an acid salt. The reaction is stirred until complete, normally 1-18 h. The crude material is isolated either by concentration in vacuo or by extraction using ethyl acetate or diethyl ether.

[0387] The title compound was prepared as described in general procedure H using 4 eq. of methylhydrazine. The crude product was isolated by adding diethyl ether and concentrating in vacuo Trituration with diethyl ether afforded a 69% yield of hydrazone as predominately the E isomer. ESI-MS m/z 447 (MH⁺), 469 (MNa⁺).

Example 55 Synthesis of 4-hydroxy-11-(phenyl-hydrazono)-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0388]

[0389] The title compound was prepared as described in general procedure H using 3 eq. of phenylhydrazine. The, crude product was isolated by extraction with ethyl acetate. Trituration with CHCl₃/hexane afforded a 62% yield of the hydrazone. ESI-MS m/z 509 (MH⁺).

Example 56 Synthesis of 11-[(2-bromo-phenyl)-hydrazono]-4-hydroxy-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0390]

[0391] The title compound was prepared as described in general procedure H using 2 eq of 2-bromophenylhydrazine hydrochloride and 2 eq. of sodium acetate. The crude product was isolated by extraction with ethyl acetate. Chromatography on SiO₂ using 20% ethyl acetate/hexane afforded a 61% yield of the hydrazone. ¹H NMR (CDCl₃): 7.48 (dd 1H), 7.38 (dd, 1H), 7.2 (m, 2H), 7.10 (d, 1H), 6.65 (m, 3H), 5.7 (br. S, 1H), 4.25 (m, 3H), 3.97 (m, 2H), 3.80 (m, IH), 3.63 (m, IH), 3.20 (m, 1H), 2.50 (dd, 1H), 2.20 (m, 1H), 1.59 (hex, 2H), 1.07 (m, 2H), 0.89 (t, 3H), 0.02 (s, 9H).

Example 57 Synthesis of 11-(dimethyl-hydrazono)-4-hydroxy-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0392]

[0393] The title compound was prepared as described in general procedure H employing 1,1-dimethylhydrazine (1.4 eq). Chromatography using 40%-50% ethyl acetate/hexane afforded the title compound in 38% yield. ESI-MS m/z 461 (MH⁺).

Example 58 Synthesis of 4-hydroxy-11-[(2-hydroxy-ethyl)-hydrazono]-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0394]

[0395] The title compound was prepared as described in general procedure H employing 2-hydroxyethyl hydrazine (1.4 eq) as the reagent. Chromatography using 50%-80% ethyl acetate/hexane afforded the title compound in 46% yield. ¹H NMR (CDCl₃) 7.25 (d, 1H), 6.70 (dd, 1H), 6.65 (d, 1H), 5.3-5.1 (br s, 1H), 4.25 (dd, 2H) 4.25-4.15 (m, 2H), 3.98-3.91 (m, 4H), 3.74 (d, 1H), 3.68 (dd, 1H), 3.21-3.19 (m, 1H), 2.41 (dd, 1H), 2.12 (ddd, 1H), 1.58 (dd, 2H), 1.24 (s, 1H), 1.04 (dd, 2H), 0.91 (t, 3H), 0.05 (s, 9H).

Example 59 Synthesis of 1 1-(thiosemicarbazono)-4-hydroxy-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0396]

[0397] The title compound was prepared as described in general procedure H employing thiosemicarbazide as the reagent. Chromatography using 50% ethyl acetate/hexane afforded the title compound in 42% yield. ESI-MS m/z 492 (MH⁺), 514 (MNa⁺).

Example 60 Synthesis of 1-(4-methyl-3-thiosemicarbazono)-4-hydroxy-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0398]

[0399] The title compound was prepared as described in general procedure H employing 4-methyl-3-thiosemicarbazide (1.4 eq) as the reagent. Chromatography using 35% ethyl acetate/hexane afforded the title compound in 35% yield. APC₁-MS m/z 506 (MH⁺), 505 (M⁻).

Example 61 Synthesis of 4-hydroxy-11-(methyl-phenyl-hydrazono)-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0400]

[0401] The title compound was prepared as in general procedure H using 1.2 eq. of N-methyl-N-phenylhydrazine. The crude product was isolated by concentration in vacuo. Chromatography on SiO₂ using 5% ethyl acetate/methylene chloride afforded a 57% yield of the hydrazone. ESI-MS m/z 523 (MH⁺), 521 (M−H)⁻.

Example 62 Synthesis of 11-(methanesulfonyl-hydrazono)-4-hydroxy-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0402]

[0403] The title compound was prepared as in general procedure H using 2.4 eq. of methanesulfonyl hydrazine. The crude product was isolated by extraction with ethyl acetate. Chromatography on SiO₂ using 35% ethyl acetate/hexane afforded a 10% yield of the Z-isomer and 50% of the E-isomer. ESI-MS 533.1 (MNa⁺).

Example 63 Synthesis of 11-(benzenesulfonyl-hydrazono)-4-hydroxy-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0404]

[0405] The title compound was prepared as in general procedure H using 2.4 eq. of benzenesulfonyl hydrazine. The crude product was isolated by extraction with ethyl acetate. Chromatography on SiO₂ using 30% ethyl acetate/hexane afforded a 62% yield of product. ESI-MS m/z 595 (MNa⁺).

Example 64 Synthesis of 11-(4-methoxybenzenesulfonyl-hydrazono)-4-hydroxy-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0406]

[0407] The title compound was prepared as described in general procedure H using 2 eq. of 4-methoxybenzenesulfonyl hydrazine. The crude product was isolated by extraction with ethyl acetate. Chromatography on SiO₂ using 40% ethyl acetate/hexane afforded an 82% yield of product. ESI-MS m/z 603 (MH⁺).

Example 65 Synthesis of 11-(acetyl-hydrazono)-4-hydroxy-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0408]

[0409] The title compound was prepared as described in general procedure H using 2.6 eq. of acetyl hydrazine. The crude product was isolated by extraction. Chromatography on SiO₂ using 50% ethyl acetate/hexane afforded a 34% yield of a 4/1 mix of E/Z isomers. ESI-MS m/z 475 (MH⁺).

Example 66 Synthesis of 4-hydroxy-11-hydroxyimino-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0410]

[0411] The title compound was prepared as described in general procedure H employing hydroxylamine (1.1 eq) and sodium acetate (2.3 eq). The crude product was isolated by extraction. Chromatography with 5% Acetone/1% acetic acid/94% dichloromethane followed by recrystallization in dichloromethane/hexane afforded the title compound in 58% yield. ESI-MS m/z 456 (MNa⁺).

Example 67 Synthesis of 4-hydroxy-11-methoxyimino-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0412]

[0413] The title compound was prepared as described in general procedure H employing methoxylamine (1.1 eq) and sodium acetate (2.3 eq). The crude product was isolated by extraction. Chromatography with 10% ethyl acetate/dichloromethane resulted in a 34% yield of the less polar isomer: ESI-MS m/z 448 (MNa⁺), 470 (MNa⁺) and a 34% yield of the more polar isomer: ESI-MS m/z 448 (MH⁺), 470 (MNa⁺).

Example 68 Synthesis of 4-hydroxy-11-phenoxyimino-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0414]

[0415] The title compound was prepared as described in the general procedure H employing 1.1 eq of O-phenylhydroxylamine and 2.3 eq of sodium acetate. The crude product was isolated by extraction. Chromatography with 30% ethyl acetate/dichloromethane afforded the title compounds as a 1:1 mixture in 63% combined yield. ESI-MS m/z 510 (MH⁺), 532 (MNa⁺).

Example 69 Synthesis of 11-benzyloxyimino-4-hydroxy-tricyclo[6.2.20^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0416]

[0417] The title compound was prepared as described in general procedure H employing 1.1 eq of benzylhydroxylamine and 2.3 eq of sodium acetate. The crude product was isolated by extraction. Chromatography with 30% ethyl acetate/dichloromethane afforded the title compounds as a 2:1 mixture of Z and E isomers in 47% combined yield. ESI-MS m/z 524 (MH³⁰ ).

Example 70 Synthesis of 4-hydroxy-11-(4-nitro-benzyloxyimino)-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0418]

[0419] The title compound was prepared as described in general procedure H employing 1.1 eq of (4-nitrobenzyl)hydroxylamine and 2.3 eq of sodium acetate. The crude product was isolated by extraction. Chromatography with 20-30% ethyl acetate/dichloromethane afforded the title compound in 28% yield. ESI-MS m/z 569 (MH⁺).

Example 71 Synthesis of 11-(5-chloro-[1,2,3]thiadiazol-4-ylmethoxyimino)-4-hydroxy-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0420]

[0421] The title compound was prepared as described in general procedure H employing 1.1 eq of (4-chloro)thiadiazolyl-5-methoxyhydroxylamine and 2.3 eq of sodium acetate. The crude product was isolated by extraction. Chromatography with 30%-40% ethyl acetate/dichloromethane afforded the title compounds as a 1:1 mixture of E and Z isomers in 92% yield. ESI-MS m/z 566 (MNa⁺).

Example 72 Synthesis of 11-(3-fluoro-benzyloxyimino)-4-hydroxy-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0422]

[0423] The title compound was prepared as described in general procedure H employing 1.1 eq of (3-fluoro)benzylhydroxylamine and 2.3 eq of sodium acetate. The crude product was isolated by extraction. Chromatography with 30% ethyl acetate/dichloromethane afforded the title compounds as a 1:1.3 mixture of E and Z isomers in 89% yield. ESI-MS m/z 542 (MNa⁺).

Example 73 Synthesis of 4-hydroxy-11-[2-oxo-2-(4-phenyl-piperazin-1-yl)-ethoxyimino]-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0424]

[0425] The title compound was prepared as described in general procedure H employing 2-aminooxy-1-(4-phenyl-piperazin-1-yl)-ethanone (1.1 eq) and sodium acetate (2.3 eq). The crude product was isolated by extraction. Chromatography with 40%-60% ethyl acetate/dichloromethane afforded the less polar E isomer in 8% yield and the more polar Z isomer in 18% yield. ESI-MS m/z 636 (MH⁺), 658 (MNa⁺).

Example 74 Synthesis of 11-(4-fluoro-benzyloxyimino)-4-hydroxy-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0426]

[0427] The title compound was prepared as described in general procedure H employing (4-fluoro)benzylhydroxylamine (1.1 eq) and sodium acetate (2.3 eq). The crude product was isolated by extraction. Chromatography with 0%-10% ethyl acetate/dichloromethane afforded the title compound in 25% yield. ¹H NMR (CDCl₃) 7.32 (dd, 2H), 7.09-6.99 (m, 3H), 6.69-6.64 (m, 2H), 5.05--5.03 (m, 3H), 4.95 (s, 1H), 4.24 (dd, 2H), 3.95 (ddd, 2H), 3.64 (d, 1H), 3.50 (dd, 1H), 3.08-3.06 (m, 1H), 2.50 (dd, 1H), 2.12 (ddd, 1H), 1.58 (dd, 2H), 1.02 (dd, 2H), 0.87 (t, 3H), 0.04 (s, 9H).

Example 75 Synthesis of 4-hydroxy-11-(2-phenoxy-ethoxyimino)-tricyclo [6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0428]

[0429] The title compound was prepared as described in general procedure H employing (3-phenoxy)ethyllhydroxylamine (1.1 eq) and sodium acetate (2.3 eq). The crude product was isolated by extraction. Chromatography with 0%-10% ethyl acetate/dichloromethane afforded the title compound in 22% yield. ¹H NMR (CDCl₃) 7.31-7.30 (m, 2H), 7.06 (d, 1H), 6.97-6.92 (m, 3H), 6.64 (dd, 1H), 6.57 (d, 1H), 5.03 (d, 1H), 4.87 (s, 1H), 4.41-4.37 (m, 2H), 4.25 (ddd, 2H), 4.16 (dd, 2H), 3.94 (ddd, 2H), 3.63 (dd, 1H), 3.51 (dd, 1H), 3.09-3.06 (m, 1H), 2.52 (dd, 1H), 2.13 (ddd, 1H), 1.57 (ddd, 2H), 1.03 (dd, 2H), 0.86 (t, 3H), 0.05 (s, 9H).

Example 76 synthesis of 11-allyloxyimino-4-hydroxy-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9, 10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0430]

[0431] The title compound was prepared as described in general procedure H employing O-allylhydroxylamine (1.1 eq) and sodium acetate (2.3 eq). The crude product was isolated by extraction. Chromatography with 25%-40% ethyl acetate/hexane afforded the title compound in 45% yield. ESI-MS m/z 496 (MNa⁺).

Example 77 Synthesis of 11-(2,4-dichlorobenzyl-oximo)-4-hydroxy-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0432]

[0433] The title compound was prepared as described in general procedure H using 1.1 eq of O-2,4-dichlorobenzyl hydroxyl amine hydrochloride and 1.1 eq of sodium acetate. The crude product was isolated by concentrating in vacuo. Chromatography on SiO₂ using 25% ethyl acetate/hexane followed by 3% ethyl acetate/methylene chloride afforded a 28% yield of Z-isomer, the less polar compound, and 33% yield of the E-isomer, the more polar compound. ESI-MS m/z, Z-isomer 592 (MH⁺), 594 ((M+2)H⁺); E-isomer 592 (MH⁺), 594 ((M+2)H⁺).

Example 78 Synthesis of 11-(semicarbazono)-4-hydroxy-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0434]

[0435] The title compound was prepared as described in general procedure H using 1.3 eq of semicarbazide hydrochloride and 1.3 eq of sodium acetate. The crude product was isolated by extraction with ethyl acetate. Chromatography on SiO₂ using 70% ethyl acetate/hexane afforded a 48% yield of product. ESI-MS m/z 498 (MNa⁺).

Example 79 Synthesis of (9,10 trans)-10-allyloxycarbonylamino-4,11-dihydroxy-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9-(2-trimethylsilanyl-ethyl) ester

[0436]

[0437] To a solution of the ketone prepared in Example 25 (12.4 mg, 0.029 mmol) in 0.5 mL methanol was added sodium borohydride (21.1 mg, 0.56 mmol). After 20 min H₂O was added, the solution acidified to pH 1 with 1% HCl, and the product extracted with ethyl acetate. The organic layer was washed with H₂O, brine, dried (Na₂SO₄) and concentrated. Flash chromatography (SiO₂, 45% ethyl acetate/dichloromethane) afforded 3.7 mg (30%) of the less polar alcohol and 4.1 mg (33%) of the more polar alcohol. ESI-MS m/z: less polar product 456 (MNa⁺), more polar product 456 (MNa⁺).

Example 80 Synthesis of (9,10 cis)-10-allyloxycarbonylamino-4,11-dihydroxy-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9-(2-trimethylsilanyl-ethyl) ester

[0438]

[0439] To a solution of the ketone from Example 3 (25.9 mg, 0.06 mmol) in methanol (1.1 mL) held at 20° C. with a water bath was added sodium borohydride (44.7 mg, 1.2 mmol). The reaction was stirred for 20 min, diluted with ethyl acetate and quenched with water followed by 1% HCl. The layers were separated, and the organic layer washed with 5% NaHCO₃, water, brine, dried (Na₂SO₄), and concentrated in vacuo. Chromatography on SiO₂ using 40% ethyl acetate/hexane afforded 13.2 mg (50%) of product as the less polar diastereomer. ESI-MS m/z 456 (MNa⁺).

Example 81 Synthesis of 4,11-dihydroxy-11-phenyl-tricyclo[[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0440]

[0441] To a solution of the compound of Example 13 (61 mg, 0.146 mmol) in tetrahydrofuran (2.9 mL) at −10° was added phenylmagnesium bromide (360 μL, 1 M). Additional aliquots (720 μL) of phenylmagnesium bromide were added at 30 min intervals until the reaction was complete by TLC. The cooling bath was removed, the reaction diluted with ethyl acetate, then quenched with 3% HCl. The layers were separated and the organic layer washed with 1% HCl, 5% NaHCO₃, H₂O, brine, and dried (Na₂SO₄). Concentration in vacuo followed by chromatography afforded 26 mg (36%) of the tertiary alcohol. ESI-MS m/z 519 (MNa⁺).

Example 82 Synthesis of 4-hydroxy-11-propylamino-tricyclo [[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0442]

[0443] To a solution of the compound of Example 13 (75 mg, 0.18 mmol) in methanol (1 mL) was added n-propylamine (75 μL, 1.8 mmol) and acetic acid (52 μL, 1.8 mmol). After 10 min sodium triacetoxy borohydride (380 mg, 1.8 mmol) was added and the solution stirred overnight. Additional aliquots of n-propylamine (600 EL), acetic acid (500 μL) and sodium triacetoxy borohydride (400 mg) were added and the reaction allowed to proceed for 1.5 h. The reaction was diluted with ethyl acetate and 5% NaHCO₃. The layers were separated, and the organic layer washed with 5% NaHCO₃, H₂0, brine, dried (Na₂SO₄), and concentrated in vacuo. Chromatography on SiO₂ using a gradient of 45% ethyl acetate/methylene chloride—2% methanol/methylene chloride—8% methanol/methylene chloride afforded a 34% yield of the less polar amine and 37% yield of the more polar amine. ESI-MS m/z 462 (MH⁺).

Example 83 Synthesis of 4-hydroxy-11-(4-methyl-Benzylamino)-tricyclo[[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0444]

[0445] To a solution of the compound of Example 13 (50 mg, 0.12 mmol) in methanol (0.5 mL) was added acetic acid (14 μL, 0.24 mmol), 4-methylbenzyl amine (31 μL, 2.1 eq.) and sodium cyanoborohydride (38 mg, 0.60 mmol). After 2 h an additional aliquot of sodium cyanoborohydride (10 mg) was added and the reaction allowed to stir for 30 more min. The reaction was then quenched with 3% HCl and diluted with ethyl acetate. The biphasic mixture was then basified to pH 8 with 5% NaHCO₃. The layers were separated, and the organic layer washed with H₂O, brine, dried (Na₂SO₄) and concentrated in vacuo. Chromatography on SiO₂ using first a gradient of 15% ethyl acetate/hexane—25% ethyl acetate/hexane followed by a second chromatography using a gradient 10% ethyl acetate/methylene chloride—17% ethyl acetate/methylene chloride afforded a 19% yield of the less polar amine and 16% of the more polar amine. ESI-MS m/z 524 (MH⁺).

Example 84 Synthesis of 4-hydroxy-11-methylamino-tricyclo[[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0446]

[0447] To a solution of the compound of Example 13 (75 mg, 0.18 mmol) in methanol (1.8 mL) was added acetic acid (260 μL, 25 eq), methylamine (40% in H₂O, 310 μL) and sodium triacetoxy borohydride (760 mg, 20 eq). After stirring overnight additional aliquots of acetic acid (200 μL), methylamine (200 μL) and reducing agent (300 mg) were added. The reaction was allowed to stir for an additional 3 h, then it was diluted with ethyl acetate and 5% NaHCO₃. The layers were separated and the organic layer was washed with 5% NaHCO₃, H₂O, brine, dried (Na₂SO₄) and concentrated in vacuo. Chromatography on SiO₂ using a gradient of 65% ethyl acetate/hexane Π 8% methanol/methylene chloride afforded a 28% yield of less polar amine and 43% of the more polar product. ESI-MS m/z: less polar compound 434 (MH⁺), more polar compound 434 (MH⁺).

Example 85 Synthesis of 4-hydroxy-11-phenylamino-tricyclo[[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0448]

[0449] To a solution of the compound of Example 13 ( 76.5 mg, 0.18 mmol) in methanol (1.5 mL) was added acetic acid (104 μL, 1.7 mmol) and aniline (82 μL, 0.9 mmol). Additional aliquots were added at 3 h and 5.5 h and the reaction allowed to proceed to completion overnight. The solution was concentrated to dryness and the residue partitioned between ethyl acetate/hexane (3/1) and 5% NaHCO₃. The layers were separated and the organic layer washed with 5% NaHCO₃, H₂O, dried (Na₂SO₄), and concentrated in vacuo. Flash chromatography on SiO₂ afforded 30.5 mg (34%) of the less polar diastereomer and 14.7 mg (16%) of the more polar diastereomer. ESI-MS ml/z 496 (MH⁺).

Example 86 Synthesis of 11-dimethylamino-4-hydroxy-tricyclo[[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0450]

[0451] To a solution of the compound of Example 13 (79.5 mg, 0.19 mmol) in methanol (0.5 mL) was added dimethylamine (40 wt % in H₂O, 600 μL, 4.8 mmol) and acetic acid (330 μL, 5.7 mmol). After 10 min sodium triacetoxy borohydride (1.0 g, 4.8 mmol) was added. Additional aliquots of reagents were added at 3 h and 4.5 h, and the reaction allowed to proceed for 2 h after the final addition of reagents. The reaction was quenched with H₂O and diluted with ethyl acetate. The layers were separated and the organic layer washed with 5% NaHCO₃, H₂O, brine, dried (Na₂SO₄) and concentrated in vacuo. Flash chromatography on SiO₂ with 5% methanol/methylene chloride afforded 9.4 mg of a single diastereomer.

Example 87 Synthesis of 11-[acetyl-(4-methyl-benzyl)-amino]-4-acetoxy-tricyclo[[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0452]

[0453] To a solution of the more polar amine from Example 83 (16.5 mg, 0.03 mmol) in methylene chloride (0.4 mL) was added N-methylmorpholine (12 μL, 0.10 mmol) followed by acetic anhydride (10 μL, 0.10 mmol). The reaction was stirred for 16 h at room temp, diluted with ethyl acetate, and quenched with 5% NaHCO3. The layers were separated, and the organic layer was washed with H₂O, brine, dried (Na₂SO₄), and concentrated in vacuo. Flash chromatography on SiO₂ with 40% ethyl acetate/hexanes afforded the amide. ESI-MS m/z 608 (MH⁺), 630 (MNa⁺).

Example 88 Synthesis of 11-[acetyl-methylamino]-4-acetoxy-tricyclo[[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0454]

[0455] A. Diastereomer 1.

[0456] To a solution of the less polar amine from Example 84 (35 mg, 0.08 mmol) in dichloromethane (1.1 mL) was added NMM (27 μL, 0.24 mmol) and acetic anhydride (15.3 μL, 0.16 mmol). The reaction was stirred for 18 h at ambient temperature, diluted with ethyl acetate and quenched with 1% HCl. The layers were separated, and the organic layer washed with 1% HCl, 5% NaHCO₃, H₂O, brine, dried (Na₂SO₄) and concentrated in vacuo. Chromatography on SiO₂ using a gradient of 45% ethyl acetate/hexane—55% ethyl acetate/hexane afforded 9.3 mg (22%) of the bis-acylated product, which by TLC is slightly less polar than the free phenol product. ¹H NMR (CDCl₃, 53° C.): 7.19 (d, 1H), 6.95 (m, 2H), 4.30 (m, 2H), 3.89 (t, 2H), 3.54 (m, 3H), 3.20 (s 3H), 2.96 (d, 1H), 2.26 (s, 3H), 2.13 (s, 3H), 1.80 (m, 2H), 1.59 (m, 2H), 1.06 (sextet, 2H), 0.91 (t, 2H), 0.07 (s, 9H).

[0457] B. Diastereomer 2.

[0458] To a solution of the more polar amine from Example 84 (58 mg, 0.13 mmol) in methylene chloride (2 mL) was added N-methylmorpholine (43 μL, 0.39 mmol) and acetic anhydride (15 μL, 0.16 mmol). The reaction was stirred at room temp for 21 h, diluted with ethyl acetate, and quenched with 1% HCl. The layers were separated, and the organic layer washed with 1% HCl, 5% NaHCO₃, H₂O, brine, dried (Na₂SO₄), and concentrated in vacuo. Multiple flash chromatographies on SiO₂ using 2% methanol/methylene chloride afforded 34 mg (53%) of the phenol as the more polar product and 14.7 mg (21%) of the phenol acetate as the less polar product. ¹H NMR (CDCl₃, 21° C., ca. 3:1 mix of rotamers): 7.24 (d, 1H), 6.90 (m, 2H), 5.21 (m, 0.75H), 4.23 (m, 2.25H), 3.90 (t, 2H), 3.52 (m, 3H), 2.99 (m, 1H), 2.30-1.96 (m, 10H), 1.56 (sextet, 2H), 1.30 (m, 1H), 1.03 (m, 2H), 0.93 (t, 2H), 0.05 (s, 9H).

Example 89 Synthesis of 11-[acetyl-methylamino]-4-hydroxy-tricyclo[[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0459]

[0460] The title compound was isolated from the preparation of Diastereomer 2 of Example 88. By TLC it is more polar than the corresponding phenol acetate. ESJ-MS m/z 476 (MH⁺), 498 (MNa⁺), 474 (M−H)⁻.

Example 90 Synthesis of 4,11-dihydroxy-tricyclo[[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-(2,4-dimethoxy-benzyl) ester 9-(2-trimethylsilanyl-ethyl) ester

[0461]

[0462] To a solution of the ketone of Example 9 (31.1 mg, 0.06 mmol) in methanol (1 mL) at 15° C. was added NaBH₄ (44.0 mg, 1.16 mmol). The reaction was stirred for 45 min, diluted with ethyl acetate, and quenched with 1% HCl. The layers were separated and the organic layer washed with 5% NaHCO₃, H₂O, brine, dried (Na₂SO₄), and concentrated in vacuo. Flash chromatography on SiO₂ using 30% ethyl acetate/methylene chloride afforded 6.5 mg (21%) of the less polar alcohol and 13.8 mg (44%) of the more polar alcohol. ESI-MS m/z, less polar product 551 (MNa⁺), more polar product 551 (MNa⁺).

Example 91 Synthesis of 11-spiro-(1,4-dioxacyclopentyl)-4-hydroxy-tricyclo[[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0463]

[0464] To a solution of the ketone of Example 13 (56.0 mg, 0.133 mmol) in benzene (1.3 mL) was added ethylene glycol (45 μL) and p-touenesulfonic acid monohydrate (4.5 mg). The solution was refluxed for 1 h, using a Dean-Stark trap to collect the water. Upon cooling the reaction was diluted with ethyl acetate and 5% NaHCO₃ was added. The layers were separated, and the organic layer washed with 5% NaHCO₃, H₂O, brine, dried (Na₂SO₄), and concentrated in vacuo. Flash chromatography on SiO₂ using 25% ethyl acetate/hexane afforded 14.1 mg (23%) of the ketal. ESI-MS In/z 485 (MNa⁺).

Example 92 Synthesis of 11-ethoxycarbonylmethylene-4-hydroxy-tricyclo[[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0465]

[0466] To a solution of triethylphosphonoacetate (59 μL, 0.30 mmol) in tetrahydrofuran (0.5 mL) at 0° C. was added a solution of potassium hexamethyldisilazide (0.45 M in toluene, 0.685 mL, 0.31 mmol). After stirring for 15 min at 0° C. a solution of the ketone from Example 13 (59.6 mg, 0.14 mmol) in tetrahydrofuran (0.9 mL) was added. The reaction was stirred for 30 min at 0° C., 3 h at ambient, then placed in a refrigerator without stirring for 66 h. Upon removal, the reaction was stirred at ambient temperature for 6 h, diluted with ethyl acetate, and quenched with 1% HCl. The layers were separated, and the organic layer washed with 1% HCl, 5% NaHCO₃, H₂O, brine, dried (Na₂SO₄), and concentrated in vacuo. Flash chromatography on SiO₂ using 17% ethyl acetate/hexane afforded 32.2 mg (46%) of product as a 1/1 mixture of E/Z isomers. ESI-MS m/z 511 (MNa⁺).

Example 93 Synthesis of 4-hydroxy-11-methylene-tricyclo[[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0467]

[0468] To a solution of methyl triphenylphosphonium bromide (236 mg, 0.66 mmol) in tetrahydrofuran (0.5 mL) was added potassium hexamethyldisilazide (0.5 M in toluene, 1.3 mL, 0.65 mmol). The yellow-orange solution was stirred for 15 min at ambient temp, then a solution of the ketone from example 13 (63.5 mg, 0.15 mmol) in tetrahydrofuran (0.3 mL) was added. After 30 min at room temp the reaction was diluted with ethyl acetate and quenched with H₂O. The layers were separated, and the organic layer washed with 1% HCl, 5% NaHCO₃, H₂O, brine, dried (Na₂SO₄), and concentrated in vacuo. Flash chromatography on SiO₂ using 15% ethyl acetate/hexane afforded 34.2 mg (54%) of the olefin. ¹H NMR (CDCl₃), 7.05 (2H), 6.63 (2H), 5.10 (1H), 4.96 (1H), 4.73 (11H), 4.25 (2H), 3.95 (3H), 3.55 (2H), 3.07 (1H), 2.49 (1H), 2.08 (2H), 1.60 (2H), 1.06 (2H), 0.88 (3H), 0.09 (9H).

Example 94 Synthesis of 4,11-dihydroxy-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0469]

[0470] To a 0.1 M solution of ketone from Example 13 in methanol was added NaBH₄ (10 eq). After stirring at rt for 20 min, the reaction was quenched with saturated aqueous ammonium chloride and diluted with dichloromethane. The aqueous phase was acidified with 1 M HCl, the phases were partitioned, and the aqueous phase extracted 3× with dichloromethane. Organic extracts were combined, dried (Na ₂SO₄) and concentrated. Chromatography with 40% ethyl acetate/hexane afforded the less polar isomer in 40% yield ESI-MS m/z 419 (M−H)⁻, and the more polar isomer in 20% yield ESI-MS m/z 419 (M−H)⁻.

Example 95 Synthesis of 11-amino-4-hydroxy-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0471]

[0472] To a 0.1 M solution of ketone from Example 13 in methanol was added 4-methylbenzylamine (3 eq), Na(OAc)₃BH (3 eq), acetic acid (3 eq) and 3A mol. sieves (300 mg/mL methanol). The reaction was stirred overnight, then quenched with aqueous NaHCO₃, and extracted with ethyl acetate. The organic extracts were combined, dried (Na₂SO₄) and concentrated. Chromatography with 5%-30% ethyl acetate/hexane afforded the less polar isomer in 29% yield.

[0473] The product from the preceding reaction was dissolved in enough ethanol to give a 0.07 M solution, which was treated with 20% palladium hydroxide on carbon (135 mg/mmol st. mat) and acetic acid (24 eq.). The reaction was stirred at rt under an atmosphere (balloon) of hydrogen gas. After 1.5 h, the reaction was filtered over Celite with dichloromethane and concentrated. Chromatography using 10%-20% methanol/dichloromethane afforded a single isomer in 45% yield. ESI-MS m/z 420 (MH⁺), 418 (M−H)⁻.

Example 96 Synthesis of 4,11-dihydroxy-11-methyl-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0474]

[0475] To a 0° C. solution of ketone from Example 13 in THF (0.12 M) was added methylmagnesium bromide (1.4 M in THF/toluene, 6.7 eq). After complete reaction and aqueous workup, the crude product was purified by column chromatography using 25%-40% ethyl acetate/hexane. The less polar isomer was isolated in 12% yield. ¹H NMR (CDCl₃) 7.26 (d, 1H), 6.99 (s, 1H), 6.82 (dd, 1H), 4.94 (s, 1H), 4.27 (ddd, 2H), 3.90 (dd, 2H), 3.90-3.85 (m, 1H), 3.35 (d, 1H), 3.28 (d, 1H), 3.18-3.15 (m, 1H), 1.77 (dd, 1H), 1.57 (dd, 2H), 1.44-1.39 (m, 1H), 1.25 (s, 2H), 1.06 (ddd, 2H), 1.01 (s, 3H), 0.89 (dd, 3H). 0.06 (s, 9H).

Example 97 Synthesis of 4,11-dihydroxy-11-methyl-tricyclo[6.2.2.^(02,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0476]

[0477] Cerium chloride (2.0 eq) was heated under vacuum, cooled and suspended in THF. The 0.3 M solution was cooled to −75° C. and treated with methylmagnesium bromide (1.4 M in THF/toluene, 4 eq) in a dropwise fashion. The slurry was stirred for 1.5 h, at which point the ketone from Example 13 was added as a 0.3 M solution in THF. The reaction was stirred at −75° C. for 2 h, then warmed to rt. After 1.5 h, reaction quenched with saturated aqueous ammonium chloride and extracted with ethyl acetate. Chromatography using 30%-40% ethyl acetate/hexane afforded the more polar isomer in 13% yield. ¹H NMR (CDCl₃) 7.26 (d, 1H), 6.70 (s, 1H), 6.68 (dd, 1H), 5.26 (s, 1H), 4.25 (ddd, 2H), 3.93 (ddd, 2H), 3.57 (dd, 1H), 3.42-3.40 (s, 1H), 3.31-3.29 (s, 1H), 2.92-2.91 (s, 1H), 1.72 (dd, 1H), 1.57 (dd, 2H), 1.56 (s, 3H), 1.40 (dm, 1H), 1.26 (s, 1H), 1.04 (dd, 2H), 0.87 (t, 3H), 0.06 (s, 9H).

Example 98 Synthesis of 4,11-dihydroxy-11-hydroxymethyl-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0478]

[0479] The olefin of Example 93 (61077) was dissolved in enough 1:1 tert-butanol:water to give a 0.06 M solution. The solution was treated with OsO₄ (4 wt. % soln. in water, 0.03 eq) and 4-methyl morpholine-N-oxide (3 eq) and heated to 50° C. After stirring overnight, the reaction was quenched with sodium bisulfite. Celite was added, and the solution allowed to stir an additional 3 hours. The solution was then diluted 20 fold with THF and filtered over a short plug of silica. The crude solids were purified by column chromatography (50%-60% ethyl acetate/hexane) to afford the less polar isomer in 36% yield. APCI-MS m/z 449 (M−H)⁻.

Example 99 Synthesis of 10-(benzyl-methyl-carbamoyl)-5-hydroxy-12-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9-carboxylic acid allyl ester

[0480]

General Procedure I for the Synthesis of 5-Hydroxy-10-amido Derivatives

[0481] A solution of the trans allyl TMS-ethyl ester prepared in Example 19 (1 equivalent) in 2 mL of TFA/H₂O (95%) was allowed to stir at rt for 30 min. The volatiles were evaporated, acetonitrile (2 mL) and toluene (5 mL) were added and the resulting solution was concentrated to dryness (2×) to afford the crude carboxylic acid. The white residue was dissolved in DMF (0.6 mL) and a selected amine (1.5 equivalents), HATU (1.2 equivalents) and NMM (2.7 equivalents) were added and the reaction mixture was allowed to stir at rt under nitrogen overnight. The solution was concentrated to dryness and dichloromethane or ethyl acetate was added (10 mL) and the organic layer was washed with HCl (1 N, 3×10 mL), NaHCO₃ solution (5%, 2×10 mL) and brine (1×10 mL). Upon drying (MgSO₄) the organic layer, the filtered solution was concentrated to dryness and column chromatography provided the desired product.

[0482] The title compound was prepared as described in general procedure I using N-methylbenzylamine, resulting in a yield of 19% (10 mg). ESI-MS m/z 442 (MNa⁺), 418 (M−H)⁻.

Example 100 Synthesis of 5-hydroxy-12-oxo-10-propylcarbamoyl-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9-carboxylic acid allyl ester

[0483]

[0484] The title compound was prepared as described in general procedure I using propylamine, resulting in a yield of 55% (24 mg). ESI 380 (MNa⁺), 356 (M−H)⁻.

Example 101 Synthesis of 4-hydroxy-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-[2-(toluene-4-sulfonyl)-ethyl]ester

[0485]

General Procedure J for the Synthesis of 9-Esters

[0486] To a 0.5 M solution of the corresponding 9-carboxylic acid prepared as described in General Procedure I in 5% DMF/THF was added TSTU (2 eq), 4-methylmorpholine (4 eq), DMAP (2 eq) and a selected alcohol (2 eq). The reaction was allowed to proceed overnight at ambient temperature, after which the reaction was quenched with saturated aqueous ammonium. chloride and diluted with 1:1 ethyl acetate:hexane. Aqueous further acidified (pH ˜2) with 1 M HCl (aq). The phases were partitioned, and the organic layer separated and washed with brine. Solution dried (Na₂SO₄) and concentrated. The products were purified by column chromatography.

[0487] Reaction run as in general procedure J using 2-(p-Tosyl)ethanol. Chromatography (ethyl acetate/hexane) affords the title compound in 61% yield. ESI-MS m/z 523 (MNa⁺), 499 (M−H)⁻.

Example 102 Synthesis of 4-hydroxy-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 9-(3,3-dimethyl-butyl) ester 10-propyl ester

[0488]

[0489] Reaction run as in general procedure J using 3,3 dimethylbutanol. Chromatography (30% ethyl acetate/hexane) affords the title compound in 55% yield. ESI-MS m/z 425 (MNa⁺).

Example 103 Synthesis of 4-hydroxy-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 9-(2-adamantan-1-yl-ethyl) ester 10-propyl ester

[0490]

[0491] Reaction run as in general procedure J using 1-adamantaneethanol. Chromatography (ethyl acetate/hexane) affords the title compound in 87% yield. ESI-MS m/z 479 (M−H)⁻.

Example 104 Synthesis of 4-hydroxy-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(3-trimethylsilanyl-propyl) ester

[0492]

[0493] Reaction run as in general procedure J using 1-(trimethylsilyl)-3-propanol. Chromatography (25%-30% ethyl acetate/hexane) affords the title compound in 38% yield. APCI-MS m/z 433 (MH⁺), 431 (M−H)⁻.

Example 105 Synthesis of 4-(4-carboxymethoxy-benzyloxy)-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2,4,6-triene-9,10-dicarboxylic acid 10-allyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0494]

[0495] A. Butyldimethylsilanyl [4-(tert-butyl-dimethyl-silanyloxymethyl)-phnoxy]-acetate

[0496] To a solution of (4-hydroxymethylphenoxy)acetic acid (10 g, 55 mmol) in dichioromethane (200 mL) was added t-butyldimethylsilyl chloride (18.2 g, 121 mmol), diisopropylethylamine (24 mL, 17.8 g, 138 mmol) and dimethylaminopyridine (2.7 g, 22 mmol). The resulting reaction mixture was allowed to stir at rt for 1.5 h, after which time it was diluted with an additional 300 ml, of dichloromethane and washed with 0.1 M citric acid (2×300 mL) and brine (3×300 mL). The resulting yellow organic layer was dried (MgSO₄), filtered and concentrated to dryness to give a white solid, wt. 22.5 g (quantitative). ¹H NMR (CDCl₃) 7.23 (d, J=8.8 Hz, 2H), 6.85 (d, J=8.8 Hz, 2H), 4.67 (s, 2H), 4.58 (s, 2H), 0.92 (s, 9H), 0.89 (s, 9H), 0.28 (s, 6H), 0.08 (s, 6H).

[0497] B. Synthesis of 2-(Toluene-4-sulfonyl) -ethyl (4-hydroxymethyl-phenoxy)-acetate

[0498] a) To a solution of the product from Step A (22.5 g, 55 mmol) in dichloromethane (200 mL) was added 2-toluenesulfonylethanol (26.4 g, 132 mmol), HATU (25 g, 65.8 mmol) and diisopropylethylamine (23 mL, 17.1 g, 132 mmol). The resulting reaction mixture was allowed to stir at rt overnight under nitrogen atmosphere, after which time it was concentrated to dryness, diluted with ethyl acetate (400 mL), washed with 0.1 M citric acid (3×330 mL), 5% NaHCO₃ solution (2×100 mL) and brine (2×100 mL). The resulting organic layer was dried (MgSO₄), filtered and concentrated to dryness to give a brown solid, wt. 49.41 g (185%). Used as is without further purification.

[0499] b) The brown residue obtained above was suspended in 80% acetic acid/water solution (500 mL) and allowed to stir at rt for 3 h. The resulting cloudy solution was then concentrated to dryness and used dichloromethane/toluene mixture to get rid of residual acetic acid. Column chromatography (45% acetone/hexane) provided the desired product, which upon trituration with methanol provided the desired product as a white solid, wt. 15.6 g (78% for the three steps). ¹H NMR (CDCl₃) 7.78 (dt, J=8.4, 1.9 Hz, 2H), 7.36 (d, J=8.0 Hz, 2H), 7.27 (dt, J=9.2, 2.5 Hz, 2H), 6.80 (dt, J=9.2, 2.5 Hz, 2H), 4.60 (s, 2H), 4.51 (t, J=6.1 Hz, 2H), 4.39 (s, 2H), 3.45 (t, J=6 0 Hz, 2H), 2.41 (s, 31H). ESI-MS m/z 387 (MNa⁺).

[0500] C. 4-(4-Carboxymethoxy-benzyloxy)-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2,4,6-triene-9.10-dicarboxylic acid 10-allyl ester 9-(2-trimethylsilanyl-ethyl) ester

[0501] a) To a solution of the phenol of Example 19 (17.4 g, 42 mmol), 2-(toluene-4-sulfonyl)ethyl (4-hydroxymethylphenoxy)acetate (18.2 g, 50 mmol) and triphenylphosphine (13.1 g, 50 mmol) in anhydrous tetrahydrofuran (175 mL) was added DEAD (8.0 mL, 8.85 g, 51 mmol). The resulting reaction mixture was allowed to stir at rt for 5 h, after which time it was concentrated to dryness. The residue was then dissolved in ethyl acetate (1.0 L) and washed with 0.1 M citric acid (2×100 mL), 5% NaHCO₃ solution (2×100 mL) and brine (2×100 mL). The resulting organic layer was dried (MgSO₄), filtered and concentrated to dryness to give a yellow oil. Column chromatography (4% acetonitrile/dichloromethane) provided the desired tosylethyl ester, wt. 23.9 g (75%).

[0502] b) To a solution of the above ester (23.9 g, 31 mmol) in acetonitrile (200 mL) was added piperidine (7.5 mL, 6.5 g, 76 mmol) and DBU (5.6 mL, 5.7 g, 37.4 mmol). The resulting mixture was allowed to stir at rt for 45 min, after which the solution was concentrated to dryness and redissolved in ethyl acetate (1 L). The organic layer was washed with 0.1 N HCl solution (850/150/150 mL) and brine (2×150 mL), dried (MgSO₄), filtered and the solvent was evaporated to give a yellow oil. Column chromatography (2% methanol/dichloromethane, 2 L, followed by 2% methanol/dichloromethane with 2% AcOH, 3 L) provided the desired product as a foamy off-white solid, wt. 15.2 g (63% over two steps). ¹H NMR (CDCl₃) 7.35 (d, J=8.5 Hz, 2H), 7.19 (d, J=8.2 Hz, 1H), 6.94(d, J=8.8 Hz, 2H), 6.85 (dd, J=8.1, 2.6 Hz, 1H), 6.80 (d, J=2.5 Hz, 1H), 5.88-5.75 (m, 1H), 5.28-5.19 (m, 2H), 4.94 (s, 2H), 4.69 (s, 2H), 4.49 (dq, J=5.6, 1.3 Hz, 2H), 4.30-4.27 (m, 2H), 4.01 (d, J=2.5 Hz, 1H), 3.77 (q, J=2. 7 Hz, 1H), 3.73 (dd, J=5.9, 2.3 Hz, 1 Hz), 3.23 (dt, J=5.8, 2.3 Hz, 1H), 2.42 (dd, J=19.0, 2.2 Hz, 1H), 2.13 (dt, J=18.7, 2.6 Hz, 1H), 1.07-1.01 (m, 2H), 0.06 (s, 9H). APCI-MS 603.3 (MNa⁺), 579.2 (M−H)⁻.

Example 106 Procedure for the Synthesis of a Library of Representative Benzobicyclooctanes

[0503]

[0504] A. Loading scaffold onto TentaGel Amine Resin (Novabiochem A18764)

[0505] 1. Place dry resin (5 g, 0.43 mmol/g loading) in Schlenk ware

[0506] 2. Swell resin with dichloromethane (2×30 mL, 2 min)

[0507] 3. Add NMP, bubble N₂ through frit and drain (4×30 mL, 5 min)

[0508] 4. Add the following solutions to swelled resin: NMP solution of Scaffold (0.5 M, 6 mL), NMP solution of DIEA (1.25 M, 7 mL) and NMP solution of HATU (0.5 M, 6.5 mL)

[0509] 5. Bubble N₂ through frit for 1.5 h; drain

[0510] 6. Wash resin with NMP (3×30 mL, 5 min)

[0511] 7. Kaiser test of resin proved negative (Kaiser, E. et al, Anal. Biochem., 1970, 34, 595)

[0512] 8. Add the following solutions to swelled resin: NMP solution of Scaffold (0.5 M, 4 mL), NMP solution of DIEA (1.25 M, 4 mL) and NMP solution of HATU (0.5 M, 4 mL)

[0513] 9. Repeat steps 5-7

[0514] 10. Wash resin with 1:1 NMP/dichloromethane (2×30 mL, 3 min)

[0515] 11. Wash resin with 1:4 NMP/dichloromethane (2×30 mL, 3 min)

[0516] 12. Wash resin with neat dichloromethane (3×30 mL, 3 min)

[0517] 13. Dry under vacuum overnight

[0518] 14. Distribute resin into 96-well plate (50 mg/well); store at about −15/−20° C. in a ziplock bag

[0519] B. Allyl Ester Deprotection/1^(st) Amide Formation

[0520] 1. Swell resin (in each well) with CHCl₃ (3×0.5 mL, 3 min); drain

[0521] 2. Add CHCl₃ solution of N-methylaniline (0.5 M, 0.5 mL)

[0522] 3. Add CHCl₃ solution of Pd(PPh₃)₄ (0.05 M, 0.5 mL)

[0523] 4. Bubble N₂ & vortex for 45 min; drain

[0524] 5. Wash with CHCl₃ (3×0.5 mL, 3 min)

[0525] 6. Repeat steps 2-5

[0526] 7. Wash resin with DMF solution of diethyldithiocarbamic acid, sodium salt trihydrate (0.03 M) and DIEA (0.06 M) (3×0.75 mL, 3 min)

[0527] 8. Wash resin with DMF (3×0.5 mL, 3 min)

[0528] 9. Wash resin with NMP (3×0.5 mL, 3 min)

[0529] 10. Add the following: NMP solution of DIEA (1.25 M, 0.15 mL), NMP solution of HATU (0.5 M, 0.1 5 mL) and NMP solution of amine (0.5 M, 0.15 mL) respectively (amine (HCl)_(z) were treated with an excess of an NMP solution of DIEA (1.25 M, (z)×0.15 mL)

[0530] 11. Bubble N₂ & vortex for 2 h; drain

[0531] 12. Wash with NMP (3×0.5 mL, 3 min)

[0532] 13. Repeat steps 10-12

[0533] 14. Wash resin with 1:1 NMP/dichloromethane (2×0.5 mL, 3 min)

[0534] 15. Wash resin with neat dichloromethane (3×0.5 mL, 3 min)

[0535] 16. Keep 96-well plate in the reaction block at rt overnight

[0536] C. TMSE Ester Deprotection/2^(nd) Amide Formation

[0537] 1. Swell resin with THF (3×0.5 mL, 3 min); drain

[0538] 2. Add THF solution of TBAF (1 M, 0.5 mL)

[0539] 3. Bubble N₂ & vortex for 45 min; drain

[0540] 4. Wash resin with THF (3×0.5 mL, 3 min)

[0541] 5. Repeat steps 2-4

[0542] 6. Wash with 1:1 THF/NMP (2×0.5 mL, 3 min)

[0543] 7. Wash with NMP (3×0.5 mL, 3 min)

[0544] 8. Add the following: NMP solution of DIEA (1.25 M, 0.15 mL), NMP solution of HATU (0.5 M, 0.15 mL) and NMP solution of amine (0.5 M, 0.15 mL) respectively (amine (HCl)_(z) were treated with an excess of an NMP solution of DIEA (1.25 M, (z)×0.15 mL))

[0545] 9. Bubble N₂ & vortex for 1.5 h; drain

[0546] 10. Wash with NMP (3×0.5 mL, 3 min)

[0547] 11. Repeat steps 8-10

[0548] 12. Wash with 1:1 NMP/dichloromethane (2×0.5 mL, 3 min)

[0549] 13. Wash with neat dichloromethane (3×0.5 mL, 3 min)

[0550] 14. Store at about −15/−20° C. in a ziplock bag

[0551] D. TFA Cleavage of Compound from Resin

[0552] 1. Swell resin with dichloromethane (2×0.5 mL, 2 min); drain

[0553] 2. Add 95:5 TFA/H₂O solution to each well (0.5 mL)

[0554] 3. Bubble N₂ & vortex for 2 h; drain into cube tubes

[0555] 4. Wash wells with TFA/H₂O (3×0.25 mL, 2 min)

[0556] 5. Add AcOH (0.5 mL) to each cube tube

[0557] 6. Concentrate under reduced pressure with heat (Savant) for about 1 h

[0558] 7. Add AcOH (0.75 mL) to each cube tube

[0559] 8. Concentrate under reduced pressure with heat (Savant) for 45 min

[0560] 9. Add AcOH (0.25 mL) and toluene (0.75 mL) to each cube tube

[0561] 10. Concentrate under reduced pressure with heat (Savant) for 2 h

[0562] 11. Add methanol (0.25 mL), vortex then add toluene (0.75 mL)

[0563] 12. Concentrate under reduced pressure with heat (Savant) overnight

[0564] A 1152-member bicyclic library was produced using TentaGel™ as the solid support and the procedure described in steps A-D above. The library was made using 36 (3*12) by 32 (4*8) sets of diverse amines (see Table 2). The acid-labile protecting groups tert-butoxycarbonyl, tert-butyl ethers, and tert-butyl esters were utilized for the protection of amines alcohols and carboxylic acids, respectively. On average, each well provided 6.5 micromoles of desired product [17.2 micromoles (of starting resin) *0.76 (% yield) *0.5 (assuming 50% purity on average)]. Each well was analyzed by MS (loop injection). In addition, 15% wells from plate 4 and 12 wells from plate 12 were analyzed by LC-MS to confirms that MS-loop injection analysis was consistent with the LC-MS data. Each compound of the 1152-member library was then placed into one of three relative purity categories: high purity, lower purity and failures. The data is summarized in Table 1. TABLE 1 Plate # of High Purity # of Lower Purity # of # wells % wells % Failures % 1 69 72 18 19 9 9 2 77 79 18 19 1 2 3 74 77 22 23 0 0 4 74 77 11 11 11 11 5 72 75 21 22 3 3 6 68 71 28 29 0 0 7 76 79 20 21 0 0 8 77 80 19 20 0 0 9 78 81 18 19 0 0 10 67 70 29 30 0 0 11 49 51 47 49 0 0 12 62 65 34 35 0 0 Totals 843 73 285 25 24 2

[0565] High purity indicates that the molecular ion and/or fragments resulting from the desired ion were the only/major peaks in the MS spectra. Lower purity refers to wells when the molecular ion and/or fragment were present in addition to a number of other peaks. Although a significant number of wells were of lower purity, the major impurity in these wells (about 90% of the wells) was the carboxylic acid resulting from incomplete coupling with the second amine. A failure indicates very little or no molecular ion or identifiable fragment was detected. TABLE 2 Structures of Combinatorial Library Compounds

NRR′ NR″R′′′ 1

1

2

2 N(C₅H₁₁)₂ 3

3

4

4

5

5

6 N(C₅H₁₁)₂ 6

7

7

8

8

9

9

10

10

11

11

12

12

13

13

14

14

15

15

16

16

17

17

18

18

19

19

20

20

21

21

22

22

23

23

24

24

11

11

12

12

13

13

14

14

15

15

16

16

17

17

18

18

19

19

20

20

21

21

22

22

23

23

24

24

Example 107 Biological Activities of Representative Bicyclooctanes Apoptosis

[0566] The protocol used for determining inhibition of apoptosis in A549 cells was adopted from a system previously described (K. Last-Barney et al., J. of Immunology 141:527-530, 1988). Briefly, 10⁵ cells in 200 μL 10% FBS/RPMI antibiotic containing culture medium were plated into 96 well round bottom culture plates and allowed to adhere for 6 hours at 37° C. in a 5% CO₂ atmosphere. The media was removed and 100 μL of RPMI+1 μg/mL actinomycin-D was added to each well, followed by 90 μL of test compound solution in 1% DMSO. This was incubated for 1 hour 10 AL TNF-α was added at its EC₅₀ (normally 1 ng/mL FAC) and the plates incubated for 18 hours. The media was aspirated from the plates and 100 μL of 0.5% crystal violet in 20% methanol was added. After 10 minutes the plates were rinsed with water to remove excess stain, air dried, and read on a Spectramax at a wavelength of 590 nm. The data obtained from the Spectramax was converted into percent inhibition data at a concentration of 20 μM or IC₅₀ measured in μM. Data is presented for representative compounds under the column titled “Apopt inh” in Table 3 as follows: “*” refers to percent inhibition from 6% to 64%; “**” refers to an IC₅₀ from 10 μM to 50 μM; “***” refers to an IC₅₀ below 10 μM.

NFκB

[0567] A549 cells were stably transfected with an E-selectin promoter containing three NFκB binding sites driving luciferase expression. For the assay, 5×10⁴ cells were incubated in 96 well round bottom plates overnight in 100 μL of 10% FBS/RPMI medium at 37° C. in a 5% CO₂ atmosphere. The following morning the medium was removed and 90 μL of a 1% DMSO solution of test compound solution was added and the plates incubated for 1 hour. 10 μL of TNF-α was added at its EC₅₀ (normally 6 ng/mL FAC) to each well and the plate incubated for 5 hours. 100 μL of luciferase buffer was added, and after 10 minutes luminescence was read on a Wallac Victor 1420 Multilabel Counter. The data obtained from the Wallac Victor was converted into % inhibition data or IC₅₀ measured in μM. Data is presented for representative compounds under the column titled “NFκB inh” in Table 3 as follows: “*” refers to percent inhibition from 6% to 64%; “**” refers to an IC₅₀ from 10 μM to 50 μM; “**” refers to an IC₅₀ below 10 μM.

[0568] The compounds of Table 3 were synthesized according to disclosed methods of Examples 1-106, and tested for activity according to the above assays. In Table 3, each compound is provided with a unique compound number, as set forth in the column “No.” TABLE 3 STRUCTURE No. Apopt inh NFκB inh

1 ** *

2 * *

3 * *

4 * *

5 ** *

6 * *

7 * *

8 * **

9 * *

10 *** **

11 ** *

12 ** **

13 ** *

14 ** **

15 ** *

16 ** **

17 * *

18 ** —

19 * *

20 * *

21 * *

22 — *

23 — **

24 — **

25 ** *

26 — *

27 ** *

28 ** *

29 ** *

30 *** —

31 * *

32 ** *

33 ** *

34 *** **

35 *** *

36 * *

37 ** *

38 *** **

39 * **

40 ** *

41 * **

42 * *

43 * *

44 * *

45 *** *

46 * *

47 * *

48 ** *

49 * *

50 *** **

51 *** **

52 * **

53 *** **

54 *** **

55 — *

56 *** *

57 ** *

58 ** *

59 *** **

60 ** **

61 ** *

62 ** *

63 * *

64 *** *

65 *** **

66 * **

67 *** **

68 *** **

69 *** *

70 * *

71 *** **

72 *** *

73 — **

74 — **

75 — *

76 — **

77 — **

78 *** —

79 *** **

80 *** **

81 *** *

82 *** **

83 *** **

84 *** **

85 — **

86 — **

87 — **

88 — *

89 — *

90 — *

91 — **

92 — **

93 — **

94 — **

95 * *

96 *** *

97 * **

98 * *

99 — **

100 — **

101 *** *

102 * *

103 * *

104 — *

105 — *

106 — **

107 — **

108 — **

109 — **

110 * *

Example 108 Biological Activities of Representative Bicyclooctanes

[0569] Compounds of the present invention were synthesized according to methods disclosed in Examples 1-106, and tested for activity according to the apoptosis and NFκB assays described in Example 107, and the CXCR1 and CXCR2 assays described below. The results from these biological testings are set forth in Table 4, where each compound is provided with a unique compound number, as set forth in the column “No.”

CXCR1

[0570] This assay is a radioligand binding assay in human recombinant CHO cells with ¹²⁵I labeled IL-8 as the ligand. The assay procedure is described in Ahuja, S. K.; Murphy, P. M;. J. Biol. Chem. 1996, 271, 20545, and was performed by Panlabs Taiwan, Ltd. Data is presented for representative compounds under the column titled “CXCR1 inh” in Table 4 as follows: “*” refers to percent inhibition from 10-36%; “**” refers to an IC₅₀ from 10 μM to 50 μM; “***” refers to an IC₅₀ below 10μM.

CXCR2

[0571] This assay is a radioligand binding assay in human recombinant CHO cells with ¹²⁵I labeled IL-8 as the ligand. The assay procedure is described in Ahuja, S. K.; Murphy, P. M;. J. Biol. Chem. 1996, 271, 20545, and was performed by Panlabs Taiwan, Ltd. Data is presented for representative compounds under the column titled “CXCR2 inh” in Table 4 as follows: “*” refers to percent inhibition from 10-36%; “**” refers to an IC₅₀ from 10 μM to 50 μM; “***” refers to an IC₅₀ below 10 μM. TABLE 4 Apopt. NFkB CXCR1 CXCR2 STRUCTURE No. Inh. inh. inh. 2inh.

111 *** ** *** ***

112 N.D. * ** ***

113 N.D. * ** **

114 N.D. * N.D. *

115 — * * *

116 *** ** * *

[0572] All other acronyms and abbreviations have the corresponding meaning as published in journals relative to the art of organic chemistry. From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

[0573] All references cited herein are incorporated by reference. 

What is claimed is:
 1. A compound of formula (I)

and optical isomers, diastereomers, enantiomers and pharmaceutically acceptable salts thereof in isolation or mixture, where, independently at each location: R¹ is selected from the following six formulae:

R² is —OR⁹ or —NR⁹R⁹; R³ is selected from hydrogen, halogen, hydroxyl or protected hydroxyl, amino or protected amino, and C₁-C₈alkyl or C₁-C₈haloalkyl; R⁴ and R⁵ are independently selected from R⁹, —OR⁹, —NR⁹R⁹ and —N═N—R⁹, or R⁴ and R⁵ may together form a group selected from ═O, ═CR⁸R⁸ and ═NR¹⁰, or R⁴ and R⁵ may together with the carbon to which they are both attached form a Spiro carbocyclic or heterocyclic ring; R⁶ is selected from hydrogen, inorganic groups having 1-8 atoms selected from boron, sulfur, phosphorous, silicon and hydrogen, and organic groups having 1-20 carbons and optionally containing 1-4 heteroatoms selected from nitrogen, oxygen and silicon: R⁷ is selected from halogen, hydroxyl or protected hydroxyl, amino or protected amino, and C₁-C₈alkyl or C₁-C₈haloalkyl; R⁸ is selected from hydrogen, alkyl, aryl and heteroalkyl; R⁹ is selected from hydrogen and organic groups having 1-30 carbons and optionally containing 1-4 heteroatoms selected from nitrogen, oxygen and silicon, with the provision that two R⁹ groups both joined to a common atom may be joined together so as to form a ring with the common atom; R¹⁰ is selected from —R⁹, —OR⁹, —NR⁹R⁹, —NH—C(O)R⁹; —NH—C(O)OR⁹ and —NH—C(S)NHR⁹; and n is 0, 1, 2 or 3; with the proviso that when R⁶ is hydrogen and R⁴ and R⁵ together form ═O and R¹ is CO₂R^(9,) then R² is not OCH₃.
 2. A compound of claim 1 wherein R¹ is


3. A compound of claim 1 wherein R¹ is


4. A compound of claim 1 wherein R¹ is


5. A compound of claim 1 wherein R⁸ is selected from hydrogen and C₁-C₈ alkyl.
 6. A compound of claim 1 where R⁸ is hydrogen.
 7. A compound of claim 1 wherein R¹ is


8. A compound of claim 1 wherein R¹ is


9. A compound of claim 1 wherein R¹ is


10. A compound of claim 1 wherein R¹ is selected from the following four formulae:


11. A compound of claim 1 wherein R⁹ is independently selected at each occurrence from hydrogen, R¹¹, R¹², R¹³, R¹⁴ and R¹⁵ where R¹¹ is selected from alkyl, heteroalkyl, aryl and heteroaryl; R¹² is selected from (R¹¹)_(p)-alkylene, (R¹¹)_(p)-heteroalkylene, (R¹¹)_(p)-arylene and (R¹¹)_(p)-heteroarylene; R¹³ is selected from (R¹²)_(p)-alkylene, (R¹²)_(p)-heteroalkylene, (R¹²)_(p)-arylene, and (R¹²)_(p)-heteroarylene; R¹⁴ is selected from (R¹³)_(p)-alkylene, (R¹³)_(p)-heteroalkylene, (R¹³)_(p)-arylene, and (R¹³)_(p)-heteroarylene, R¹⁵ is selected from (R¹⁴)_(p)-alkylene, (R¹⁴)_(p)-heteroalkylene, (R¹⁴)_(p)-arylene, and (R¹⁴)_(p)-heteroarylene, and p is selected from 0, 1, 2, 3, 4 and 5, with the provision that two R⁹ groups both joined to a common atom may be joined together so as to form a ring with the common atom.
 12. A compound of claim 1 wherein R⁹ is independently selected at each occurrence from R¹¹, R¹², R¹³, R¹⁴ and R¹⁵ where R¹¹ is selected from alkyl, heteroalkyl, aryl and heteroaryl; R¹² is selected from (R¹¹)_(p)-alkylene, (R¹¹),-heteroalkylene, (R¹¹)_(p)-arylene and (R¹¹)_(p)-heteroarylene; R¹³ is selected from (R¹²)_(p)-alkylene, (R¹²)_(p)-heteroalkylene, (R¹²)_(p)-arylene, and (R¹²)_(p)-heteroarylene ; R¹⁴ is selected from (R¹³)_(p)-alkylene, (R¹³)_(p)-heteroalkylene, (R¹³)_(p)-arylene, and (R¹³)_(p)-heteroarylene, R¹⁵ is selected from (R¹⁴)_(p)-alkylene, (R¹⁴)_(p)-heteroalkylene, (R¹⁴)_(p)-arylene, and (R¹⁴p-heteroarylene, and p is selected from 0, 1, 2, 3, 4 and
 5. 13. A compound of claim 11 wherein R⁹ is selected from hydrogen, heteroalkyl, C₁-C₁₅alkyl, (heteroaryl)C₁-C₁₅alkylene, (C₆-C₁₀aryl)C₁-C₁₅alkylene, C₆-C₁₀aryl fused to C₁-C₁₅alkylene, (alkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene, (C₆-C₁₀aryl)(C₆-C₁₀arylene)C₁-C₁₅alkylene, (C₁-C₁₅alkyl)_(p)(heteroarylene)C_(1-C) ₁₅alkylene, and (heteroalkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene, or two R⁹ groups bonded to a common nitrogen of R¹ may be joined together to form a 5-8 membered heterocycle including the common nitrogen, where this 5-8 membered heterocycle may be substituted with 0-5 groups selected from alkyl and heteralkyl, where p is selected from 1, 2, 3, 4 and
 5. 14. A compound of claim 11 wherein R⁹ is selected from hydrogen, heteroalkyl, C₁-C₁₅alkyl, (C₆-C₁₀aryl)C₁-C₁₅alkylene, (heteroaryl)C₁-C₁₅alkylene, and (heteroalkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene, or the two R⁹ groups joined to a common nitrogen of R¹ may be joined together to form a 5-8 membered heterocycle including the common nitrogen.
 15. A compound of claim 11 wherein R⁹ is selected from heteroalkyl, C₁-C₁₅alkyl, (C₆-C₁₀aryl)C₁-C₁₅alkylene, (C₆-C₁₀aryl)(C₆-C₁₀arylene)C₁-C₁₅alkylene, C₁-C₁₅alkyl)_(p)(heteroarylene)C₁-C₁₅alkylene, and C₆-C₁₀aryl fused to C₁-C₁₅alkylene.
 16. A compound of claim 11 wherein R¹ is selected from hydrogen, heteroalkyl, C₁-C₁₅alkyl, (C₆-C₁₀aryl)C₁-C₁₅alkylene, (C₆-C₁₀aryl)(C₆-C₁₀arylene)C₁-C₁₅alkylene, (C₁-C₁₅alkyl)_(p)(heteroarylene)C₁-C₁₅alkylene, and C₆-C₁₀aryl fused to C₁-C₁₅alkylene.
 17. A compound of claim 11 wherein R⁹ is selected from hydrogen, heteroalkyl, C₁-C₁₅alkyl, (heteroaryl)C₁-C₁₅alkylene, and (heteroalkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene.
 18. A compound of claim 11 wherein R⁹ is selected from hydrogen, heteroalkyl, C₁-C₁₅alkyl, (heteroaryl)C₁-C₁₅alkylene, (C₆-C₁₀aryl)C₁-C₁₅alkylene, (alkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene, or the two R⁹ groups of R¹ may be joined together to form a 5-8 membered heterocycle including the common nitrogen, where this 5-8 membered heterocycle may be substituted with 0-5 groups selected from alkyl and heteralkyl.
 19. A compound of claim 1 wherein R² is —OR⁹.
 20. A compound of claim 1 wherein R² is —NR⁹R⁹.
 21. A compound of claim 1 wherein R⁹ of R² is selected from hydrogen, R¹¹, R¹², R¹³, R¹⁴ and R¹⁵ where R¹¹ is selected from alkyl, heteroalkyl, aryl and heteroaryl; R¹² is selected from (R¹¹)_(p)-alkylene, (R¹¹)_(p)-heteroalkylene, (R¹¹)_(p)-arylene and (R¹¹)_(p)-heteroarylene; R¹³ is selected from (R¹²)_(p)-alkylene, (R¹²)_(p)-heteroalkylene, (R¹²)_(p)-arylene, and (R¹²)_(p)-heteroarylene; R¹⁴ is selected from (R¹³)_(p)-alkylene, (R¹³)_(p)-heteroalkylene, (R¹³)_(p)-arylene, and (R¹³)_(p)-heteroarylene, R¹⁵ is selected from (R¹⁴)_(p)-alkylene, (R¹⁴)_(p)-heteroalkylene, (R¹⁴)_(p)-arylene, and (R¹⁴)_(p)-heteroarylene, and p is selected from 0, 1, 2, 3, 4 and
 5. 22. A compound of claim 1 wherein R⁹ of R² is selected from hydrogen, heteroalkyl, C₁-C₁₅alkyl, (C₆-C₁₀aryl)(C₆-C₁₀arylene)C₁-C₁₅alkylene, (C₁-C₁₅alkyl)_(p)-(heteroarylene)C₁-C₁₅alkylene, (C₁-C₁₅alkyl)_(p)(heteroarylene)heteroalkylene, (heteroalkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene,land(C₁-C₁₅alkyl)_(p)(C₆-C₁₀arylene)heteroalkylene.
 23. A compound of claim 1 wherein R² is —OR⁹ where R⁹ is selected from a heteroalkyl group having 1-10 carbons and 1-4 heteroatoms selected from nitrogen, oxygen, silicon and sulfur.
 24. A compound of claim 1 wherein R² is —NR⁹R⁹ and R⁹ is selected from hydrogen, heteroalkyl, C₁-C₁₅alkyl, (heteroaryl)C₁-C₁₅alkylene, (heteroalkyl)_(p)(aryl)-heteroalkylene, (heteroalkyl)_(p)(aryl)C₁-C₁₅alkylene, and (C₁-C₁₅alkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene.
 25. A compound of claim 1 wherein R³ is selected from hydrogen and alkyl.
 26. A compound of claim 25 wherein R³ is hydrogen.
 27. A compound of claim 1 wherein R⁴ and R⁵ are independently selected from R⁹, —OR⁹, —NR⁹R⁹ and —N═N—R⁹.
 28. A compound of claim 27 wherein R⁹ of R⁴ and R⁵ is selected from hydrogen, R¹¹, R¹², R¹³, R¹⁴ and R¹⁵ where R¹¹ is selected from alkyl, heteroalkyl, aryl and heteroaryl; R¹² is selected from (R¹¹)_(p)-alkylene, (R¹¹)_(p)-heteroalkylene, (R¹¹)_(p)-arylene and (R¹¹)_(p)-heteroarylene; R¹³ is selected from (R¹²)_(p)-alkylene, (R¹²)_(p)-heteroalkylene, (R¹²)_(p)-arylene, and (R¹²)_(p)-heteroarylene; R¹⁴ is selected from (R¹³)_(p)-alkylene, (R¹³)_(p)-heteroalkylene, (R¹³)_(p)-arylene, and (R¹³)_(p)-heteroarylene, R¹⁵ is selected from (R¹⁴)_(p)-alkylene, (R¹⁴)_(p)-heteroalkylene, (R¹⁴)_(p)-arylene, and (R¹⁴)_(p)-heteroarylene, and p is selected from 0, 1, 2, 3, 4 and
 5. 29. A compound of claim 27 wherein each of R⁴ and R⁵ is hydrogen.
 30. A compound of claim 27 wherein at least one of R⁴ and R⁵ is selected from C₁-C₁₅alkyl, heteroalkyl, and C₆-C₁₀aryl.
 31. A compound of claim 27 wherein one of R⁴ and R⁵ is hydrogen and the other of R⁴ and R⁵is selected from hydrogen, —OR⁹, —NR⁹R⁹ and —N═N—R⁹ where the R⁹ is selected from hydrogen, R¹¹, R¹², R¹³, R¹⁴ and R¹⁵ where R¹¹ is selected from alkyl, heteroalkyl, aryl and heteroaryl; R¹² is selected from (R¹¹)_(p)-alkylene, (R¹¹)_(p)-heteroalkylene, (R¹¹)_(p)-arylene and (R¹¹)_(p)-heteroarylene; R¹³ is selected from (R¹²)_(p)-alkylene, (R¹²)_(p)-heteroalkylene, (R¹²)_(p)-arylene, and (R¹²)_(p)-heteroarylene; R¹⁴ is selected from (R¹³)_(p)-alkylene, (R¹³)_(p)-heteroalkylene, (R¹³)_(p)-arylene, and (R¹³)_(p)-heteroarylene, R¹⁵ is selected from (R¹⁴),-alkylene, (R¹⁴)_(p)-heteroalkylene, (R¹⁴)_(p)-arylene, and (R¹⁴)_(p)-heteroarylene, and p is selected from 0, 1, 2, 3, 4 and
 5. 32. A compound of claim 1 wherein R⁴ and R⁵ together form a group selected from ═O, ═CR⁸R⁸ and ═NR¹⁰.
 33. A compound of claim 32 wherein R⁴ and R⁵ together form ═O.
 34. A compound of claim 32 wherein R⁴ and R⁵ together form ═NR¹⁰ and R¹⁰ is —OR⁹ where R⁹ is selected from hydrogen, C₆-C₁₀aryl, C₁-C₈alkyl, heteroalkyl, (C₆-C₁₀aryl)heteroalkyl, (C₆-C₁₀aryl)C₁-C₁₅alkylene, (heteroalkyl)_(p)(heteroarylene)C₁-C₁₅alkylene, (heteroalkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene, and (C₁-C₁₅alkyl)_(p)(C₆-C₁₀arylene)heteroalkylene.
 35. A compound of claim 32 wherein R⁴ and R⁵ together form ═NR¹⁰ and R¹⁰ is —N(R⁹)(R⁹) where R⁹ is selected from hydrogen, C₁-C₈alkyl, heteroalkyl, C₆-C₁₀aryl, (C₆-C₁₀aryl)heteroalkylene, (heteroalkyl)_(p)C₆-C₁₀arylene, (C₁-C₁₅alkyl)_(p)C₆-C₁₀arylene, (heteroalkyl)_(p)(C₆-C₁₀arylene)heteroalkylene, (C₁-C₁₅alkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene, and (C₁-C₁₅alkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅heteroalkylene.
 36. A compound of claim 32 wherein R⁴ and R⁵ together form ═CR⁸R⁸, and one of R⁸ is hydrogen while the other R⁸ is selected from hydrogen, C₁-C₈alkyl and heteroalkyl.
 37. A compound of claim 32 wherein R⁸ is selected from hydrogen and C₁-C₈alkyl, and R¹⁰ is selected from hydrogen, R¹¹, R¹², R¹³, R¹⁴ and R¹⁵ where R¹¹ is selected from alkyl, heteroalkyl, aryl and heteroaryl; R¹² is selected from (R¹¹)_(p)-alkylene, (R¹¹)_(p)-heteroalkylene, (R¹¹)_(p)-arylene and (R¹¹)_(p)-heteroarylene; R¹³ is selected from (R¹²)_(p)-alkylene, (R¹²)_(p)-heteroalkylene, (R¹²)_(p)-arylene, and (R¹²)_(p)-heteroarylene; R¹⁴ is selected from (R¹³)_(p)-alkylene, (R¹³)_(p)-heteroalkylene, (R¹³)_(p)-arylene, and (R¹³)_(p)-heteroarylene, R¹⁵ is selected from (R¹⁴)_(p)-alkylene, (R¹⁴)_(p)-heteroalkylene, (R¹⁴)_(p)-arylene, and (R¹⁴)_(p)-heteroarylene, and p is selected from 0, 1, 2, 3, 4 and
 5. 38. A compound of claim 30 wherein R⁸ is hydrogen.
 39. A compound of claim 28 wherein R¹⁰ is R¹¹.
 40. A compound of claim 1 wherein R⁴ and R⁵ together with the carbon to which they are both attached form a spiro carbocyclic or heterocyclic ring.
 41. A compound of claim 1 wherein R⁶ is selected from hydrogen, R¹¹, R¹² R¹³, R¹⁴ and R¹⁵ where R¹¹ is selected from alkyl, heteroalkyl, aryl and heteroaryl; R¹² is selected from (R¹¹)_(p)-alkylene, (R¹¹)_(p)-heteroalkylene, (R¹¹)_(p)-arylene and (R¹¹)_(p)-heteroarylene; R¹³ is selected from (R¹²)_(p)-alkylene, (R¹²)_(p)-heteroalkylene, (R¹²)_(p)-arylene, and (R¹²)_(p)-heteroarylene; R¹⁴ is selected from (R¹³)_(p)-alkylene, (R¹³)_(p)-heteroalkylene, (R¹³)_(p)-arylene, and (R¹³)_(p)-heteroarylene, R¹⁵ is selected from (R¹⁴)_(p)-alkylene, (R¹⁴)_(p)-heteroalkylene, (R¹⁴)_(p)-arylene, and (R¹⁴)_(p)-heteroarylene, and p is selected from 0, 1, 2, 3, 4 and
 5. 42. A compound of claim 41 wherein R⁶ is selected from C₁-C₁₅alkyl, C₁-C₁₅heteroalkyl, (C₆-C₁₀aryl)C₁-C₁₅alkylene, (C₆aryl)(C₆aryl)C₁-C₁₅alkylene, (C₂-C₆heteroaryl)C₁-C₁₅alkylene, (C₆-C₁₀aryl)C₁-C₁₅heteroalkylene, (heteroalkyl)_(p)(C₆-C₁₀arylene)C₁-C₁₅alkylene, (heteroalkyl)_(p)(C₂-C₆heteroarylene)C₁-C₁₅alkylene, and (heteroalkyl)_(p)(C₆arylene)(heteroalkylene)(C₆arylene)C₁-C₁₅alkylene.
 43. A compound of claim 41 wherein R¹ is hydrogen.
 44. A compound of claim 1 wherein n is
 0. 45. A compound of claim 1 wherein n is
 1. 46. A compound of claim 1 wherein R³ is hydrogen; R⁴ and R⁵ are selected from (a) R⁴ is hydrogen and R⁵ is hydroxyl or protected hydroxyl and (b) R⁴ and R⁵ together form carbonyl; R⁶ is hydrogen; and n is
 0. 47. A compound of claim 46 wherein R² is —OR⁹.
 48. A compound of claim 47 wherein R² is —OCH₂CH₂Si(CH₃)₃.
 49. A compound of claim 46 wherein R¹ is


50. A compound of claim 49 wherein R⁹ is a C₁-C₆ hydrocarbyl.
 51. A compound of claim 50 wherein R⁹ is selected from n-propyl and —CH₂—CH═CH₂.
 52. A compound of claim 46 wherein R¹ is


53. A compound of claim 52 wherein R⁸ is hydrogen and R⁹ is C₁-C₆ hydrocarbyl.
 54. A compound of claim 53 wherein R⁹ is —CH₂—CH═CH₂.
 55. 4-Hydroxy-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester, and optical isomers, enantiomers and pharmaceutically acceptable salts thereof in isolation or mixture.
 56. 4-Hydroxy-11-oxo-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-allyl ester 9-(2-trimethylsilanyl-ethyl) ester, and optical isomers, enantiomers and pharmaceutically acceptable salts thereof in isolation or mixture.
 57. 4,11-Dihydroxy-tricyclo[6.2.2.0^(2,7)]dodeca-2(7),3,5-triene-9,10-dicarboxylic acid 10-propyl ester 9-(2-trimethylsilanyl-ethyl) ester and optical isomers, diastereomers, enantiomers and pharmaceutically acceptable salts thereof in isolation or mixture
 58. A compound of claim 1 wherein the stereochemistry of the R¹ and C(═O)R² groups being as shown in formula Ia, with R¹ and C(═O)R² in a cis arrangement, both over the benzo ring substituted with —OR⁶


59. A compound of claim 1 wherein the stereochemistry of the R¹ and C(═O)R² groups being as shown in formula Ib, with R¹ and C(═O)R² in a trans arrangement, with only C(═O)R² over the benzo ring substituted with —OR⁶


60. A compound of claim 1 with the stereochemistry of the R¹ and C(═O)R² groups being as shown in formula Ic, with R¹ and C(═O)R² in a trans arrangement, with only R¹ over the benzo ring substituted with —OR⁶


61. A compound of claim 1 with the stereochemistry of the R¹ and C(═O)R² groups being as shown in formula Id. with R¹ and C(═O)R² in a cis arrangement, with neither of the R¹ nor C(═O)R² groups being over the benzo ring substituted with —OR⁶


62. A composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, adjuvant or incipient.
 63. A method for inhibiting a TNF-α mediated processes, comprising administering to a patient in need thereof, through a therapeutically or prophylactically acceptable manner, a therapeutically or pharmaceutically effective amount of a composition comprising a compound of claim
 1. 64. The method according to claim 63 wherein the administering is selected from transdermal, oral, intravenous, intramuscular, vaginal, rectal, pulmonary, subcutaneous, sublingual and transmucosal administration.
 65. A method for inhibiting a CXCR1 and/or CXCR2 mediated processes, comprising administering to a patient in need thereof, through a therapeutically or prophylactically acceptable manner, a therapeutically or pharmaceutically effective amount of a composition comprising a compound of claim
 1. 66. The method of claim 65 wherein the method inhibits a CXCR1 mediated processes.
 67. The method of claim 65 wherein the method inhibits a CXCR2 mediated processes.
 68. The method according to claim 65 wherein the administering is selected from transdermal, oral, intravenous, intramuscular, vaginal, rectal, pulmonary, subcutaneous, sublingual and transmucosal administration.
 69. A method for treating an inflammation event, comprising administering to a patient in need thereof, through a therapeutically or prophylactically acceptable manner, a therapeutically or pharmaceutically effective amount of a composition comprising a compound of claim
 1. 70. The method according to claim 65 wherein the administering is selected from transdermal, oral, intravenous, intramuscular, vaginal, rectal, pulmonary, subcutaneous, sublingual and transmucosal administration.
 71. A library of benzobicyclooctanes where said library comprises a plurality of compounds each having a structure of formula (I) according to claim 1, where diversity is present among the R¹, R², R³, R⁴, R⁵, R⁶ , and R⁷ groups.
 72. A process for preparing a combinatorial library of benzobicyclooctane compounds, wherein said library comprises a plurality of compounds of formula (I) as recited in claim 1, said process comprising the steps: (a) providing a compound bound to a solid support according to formula (II)

wherein PG1 and PG2 refer to first and second protecting groups, respectively, where the first protecting group can be removed in the continued presence of the second protecting group, and the second protecting group can be removed in the continued presence of the linker, and (SS) refers to a solid support; (b) removing the first protecting group but not the second protecting group, to provide a first deprotected product; (c) reacting the first deprotected product with a plurality of amines of the formula HNRR′ to provide a plurality of compounds bound to a solid support, each according to formula (IIa)

 where R and R′ are each independently selected from R⁹; (d) removing the second protecting group from (IIa) to provide a second deprotected product; (e) reacting the second deprotected product with a plurality of amines of the formula HNR″R′″ to provide a plurality of compounds bound to a solid support, each according to formula (IIb)

 where R′ and R′″ are each independently selected from R⁹; (f) removing the scaffold from the linker to provide a library of compounds according to formula (IIc)


73. The process of claim 72 wherein PG1 is —CH₂CH═CH₂.
 74. The process of claim 72 wherein PG2 is —CH₂CH₂—Si (CH₃)₃.
 75. The process of claim 72 wherein linker is


76. The process of claim 72 wherein PG1 is —CH₂—CH═CH₂; PG2 is —CH₂CH₂—Si(CH₃)₃; and linker is


77. The process of claim 72 wherein removing the first protecting group but not the second protecting group, to provide a first deprotected product according to step (b), is accomplished by reacting (II) with Pd(PPh₃)₄ and N-methylaniline.
 78. The process of claim 72 wherein removing the second protecting group from (IIa) to provide a second deprotected product according to step (d) is accomplished by treating (IIa) with tetrabutylammonium fluoride solution.
 79. The process of claim 72 wherein removing the scaffold from the solid support to provide a library of compounds according to formula (IIc) is accomplished by treating (IIb) with aqueous trifluoroacetic acid.
 80. The process of claim 72 wherein R³ is H, R⁴ and R⁵ collectively form ═O, and n is zero.
 81. A method for identifying a binding partner to a compound of claim 1, wherein the method comprises: a. immoblizing proteins known to be involved in the TNF-a signaling pathway onto a suitable carrier; and b. passing a solution of said compounds in isolation or mixture over said proteins and analyzing for compound:protein complex formation using surface plasmon resonance.
 82. A method for identifying a binding partner to a compound of claim 1, wherein the method comprises: a. providing said compound(s) bound to a solid support to provide solid phase compounds; b. contacting a cell or cell components with said solid phase compounds in isolation or mixture; and c. removing uncomplexed cellular material from said solid phase compounds; and d. recovering said binding partner from said solid phase compounds. 